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The key factors shaping consumption involve a feeling of hunger (determines search for 
calories), satiation (underpins termination of ingestive behaviour), and reward (adjusts 
consumption to the 'pleasantness' of food, regardless of actual energy needs). Though 
each of the many feeding-related neural systems affects the select facets of appetite to a 
different degree, most basic research (and subsequently, also clinical) studies exploring 
anorexigenic potential of neuroactive molecules, focus on targeting only one system. This 
single-system approach has been the case for one of the most potent anorexigens 
identified to-date, oxytocin (OT). OT is known to promote satiation and its release 
coincides with, e.g., excessive stomach distension and osmolality. OT’s effects on feeding 
reward are weaker as they are mitigated by macronutrient composition, flavour and 
energy density. Its potential influence on perceived hunger is unknown. Therefore, in this 
thesis I wished to examine whether by combining OT with a ligand that targets those 
facet(s) of feeding largely unaffected by OT, a synergistic effect on feeding can be 
achieved. Considering that opioid receptor antagonists mainly reduce reward-driven 
feeding, but do not promote satiety (notably, their effect on hunger remains undefined), I 
focused on investigating the simultaneous effects of OT receptor stimulation and opioid 
receptor blockade on food intake.   
As potential impact of either opioid antagonists or OT alone on hunger perception has 
never been examined, prior to studying simultaneous effects of the two types of molecules 
on feeding, I investigated whether either OT or opioid ligands individually reduce a 
feeling of hunger. The first set of experiments explored whether hypophagic doses of OT 
would alter hunger responsiveness in rats trained to discriminate between 22 h (hunger) 
vs 2 h (no hunger) food deprivation in a two-lever, operant discrimination procedure. 
Intraperitoneal (i.p.) OT did not decrease 22-h deprivation-appropriate responding to 
 
iii 
match that following 2-h food deprivation, thus, it did not reduce the perceived level of 
hunger. In order to understand mechanisms behind this ineffectiveness of OT, I used c-
Fos immunohistochemistry to determine whether OT activates a different subset of brain 
sites under 22- vs. 2-h deprivation. I found that in sated animals, OT induces c-Fos 
changes in a broader network of hypothalamic and brain stem sites compared to the 
hungry state. Finally, by employing qPCR, I found that fasted animals had lower OT 
receptor mRNA levels in the brain stem, a CNS “entry” region for peripheral OT, than 
their ad libitum-fed counterparts. It can be concluded that OT does not diminish a feeling 
of hunger and that, therefore, OT's anorexigenic properties are manifested once 
consumption has already begun which is—at least to some extent—driven by changes in 
brain responsiveness to OT treatment in the hungry vs. fed state.   
In the second set of experiments, I explored whether opioid receptor ligands, acting 
primarily on reward-related drivers of consumption and not on satiation, might also 
expand onto the third facet of feeding, i.e., hunger. I subsequently utilized the 
aforementioned hunger discrimination paradigm to measure behavioural responses 
associated with hunger to explore whether modulating the opioid receptor network will 
alter the perception of energy deficit (hunger).  While a hunger-inducer, neuropeptide Y 
(NPY), shifted hunger-associated operant responses in 2-hr-deprived (sated) animals, 
which is reflective of an increase in hunger, opioid receptor agonists (DAMGO, DSLET, 
orphanin FQ and butorphanol) did not induce such changes. In line with that, hypophagic 
doses of an opioid antagonist, NTX, did not reduce the hunger discriminative stimuli 
induced by either 22 h deprivation, or by NPY administration in 2 h food-restricted rats.  I 
therefore conclude that the opioid system, similarly to OT, does not affect perceived 
hunger.  
The subsequent experiments relied on the hypothesis that by combining the effect of 
opioid receptor blockade on diminishing feeding reward and of OT on promoting early 
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satiation, a synergistic effect can be achieved. This hypothesis was strengthened by a 
recent case report involving a male with hypothalamic obesity, concurrent administration of OT 
and NTX, synergistically affected energy balance. In the third set of studies performed in 
adolescent rats I indeed found that, while OT reduces deprivation-induced chow intake, 
and NTX reduces palatable food intake, that the combination of these drugs at 
subthreshold (ineffective in the context of feeding) doses produces a hypophagic effect 
on acute food intake. Furthermore, using c-Fos immunochemistry, I found robust changes 
in feeding-related brain regions within the brain stem-hypothalamic network as a result 
of this drug combination. I conclude that administration of combined OT and NTX 
acutely suppresses food intake, likely by modulating activity of brain regions associated 
with both satiety and reward.   
Importantly, the OT-NTX synergy described above pertained to adolescent animals and 
to short-term food intake. Thus, in the fourth set of studies, I examined both acute feeding 
responses and longer-term feeding and body weight changes in adult rats treated with OT-
NTX. I found that in adult animals, OT-NTX did not appear to produce a significant acute 
effect on standard chow intake as in adolescents, but I still observed the acute hypophagic 
effect in palatable feeding scenarios. Furthermore, while the drug combination indeed had 
a cumulative effect on reducing palatable food intake with chronic administration, the 
beneficial effects on caloric intake and body weight were offset by compensatory elevated 
intake of standard chow in the remainder of the day. The results of PCR gene expression 
analysis across three brain regions (hypothalamus, brain stem and nucleus accumbens) 
showed that the OT-NTX combination produced unique mRNA level changes in brain 
stem-hypothalamic networks.   
Overall, evidence gathered throughout this project shows that co-administration of two 
molecules that do not diminish hunger, but that do affect distinct facets of feeding: OT 
(early satiation) and NTX (eating for pleasure), generates a synergistic effect in reducing 
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food intake. This effect can be attained with doses of drugs that individually would be too 
low to mitigate feeding, most likely thanks to the unique action of the combined drugs at 
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Obesity is a prevalent issue in Western society and treatments to reduce unhealthy 
consumption are in high demand. Treatments that target multiple aspects of the drive to 
consume may be promising pharmacological strategies to reduce food intake. While it 
has been shown beyond reasonable doubt that oxytocin (OT) decreases feeding for 
calories and for sweet/carbohydrate-driven reward by signalling early satiation, it is 
unclear why this seemingly potent anorexigenic system does not guard against overeating 
(especially, of palatable tastants). A case study using a combination of OT to target 
satiation, and naltrexone (NTX) to address reward-related drives to consume, has shown 
promise in reducing food intake, resulting in significant body-weight loss. This may be 
the result of a potentiating effect of these drugs when co-administered.  
A recent case study of a child suffering from craniopharyngioma leading to uncontrollable 
overeating and unhealthy increases in body-weight, trialled treatment by co-
administration of OT and NTX, and reported a significant decrease in the intake of 
palatable foods, and in the subject’s body weight [1]. This study may outline a 
potentiating effect of OT and NTX when combined. Therefore, in the following studies, 
I investigate the effects of OT and NTX administered systemically (intravenously and 
intraperitoneally), and observe changes in food intake and body weight, and the 
associated neuromolecular effects. 
Firstly, I will here explore the fundamentals of the OT system and how this may be 
utilized to regulate one component of addiction, the physiological drive from the 
homeostatic system.  
 
2 
1.1 OT and its receptor 
Oxytocin (OT) is an evolutionarily ancient and biologically fundamental peptide for 
vertebrates. OT-like molecules have been detected in virtually all vertebrates, and the 
nonapeptide sequence of OT (CYIQNCPLG) is well conserved (Figure 1.1.). This is in 
line with the involvement of this peptide in the most basic mechanisms (such as 
osmoregulation, reproduction or feeding) common for organisms, regardless of their level 
of organizational complexity [2]. OT-like precursor polypeptides in invertebrate species 
also display a high level of homology to the corresponding vertebrate molecule as 
documented, for example, in the preproannetocin sequence analysis of the earthworm, 
Eisenia foetida. Interestingly, infusion of OT homologues in invertebrates affects similar 
processes as those regulated by OT in mammals, e.g., gut motility and reproductive 





Figure 1.1. Oxytocin and binding sites on oxytocin receptor. This figure illustrates molecular 
docking of the three-dimensional models of activated human oxytocin receptor with oxytocin 
obtained by MolDock Optimizer algorithm from Molegro Virtual Docker software. (A) The front 
upright view position (side view) of the receptor structure with oxytocin. (B) Panel B shows an 
intracellular view (i.e. rotation by 90˚ out of plane). (C) Conformational view of oxytocin 
molecule. (D) The schematic model of the human oxytocin receptor with marked amino-acid 
residues that are putatively involved in ligand-binding. From [3] 
 
OT binds to its receptor, a member of the Rhodopsin-type G protein-coupled receptor 
family [19; 30], and the cyclic rather than linear part of the neuropeptide’s molecule 
determines binding selectivity [4] (Figure 1.2.). The OT receptor is also bound by 
vasopressin (VP) with only 10 times less affinity than for OT, and the concentration of 
VP necessary to induce a response comparable to that elicited by OT is approximately 
100 times higher [4; 5]. VP is regarded as a partial agonist at the OT receptor and many 
studies have revealed that the VP receptor agonists have a dual OT-VP receptor binding 
profile [5]. However, OT and VP receptors’ affinities for their respective antagonists have 
much less overlap since antagonists target a different and more sequence-specific protein 





Figure 1.2. Structure of the human oxytocin receptor showing the 7 trans-membrane 
domains, the N terminal extracellular hormone binding domain and the C terminal 
intracellular domain. Each circle represents an amino acid identified by their standard one-letter 
codes. (Modified from [10]) 
 
As first documented in a study identifying the most prevalent hypothalamus-specific 
mRNAs, OT was found to be the most abundant of 43 neuropeptide transcripts [4]. 
Overall, the cyclic nonapeptide OT and its structurally related peptides facilitate 
reproduction in all vertebrates at several levels [5]. 
1.2 Genes encoding elements of the OT system 
The OT precursor protein gene is estimated to date back at least 500 million years [6].  
Human physiological and pathophysiological studies supported by rodent and cell culture 
experiments have identified three genes as the functional core of the OT 
system: OXT (structural gene for oxytocin), OXTR (oxytocin receptor), 
and CD38 [13]. CD38 is involved in OT secretion via Ca2+ release , and oxytocin-
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neurophysin I (OXT) encodes the OT prepropeptide containing the nonapeptide OT and 
the carrier protein neurophysin-I [13; 14]. 
The human gene for OT-neurophysin I encoding the OT prepropeptide is mapped to 
chromosome 20p13 [9] and consists of three exons (Figure 1.3). The first exon encodes a 
translocator signal, the nonapeptide hormone, the tripeptide processing signal (GKR), and 
the first nine residues of neurophysin; the second exon encodes the central part of 
neurophysin (residues 10–76); and the third exon encodes the COOH-terminal region of 
neurophysin (residues 77–93/95) [10]. 
 
 
Figure 1.3. Organization of the oxytocin (OT) and vasopressin (VP) gene structure including 
schematic depiction of the putative cell-specific enhancers (open circle, enhancer of OT gene; 
shaded circle, enhancer of VP gene). [Modified from Gainer et al. [11].] A: details of the 
approximately −160-bp region (composite hormone response element) of the upstream OT gene 
promoter conserved across five species including the sequences of the response elements estrogen 
response element (ERE), chicken ovalbumin upstream promoter transcription factor I (COUP-
TF), and steroidogenic factor-1 (SF-1) are indicated. [Modified from Ivell et al. [12].] B: domain 
organization of preprooxytocin including the processing sites. The precursor is split into the 
indicated fragments by enzymatic cleavages, one involving a glycyl-lysyl-arginine (GKR) 




The OXTR gene is present in a single copy in the human genome and it was mapped to 
the gene locus 3p25–3p26.2 [15-17]. The gene spans 17 kb and contains 3 introns and 4 
exons. Exons 1 and 2 correspond to the 5′noncoding region. Exons 3 and 4 encode the 
amino acids of the OT receptor. Intron 3, which is the largest at 12 kb, separates the 
coding region immediately after the putative transmembrane domain 6. Exon 4 contains 
the sequence encoding the seventh transmembrane domain, the COOH terminus, and the 
entire 3′ -noncoding region, including the polyadenylation signals (Figure 1.3). 
Although many GPCRs have an intron-less gene structure, the genes for some other 
members of the GPCR family including the human vasopressin V2 receptor [15; 18] 
contain an intron at the same location after transmembrane domain 6. The transcription 
start sites lie 618 and 621 bp upstream of the initiation codon as demonstrated by primer 
extension analysis. Nearby, a TATA-like motif and a potential SP-1 binding site is found 
in the human OT receptor gene. The 5′-flanking region also contains invert GATA-1 
motifs, one c-Myb binding site, one AP-2 site, two AP-1 sites, but no complete estrogen 
response element (ERE). Instead, there are two half-palindromic 5′-GGTCA-3′ motifs 
and one half-palindromic 5′-TGACC-3′  motif of ERE. Moreover, there are two 
nucleofactor interleukin-6 (NF IL-6) binding consensus sequences and two binding site 




Figure 1.2. Organization of the human OXTR gene including the localization of consensus 
sequences for transcription factors. The human OXTR gene consists of four exons. Exons 3 
and 4 encode the amino acid sequence for the OT receptor. The start (ATG) and stop (TGA) 
codons of the receptor cDNA are indicated. The DNA sequences encoding for transmembrane 
regions I–VII are indicated by black areas. [Modified from Inoue et al. [15].]  
 
One fundamental question concerns the possible existence of OT receptor subtypes [20; 
21]. Such subtypes have been suggested to be possibly present, e.g., in the rat uterus [22; 
23], kidney [24], or brain [25; 26], and – if true – this could explain differential 
pharmacological profiles or immunoreactivity patterns occasionally reported in 
conjunction with some organs. However, application of polymerase chain reaction (PCR) 
methods and Southern analysis in several tissues known to possess OT binding activity 
failed to identify a gene encoding a further OT receptor subtype [21; 27]. 
1.3 Structure 
OT was the first peptide hormone to have its structure determined, and the first to be 
chemically synthesized in a biologically active form [10; 28]. OT belongs to the family 
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of neurohypophyseal nonapeptide hormones, which are characterized by a cyclic 
hexapeptidic part with a disulfide bridge between Cys1 and Cys6 and a C-terminal linear 
tripeptidic extension [4] (Figure 1.4). 
 
Figure 1.3. Molecular structure of oxytocin 
 
This results in a peptide constituted of a six-amino acid cyclic part and a COOH-terminal 
α-amidated three-residue tail. Based on the amino acid at position 8, these peptides are 
classified into vasopressin and OT families: the vasopressin family contains a basic amino 
acid (Lys, Arg), and the OT family contains a neutral amino acid at this locus (Figure 
1.5). Isoleucine in position 3 is essential for binding the OT receptor, and Arg or Lys in 
position 8 for acting on vasopressin receptors. The difference in the polarity of these 
amino acid residues is thought to enable the vasopressin and OT peptides to interact with 






Figure 1.4. Schematic representation of amino acid composition of vasopressin, oxytocin, 
two related hormones, and an oxytocin antagonist. All four agonists are cyclic nonapeptides, 
which differ in their amino acid positions 3 and/or 8. Arginine vasopressin (AVP) and oxypressin 
(OP) are identical in their cyclic hormone part; this is also the case for arginine vasotocin (AVT) 
and oxytocin (OT). With regard to the acyclic portion, AVP and AVT are identical on the one 
hand and OP and OT on the other. The oxytocin antagonist (OTA) has some non-natural amino 
acids: Mca, 1-(β-mercapto-β,β-cyclopentamethylene propionic acid); Tyr (Me), methyl ether of 




1.4 Basic regulatory function at cell level 
The OT prepropeptide is cleaved while being transported down the axon to terminals 
located in the posterior pituitary [31]. The mature peptide products, OT and its carrier 
molecule neurophysin, are stored in axon terminals until neuronal membrane 
depolarization elicits their release [32]. The main function of neurophysin, a small (93–
95 residues) disulfide-rich protein, appears to be related to the proper targeting, packaging, 
and storage of OT within the granules before release into the bloodstream. OT is found 
in high concentrations (>0.1 M) in the neurosecretory granules of the posterior pituitary, 
in a 1:1 ratio complex with neurophysin. In such complexes, OT-neurophysin dimers are 
the basic functional units as suggested by the crystal structure of the neurophysin-OT 
complex [33]. Cys-1 and Tyr-2 in the OT molecule are the principal neurophysin binding 
residues. In particular, the protonated α-amino group (Cys-1) in OT forms an essential 
contact site to neurophysin via electrostatic and multiple hydrogen bonding interactions. 
Due to its dependence on amino group protonation (pKa ∼6.4), the binding strength 
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between OT and neurophysin is much higher in an acidic compartment, like the 
neurosecretory granules (pH ∼5.5). Conversely, the dissociation of the complex is 
facilitated as the complex is released from the neurosecretory granules and enters the 
plasma (pH 7.4) [10]. The specific morphology of OT neurons allows OT to have a dual 
role as both a hormone and neurotransmitter. Neurosecretory granules containing OT are 
widely distributed in Purkinje fibres and distributed along neurons.  
OT receptors can be coupled to subunits such as Gq, Gi1, Gi2, Gi3, GoA, and GoB, 
causing an increase in cytosolic calcium concentration (coupling to the Gq subunit) or 
inhibition of adenylate cyclase activity (coupling with the Gi subunit). OT promotes 
uterine contraction through the activation of calcium channels associated with receptors 
and the release of sarcoplasmic reticulum calcium. OT binds to the receptor where its 
effect is mediated by a second messenger, which is regulated by voltage or hormone 
regulation on the muscle cell membrane and by contractor-mediated extracellular calcium 
influx. OT increases the production of inositol 1,4,5-triphosphate, and the mobilization 
of 5-trisphosphate inositol stores intracellular calcium release in the endoplasmic 
reticulum and sarcoplasmic reticulum. In addition, OT causes cells to produce inward 
currents through receptor-activated, non-selective cation channels that depolarize cell 
membranes, producing action potentials and muscle contractions. A recent study showed 
that OT synthesized in the brain and secreted into the circulation binds to receptor for 
advanced glycation end-products (RAGE) molecules on capillary endothelial cells, a 
component of the blood brain barrier (BBB), and is thus transported across the blood 
brain barrier. By being transported into the brain, OT can there exert central nervous 
functions [34]. Prostaglandins are mediators of OT actions, such as during excitation of 
neurons in the supraoptic nuclei, where they are released in response to OXTR agonists 




Figure 1.5. Intracellular Oxytocin signalling pathway. PLC: phospholipase C, RhoA: Ras 
homolog family member A, MLC: megalencephalic leukoencephalopathy with subcortical cysts, 
PKC: Protein kinase C, DAG: dystrophin-associated glycoprotein, PIP2: Phosphatidylinositol 4, 
5-biphosphate, cPLA2: calcium-dependent phospholipase A2. (Modified from [35]) 
 
It should be emphasized that the intake of a sufficient amount of energy does not appear 
to be the main or the necessary factor that induces OT neuronal activity underlying 
termination of ingestive behaviour. In fact, OT neuronal activity and release coinciding 
with termination of feeding occur upon changes in calorie-independent parameters 
associated with consumption. Those parameters include excessive stomach distension and 
elevated plasma osmolality [36-38]. In addition, central OT inhibits consumption of 
toxin-tainted foods and supports long-term avoidance of those by acting through not only 
the brain stem but also the amygdala [39; 40]. 
It has been speculated that, under basic physiological conditions, activation of the OT 
system by orexigenic factors, serves as the feedback mechanism that does not allow 
dangerously excessive food intake to occur [2]. Activity of the OT system is elicited by 
administration of anorexigenic peptides and it reflects a general increase in activation of 
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circuitry that mediates satiation. However, an elevated response of OT cells has been 
shown also upon injection of powerful orexigens, such as NPY and ghrelin, in both males 
and females [41]. 
A powerful bioinformatics study, derived from a review of over 1800 PubMed articles, 
has recently characterized the entire array of OT signalling pathways (Figure 1.8.) [42]. 
Findings showed that OXTR stimulation is primarily mediated through Gαi/Gαq/Gαo 
protein activation. OT induces pro-inflammatory cytokine overexpression through 
mitogen-activated protein kinase (MAPK)/Nuclear factor kappa B (NFκB) pathway, 
which in turn is associated with onset of labour [43]. Prostaglandins (PGE2 and PGF2 
alpha) production through arachidonic acid cleavage is one of the effective mediators in 
OT-induced processes especially to those related to onset of labour [44; 45]. OT also 
triggers osteoclastogenesis and osteoblast differentiation through MAPK1/3 activation 
and, thus, it may play a significant role as a therapeutic agent in osteoporosis [46]. It also 
affects functions associated with the CNS such as regulation of nociception, which is 
mediated by activation of potassium ion channel (KCJN11) [47], and anxiolytic effects 
mediated through expression of regulator of G-protein signalling 2 (RGS2) [48]. In the 
heart, OT elicits cardioprotective function by reducing infarct size and postischemic 
recovery, and this recovery is mediated through PI3K-AKT/ NOS/natriuretic peptide A 






Figure 1.6. A schematic representation of intracellular reactions induced by oxytocin. The 
pathway map depicts reactions induced by stimulatory action of OXT through OXTR. Reactions 
represented in map are protein-protein interaction, post-translational modification, 
activation/inhibition and gene/ protein expression. Sites and residues for post-translational 
modifications are also shown. Legend is provided for identification of different pathway reactions. 
From [42] 
 
OT affects peripheral tissues directly by binding its G protein-coupled receptor localized 
in, to name a few, the mammary gland, ovary, uterus and bone [50; 51]. 
At the genetic level, deletion of the gene encoding OT or OT receptor in mice indeed 
sheds more light on feeding-related mechanisms regulated by the OT system. Nishimori 
et al. raised mice deficient in the OT receptor gene and found that despite similar food 
intake as seen in wild-type controls, the KO animals started developing obesity in week 
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12 after birth [52]. They had a much higher mass of both white and brown fat. The 
impairment of the adrenergic receptor system in these animals may also contribute to the 
elevated adipose tissue weight. Takayanagi et al. provided further characterization of the 
OT receptor −/− obese phenotype [53]. They reported an increase in the mass of 
abdominal fat pads and elevated triglycerides in the blood in the KO strain. This high 
adiposity was not associated with an altered feeding or locomotor activity profiles, though 
thermogenesis was impaired in these mice [2]. 
Data pertaining to obesity in OT-deficient mice are somewhat conflicting with some 
authors reporting no body weight differences between KO and wild-type animals, 
whereas others have shown an increase in adiposity whose onset occurs as late as at 4–6 
months of age. Camerino found that OT KO mice develop hyperleptinemia, a decreased 
insulin sensitivity and glucose intolerance as well as lower adrenaline levels [54], which 
led to the hypothesis that the metabolic changes accompanying OT deficiency stem from 
a decreased sympathetic nervous tone. They exhibit altered macronutrient preference 
profiles and eating patterns. For example, OT KO mice display enhanced preference for 
carbohydrates, particularly sweet ones [55]. In line with the KO data, recent real-time 
PCR studies in wild-type rats showed the effect of scheduled volume-unrestricted 
consumption of high-sugar versus regular diet on OT gene expression levels in the 
hypothalamus [56].  
1.5 Distribution in periphery and brain:  
1.5.1 OT neurons 
OT is a nonapeptide hormone produced primarily by the magnocellular neurons of the 
supraoptic and paraventricular nuclei of the hypothalamus. After synthesis as an inactive 
precursor, it is conveyed axonally to the posterior pituitary where it can be released into 
peripheral tissue [10]. The PVN also contains smaller parvocellular OT neurons. Forty 
percent of these terminate in the pituitary, whereas the rest send axons throughout the 
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brain [10; 57; 58]. The topography of this central innervation parallels OT’s involvement 
in food intake [59; 60]. The PVN OT fibres innervate central targets, most prominently, 
the dorsal vagal complex in the brain stem [61; 62]. The brainstem dorsal vagal complex 
(DVC) is the first site for integration of visceral synaptic and hormonal cues that act to 
inhibit food intake [63]. The DVC consists of three nuclei: the nucleus of the solitary tract 
(NTS), the dorsal motor nucleus of the vagus (DMNV) and the area postrema (AP). The 
NTS serves as a ”relay” station for a number of peripheral signals, including those related 
to gut functioning; the DMNV is part of the efferent and afferent vagal innervation of the 
stomach; and, finally, the AP mediates gastric responses triggered by high osmolality or 
presence of toxins in the blood [59; 61]. Neurons of the sensory branch of the vagus nerve 
make glutamatergic synapses onto NTS neurons to relay information from the periphery, 
including the stomach and upper intestine [64; 65]. Targeted chemogenetic activation of 
appetite‐responsive NTS neuronal populations causes short term decreases in food 
intake [66-69]. Importantly, the OT-brainstem innervation is reciprocal, i.e., brainstem 
neurons terminate in the proximity of OT perikarya in the hypothalamus and OT terminals 
are found in the hindbrain, such as in the case of a powerful anorexigen, glucagon-like 
peptide-1 (GLP-1) [70]. However, OT terminals as well as the OT-receptor detected with 
in situ hybridization or autoradiography, are also present outside this basic brainstem-
hypothalamus pathway [71].  
1.5.2 OT receptor 
The distribution of the OT receptor (OXTR) mRNA across the brain provides a proxy for 
the distribution of OT binding [72], allowing for a detailed mapping of the anatomical 
geography of the OT system in the brain. Seminal animal work using histochemistry and 
immunohistochemistry revealed high concentrations of OXTR mRNA in the 
hypothalamus, amygdala, olfactory bulb, ventral pallidum, and the dorsal vagal nucleus 
in rodents [25; 73]. Further, experimentally increasing [74] or decreasing [75] OXTR 
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expression in the prairie vole nucleus accumbens modulated partner preference behaviour, 
suggesting a correspondence between the spatial distribution of OXTR mRNA, its 
functional neuroanatomy, and behavioural relevance [13]. In addition, OT fibres 
terminate at OT perikarya expressing OT receptors, which suggests a positive feedback 
loop as the OT receptor has excitatory properties [76]. This auto-amplification of OT 
release plays a role in lactation [77; 78], but it has not been examined in association with 
other processes [2]. A schematic representation of the OT system in the brain in relation 
to feeding is presented in Figure 1.9. 
 
Figure 1.7. Topography of central OT pathways involved in food intake regulation with 
special emphasis on functional significance of the circuits. OT neurons project from 
parvocellular PVN neurons in the hypothalamus to brainstem sites known to regulate feeding 
(NTS, AP, DMNV) and to the pituitary, where OT is released to the general circulation. While 
the brainstem-hypothalamus pathways have been extensively studied in relation to OT’s 
involvement in anorexigenic responses stemming from peripheral parameters, such as GI tract 
distension, osmolality of the blood, etc., many other feeding-related sites that contain OT 
terminals or OT receptors have not been comprehensively evaluated in relation to anorexigenic 
action of OT. These include areas involved in reward (ventral tegmental area, VTA; nucleus 
accumbens, NAc; bed nucleus of the stria terminalis, BST), affect (dorsal raphe nucleus, DR), 
energy homeostasis (ventromedial hypothalamic nucleus, VMH) and stress (amygdala, Amy; and 




1.6 Feeding-unrelated roles of the OT peptide system 
While OT maintains homeostasis, these homeostatic signals must rapidly change as 
demand increases, especially during pregnancy, and this may occur by altered 
responsiveness of the OT system. Such altered sensitivity of the homeostatic system may 
also occur from overstimulation of opioid receptors responsible for hedonic signalling. 
OT is known to control parturition and maternal behaviour. It is released after dilation of 
the cervix during labour; and in lactating animals, it stimulates milk ejection [83; 84].  
Data from human and laboratory animal studies link OT receptor activation/availability 
with modifications in non-feeding rewards (from natural rewards, such as social and 
reproductive behaviours to administration of drugs of abuse). For example, Jarrett and 
colleagues found that cocaine treatment changes OT receptor binding density in the bed 
nucleus of the stria terminalis in female rats [87]. Baracz et al. reported that direct 
intraparenchymal administration of OT in the core of the nucleus accumbens dose-
dependently decreases methamphetamine-seeking behaviour [88]. The same group of 
investigators found also that intra-accumbens core OT attenuates methamphetamine-
induced conditioned place preference in rats [89]. In another set of experiments 
employing OT receptor ligand injections in the nucleus accumbens and lentiviral-
mediated overexpression of the OT receptor in this site, Bahi showed that OT attenuates 
the development, maintenance, and primed reinstatement of ethanol-induced conditioned 
place preference [90]. Intracranial infusions of OT in female mice promote the 
development of a conditioned social preference [40; 91]. 
Damiano et al. showed by using functional magnetic resonance imaging (fMRI) that 
certain single nucleotide polymorphisms in the OT receptor gene are associated with a 
differential response of the mesolimbic system during anticipation of monetary rewards 
in healthy human subjects [92]. Furthermore, neurochemical studies have pointed to a 
relationship between OT and dopamine in modification of perceived rewards. In one such 
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study in mice, central administration of OT has been found to reduce methamphetamine-
elicited dopamine release in the striatum and nucleus accumbens [93] and promote a 
concomitant decrease in glutamate release and increase in extracellular presence of γ-
aminobutyric acid (GABA) in the medial prefrontal cortex [40; 94]. 
Research on humans has further shown beneficial effects of intranasal OT on performance 
on tests assessing social cognition [95] and gaze to the eye region [13; 96]. Importantly, 
one of the most fundamental roles of OT is promoting various facets of social behaviour. 
OT has prosocial effects and is essential for initiating social interactions in rats [97]. It 
plays a key role in parent–infant bonding in rats, prairie voles, sheep, and primates 
including humans [98-100], and it reduces the occurrence of maternal neglect [101]. 
Pharmacological manipulations of the OT system alter partner-directed activities during 
pair interactions in marmosets [102]. In same-sex meadow voles, OT injection enhanced 
non-reproductive affiliative preferences beyond baseline levels, and this effect was 
counteracted by blockade of the OT receptor [103]. OT facilitates altruistic behaviours, 
such as sharing resources to benefit others. OT in humans increases cooperation directed 
toward in-group functions, defending and strengthening the in-group by modulating 
parochial altruism, and increasing in-group trust (e.g. expectation of self-sacrifice to 
promote group welfare)[104]. OT promotes generosity: OT-treated subjects are more 
inclined to help a stranger by splitting a set amount of money more generously [105] and 
they donate more to charity [106]. Empathy toward strangers is associated with OT 
release and it leads to subsequent acts of generosity [107]. Finally, intranasal OT increases 
the ease of imagining compassionate qualities [108]. 
The complexity of interactions between an animal and its social environment depends on 
many factors, such as a species, sex, (patho)physiological status, availability of resources, 
stressors as well as hierarchy within a group [109]. This is governed by a host of 
neuroregulators, including OT, which aside from controlling social behaviours, acts as an 
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anorexigen. Interestingly, Olszewski et al. showed that dominant mice consuming sugar 
have a significantly higher level of OT mRNA in hypothalami than their subordinate 
conspecifics. Thus, it is not just the pharmacological treatment with the OT ligand that 
differentially affects sugar consumption in dominant versus subordinate animals, but also 
the endogenous OT system is affected differently by sugar consumption in animals 
subjected to in-group hierarchy [110]. 
This relation between social interactions and feeding may stem from the fact that some 
forms of social interaction include an anxiogenic component, which is further exacerbated 
by the challenge of food availability, palatability and preference [110]. In this context, it 
is particularly crucial that OT exerts anxiolytic effects [111]. A number of studies 
examining the link between a social status and feeding/energy metabolism have suggested 
that social environment-driven modifications in animals' anxiety profile affect appetite, 
metabolism and endocrine parameters in seemingly related experimental paradigms. For 
example, subordinate mice given a cafeteria diet and subjected to several days of sensory 
contact increased their body weight and shifted their preference towards fatty foods, 
whereas dominant mice increased their carbohydrate intake [112]. It should also be noted 
that OT promotes “altruistic” behaviours whose occurrence benefits only one’s own 
social group [113]. Olszewski et al. surmises that the interaction might partially stem from 
the OT's presumed effect on the propensity to share resources (food), and in the dominant-
submissive stable dyads, the dominant animal exhibits greater sensitivity to the OT 
receptor blockade [110]. 
While OT has been known to increase prosocial behaviours, recently it has also been 
linked to tribal behaviours and aggression [114]. This finding may reinforce the “social 
salience” hypothesis. This is the idea that what OT really does, is make us more aware of 
social cues. Therefore, one may notice more social signals when the drug is in its system 
than when it is not. Further studies using connectivity/imaging data showing both activity 
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in the salience network, and heightened pattern recognition would solidify this hypothesis, 
and might help elucidate if this effect begins in the thalamus, or is perhaps the result of a 
more top down filtering from the medial prefrontal cortex. These findings may reinforce 
the idea that OT strengthens in-group bonds, and exacerbates division toward out-groups. 
This could serve the purpose of maintaining tribes, or small in-groups, at the exclusion of 
others in an effort to retain resources. 
An interesting note about OT is that this molecule has also been proposed to participate 
in the regulation of learning and memory performance, and its concentration may increase 
during flow states, or optimum performance cognitive states[115]. This state of peak 
performance results in reduction in self-referential thinking and amplified focus, that can 
increase task performance, and may involve a component of OT release. If this is indeed 
the case, OT’s social effects may fit better with the social salience hypothesis than simply 
the love/trust hypothesis [114]. In line with this, a 2020 study proposes that OT could 
help to treat cognitive disorders, including Alzheimer’s disease. Researchers 
demonstrated that OT reversed the effects of amyloid-beta on hippocampal long-term 
potentiation (LTP) in mice. These effects were blocked by pre-treatment with the 
selective OT receptor antagonist L-368,899. Furthermore, the treatment with the 
extracellular signal-regulated kinase (ERK) inhibitor U0126 and selective Ca2+-
permeable AMPA receptor antagonist NASPM completely antagonized the effects of OT. 
The findings suggest OT could be used as a therapeutic for the treatment of Alzheimer’s 
disease and other dementias, and that ERK phosphorylation and Ca2+-permeable AMPA 
receptors are involved in this effect of OT [116]. 
Cardiac activity of OT involves maintenance of blood pressure, increased angiogenesis 
and anti-inflammatory activity [117]. Further, OT has a significant role in bone 
development and is implicated in skeletal remodelling and osteoblast maturation [118]. 
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In addition to this, it is involved in the pathophysiology of various disorders such as 
diabetes, osteoporosis and neuropsychiatric disorders [119; 120]. 
1.7 Involvement of OT in regulation of consumption 
By the start of the 1980’s, several research groups showed that lesioning of the PVN and 
disruption of the PVN-hindbrain pathways resulted in hyperphagia and significant body 
weight gain in rats [121-123]. Lesions that extended beyond the PVN did not generate a 
greater effect on ingestive behaviour or obese phenotype [124]. Knife cuts leading to the 
disruption of the PVN-hindbrain pathways were shown to be crucial in the development 
of hyperphagia and obesity [81; 125]. The search was then undertaken for neuropeptides 
derived from the PVN whose lack precipitated this effect. Release of OT and increased 
activity of OT neurons was shown to coincide with satiation-associated termination of 
feeding in laboratory animals [50]. Injection studies provided preliminary evidence 
linking OT with feeding termination. Arletti et al. were first to report that 
intracerebroventricular (ICV) injection of OT causes a marked reduction in deprivation-
induced food intake in rats [126]. Many authors have confirmed the finding and, by using 
intraparenchymal OT receptor ligand injections or employing OT receptor-specific 
cytotoxins, have identified the hindbrain (particularly the dorsal vagal complex) as the 
area through which OT-driven feeding inhibitory mechanisms are executed [40; 127]. 
Importantly, hyperphagia and obesity occur in mutations that lead to insufficiencies in 
OT PVN neuronal population development, such as that observed in the single-minded-
1 (SIM-1) mouse model, and these negative symptoms can be reversed by OT treatment 
[128]. ICV injections of OT and OT receptor agonists dose-dependently suppressed chow 
intake in male and female rats stimulated to eat by scheduled feeding or by food 
deprivation [50; 129; 130]. This effect was reversible by administration of OT receptor 
antagonists, although OT receptor antagonism by itself did not increase energy intake 
[50]. Peripheral administration of only high doses of OT generated hypophagia, which 
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strongly suggested that central OT affects feeding [129; 130]. Interestingly, OT 
homologue injection experiments in several other species have shown that this feeding 
inhibitory function seems to be as well conserved as the OT molecule itself. For example, 
ICV infusions of OT in birds caused a dose-dependent decrease in feed intake, feeding 
time and pecking frequency [131]. The observed hypophagic outcome of central 
treatment with OT agents produced little explanation as to what mechanisms underlie this 
effect. Subsequent studies that focused on defining the physiological basis of OT's effect 
on feeding generated substantial evidence indicating that OT acts as a “homeostatic” 
inhibitor of ingestive behaviour. The OT system is also involved in gastric motility. As it 
responds to significant stomach distention, to elevated plasma osmolality that 
accompanies food intake, blocks consumption of toxic tastants, and promotes avoidance 
of such tastants upon subsequent presentations, it was concluded that OT prevents the 
animal from maintaining consumption that could potentially jeopardize the internal 
milieu (Figure 1.10) [132]. 
 
Figure 1.8. A schematic representation of functional relationship between OT neuronal 
activity/release and feeding-related behaviours, processes and physiological conditions. 
Modified from [2] 
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In individually housed rodents, injections of OT receptor antagonists elevate consumption 
of carbohydrates [133-135], OT preferentially decreases appetite for sugar [134], and 
consumption of high-sugar diets modifies OT gene expression [135].  
1.7.1 Osmolality 
Increases in plasma osmolality signify dehydration, improper fluid homeostasis or 
ingestion of highly osmotic foods. Changes in the osmotic status activate OT neurons 
projecting within the CNS and to the pituitary. Hyperosmolality resulting from water 
deprivation induced expression of an immediate-early gene, c-Fos, in magnocellular OT 
neurons in the SON and PVN [136-138]. Van Tol reported that prolonged osmotic 
stimulation through long-term exposure to 2% NaCl instead of drinking water increased 
OT mRNA levels of OT-immunoreactive neurons in these sites [139]. Consequently, 
intraperitoneal (IP) injections of NaCl solutions as well as hypovolemia due to 
dehydration produced an elevated plasma OT profile [140]. Importantly, dehydration by 
itself suppresses food intake: mice deprived of both food and water ingested less chow 
during a 60-min re-feeding period than animals deprived of only food [141]. Conversely, 
administration of hypertonic NaCl inhibited food intake and stimulated concurrent OT 
release [141-143]. Puryear et al. found that in OT knockout (KO) mice, the hypophagic 
effect of water restriction was attenuated [144]. This group additionally showed that 
animals deficient in OT displayed an increased consumption of NaCl compared to wild-
type controls. Furthermore, genetic deletion of the OT receptor decreased salt appetite 
[144; 145]. It is noteworthy that stimulatory effects of intravenous (IV) infusions of NaCl 
on plasma OT levels were blunted in rats with lesions of the AP, which suggested that 
AP neurons facilitate OT responses to osmotic challenge. It should be noted, however, 
that once an IV infusion of 0.5 M NaCl was combined with that of 1 M mannitol in AP-
lesioned animals, plasma OT levels increased normally [59; 146]. Moreover, no effect of 
AP lesions on the increases of plasma OT levels after plasma volume deficits was 
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observed, indicating that the AP is important only for secretion of OT in response to 
hypernatremia [59]. Interestingly, some authors argued that the involvement of OT in the 
regulation of osmotic balance does not serve as a proof of this peptide's involvement in 
the control of consummatory behaviour, but rather links OT merely to an improper water 
balance. Nevertheless, it was later noted that the role of OT as an osmotic regulator in 
some species (e.g., in sheep) is taken over by VP; in these animals, OT retains its 
anorexigenic properties [147]. 
1.7.2 Taste Aversion 
OT has been proposed to inhibit food intake in order to prevent the organism from 
ingestion of toxic substances. This notion is supported by conditioned taste aversion 
(CTA) studies. In natural conditions, aversion develops upon ingestion of food that causes 
unpleasant gastrointestinal sensation (sickness, malaise and/or nausea) driven by toxicity. 
The set of behavioural responses follows and it includes termination of consummatory 
behaviour and subsequent avoidance of tastants of a similar flavour recognized as 
“tainted”. In the laboratory setting, a CTA, as an associative phenomenon, is generated in 
a paradigm in which presentation of a novel food is paired with an injection of a toxin 
[148-150]. Consumption of this tastant upon subsequent presentations is significantly 
reduced [2]. Central mechanisms responsible for the development and maintenance of 
aversion-based hypophagia are complex. The brainstem sites: the NTS, AP, DMNV and 
parabrachial nucleus (PBN), take part in the recognition and integration of peripheral 
aversive signals, including the presence of toxins in the circulation and changes in the 
gastrointestinal (GI) tract motility parameters. Among these sites, the AP seems to play a 
particularly crucial role as its lesions prevent animals from acquiring an aversive response. 
This was shown by Curtis et al. who reported that while sham-operated and non-operated 
control animals developed a CTA to the novel tastant whose initial presentation was 
paired with a single LiCl injection, animals with AP lesions failed to show any signs of 
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aversion [151]. In line with those findings, AP as well as the NTS and PBN display an 
increased Fos immunoreactivity following CTA inducing treatments, such as LiCl or 
copper sulfate injections [152]. This signifies the importance of not only the hypothalamic 
OT system, but also the relay sites that allow the OT neurons to act at central target sites 
and, in the case of aversion which involves also the pituitary OT release, at peripheral 
tissues. The CTA-dependent activity of OT neurons most likely diminishes a drive to 
consume a tastant associated with sickness and favours an abrupt inhibition of 
consumption that has already been undertaken. One should note however that there is a 
significant magnocellular (thus, pituitary/peripheral) component of the OT system's 
response to aversive stimulation. Since peripheral OT generally does not inhibit 
consummatory behaviour, the role of OT in the periphery in aversion is likely unrelated 
to consumption, but it may rather be associated with facilitation of mechanisms preparing 
peripheral tissues and organs for consequences of toxicity. In fact, involvement of 
circulating OT in cardiovascular or natriuretic responses supports this hypothesis [153-
157]. OT signalling is observed regardless of the nature of agents that induces sickness; 
those include chemicals, such as LiCl or copper sulfate, as well as natural or synthetic 
ligands of central receptors, e.g., high doses of CCK and naloxone [152; 158; 159]. This 
indicates that OT is the final component of many pathways involved in the mediation of 
CTAs rather than being limited to treatment-selective mechanisms that activate a specific 
group of receptors and engage specific mechanisms. Although OT is thought to be the 
final component of neural circuitry supporting CTA responsiveness, it is not a sole or 
necessary one: OT administration has not been shown to elicit aversive consequences, 
whereas LiCl-treated animals, incapable of developing CTAs due to the AP lesion, still 
display a surge in OT release [151]. It seems particularly interesting however that, while 
intraperitoneal LiCl given in rats with AP lesions does not induce a CTA, it produces 
anorexia accompanied by increased OT levels [151]. Therefore, OT may play an auxiliary 
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role in the CTA process, being one of the factors ensuring inhibition of consummatory 
behaviour [2]. 
One should note that agents that mediate satiation (such as the aforementioned CCK and 
naloxone), within a certain range of doses, terminate feeding without aversive 
consequences. However, once injected at higher doses, they precipitate a CTA. This 
brings about an interesting hypothesis that perhaps extremely robust, uncontrollable 
eating that could potentially disturb homeostasis has such a profound effect on feeding-
related peptide plasma and central profiles that it is eventually curbed by activated 
aversive feeding termination mechanisms that encompass OT neurons [2]. This could 
explain temporary avoidance of foods that had been greatly overconsumed during a single 
meal. Aversion-like eating restrictive behaviours have been observed in humans who 
interspace binge eating episodes with periods of avoidance of diets that were part of a 
binging event [160; 161]. 
A reduction in the number of OT neurons has been reported for Prader–Willi syndrome 
patients exhibiting extreme overeating [162], which may lead to the hypothesis that 
administration of OT, paired with the inhibition of reward pathways, may mitigate such 
behaviours. Notably, the ventromedial hypothalamic (VMH) nucleus has been identified 
as a hypothalamic site through which OT causes early meal termination in free feeding 
and fasted rats [163]. In addition, central OT inhibits consumption of toxin-tainted foods 
and supports long-term avoidance of those by acting through not only the brain stem but 
also the amygdala[39], implying that OT receptor antagonism blunts responsiveness of 
the amygdala to aversive foods.  
According to histological analyses, sites that integrate OT signalling include components 
of the reward network that mediate the portion of feeding driven by pleasure (e.g., the 
ventral tegmental area, nucleus accumbens and bed nucleus of the stria terminalis), areas 
that alter food intake under stressful conditions (e.g. the amygdala) as well as those that 
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modify affective functions and can consequently change various aspects of eating 
behaviour (the dorsal raphe nucleus) [73; 164; 165].  
 
1.8 OT and reward 
OT mRNA has been shown to be highly expressed in human paraventricular nucleus of 
the hypothalamus, the lateral hypothalamic area, and the supraoptic nucleus, and there is 
evidence of co-expression with OXTR mRNA and the μ and κ types opioid receptor 
mRNA [166], providing a putative avenue for interactions between the OT and opioid 
pathways [13].  
Quintana et al. showed that expression of three selected OT pathway genes was enriched 
in subcortical and olfactory regions and there was high co-expression with several 
dopaminergic and muscarinic acetylcholine genes, reflecting an anatomical basis for 
critical gene pathway interactions. fMRI meta-analysis revealed that the OT pathway 
gene maps correspond with the processing of anticipatory, appetitive, and aversive 
cognitive states. The OT signalling system may therefore interact with dopaminergic and 
muscarinic acetylcholine signalling to modulate cognitive state processes involved in 
complex human behaviours [13]. 
 
1.9 Beyond oxytocin & homeostasis 
An interesting issue arises regarding what other neural factors mediating sugar reward 
might act to diminish the activity of the OT system, either directly (via synaptic 
connectivity) or indirectly (as part of a larger network). Opioids are likely candidates for 
this interaction. Opioid receptor agonists are particularly effective at inducing intake of 
palatable foods, including those high in sugar; conversely, antagonists block reward-
driven consumption. Regular exposure to high sucrose foods evokes changes in 
expression of genes coding opioid peptides and receptors [172]. Interestingly, opioids do 
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not seem just to stimulate feeding, but they have been suggested to maintain 
consummatory behaviour by inhibiting activity of neural systems associated with 
termination of feeding, such as via OT. Preliminary studies have suggested that activation 
of OT neurons at the end of a meal may be particularly vulnerable to modification by 
opioids. Administration of a wide-spectrum opioid receptor agonist, butorphanol tartrate, 
inhibits activity of PVN OT cells upon feeding termination; this effect is particularly 
pronounced when a high-sugar diet is given [167]. NTX is a commonly used opioid-
receptor antagonist, and has been shown to reduce food intake, especially of palatable 
foods [168]. Opioids mediate rewarding aspects of consumption also in schedule-fed rats. 
Elevated intake of high-sugar foods during scheduled meals is associated with 
upregulation of genes encoding for orexin and OT in the hypothalamus and NPY in the 
brainstem [56]. 
Release of the anorexigenic neuropeptide OT is linked with satiation and has been 
associated with the end of a meal. It has been reported that OT plasma levels rise at 
feeding termination and elevated activity of OT neurons occurs at that time [169]. The 
activity of OT neurons can be determined immunohistochemically based on the level of 
colocalization of an immediate-early gene transcription factor, c-Fos, that indicates 
neuronal activity in OT neurons. Moreover, administration of OT directly in the brain 
dose-dependently decreases food intake in free-feeding rats, as well as in schedule-fed 
food-deprived rats [129]. Injections of agents that induce early satiety, such as alpha-
melanocyte stimulating hormone and glucagon-like peptide-1 activate OT neuronal firing 
[170]. Finally, stimulation of OT neurons has been linked with ingestion of substances 
that jeopardize homeostasis, including toxins and ions [169]. Under such conditions, OT 
seems to serve as a signalling molecule that precipitates an immediate termination of 
ingestive behaviour in order to minimize the consumption of tainted food. 
Overconsumption of preferred tastants is thought to be strongly dependent on the activity 
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of the reward system; opioid peptides and receptors constitute one of its main components. 
For example, studies have shown that blocking of opioid receptors with selective (binding 
preferentially to opioid receptors of a certain subtype) and non-selective antagonists, such 
as naloxone or NTX; leads to decreased intake of a high-sucrose diet [171], and that 
opioid receptor agonists are particularly effective at increasing consumption of preferred 
foods. Prolonged intake of palatable foods leads to changes in mRNA levels of genes 
encoding components of the opioid system in several feeding-related brain sites [172]. 
One of the most puzzling questions is how palatability can possibly be capable of leading 
to significant food overconsumption that goes beyond energy needs, that subjects the 
organism to dangerously high levels of ions in the blood or food volume in the stomach. 
In fact, it has been conceptualized that the release of opioids occurring at the time of 
anticipated or actual consumption of palatable food causes inhibition of central pathways 
that mediate satiety. It has been suggested that endogenous opioids target, among others, 
the anorexigenic OT system. Antagonism of opioid receptors leads to an increase in 
activation of OT neurons in the paraventricular nucleus of the hypothalamus (PVN) [56], 
the site hosting the largest population of these cells in the brain and known for its role in 
feeding control [172]. Previous experiments have shown that rats injected with an opioid 
receptor agonist had significantly lower OT neuronal activity at the end of a tasty meal 
than control animals did [173]. Aside from the PVN, opioid receptors are present in nearly 
all of the central sites that are related to food intake regulation. They have been found in 
sites that are mainly associated with reward, such as the nucleus accumbens (NAcc), 
ventral tegmental area (VTA), bed nucleus of the stria terminalis (BST) and caudate 
putamen (CP), as well as in the hypothalamic arcuate nucleus and brainstem nucleus of 




1.10 Reward system: Principles of central processing of consumption 
driven by palatability 
Feeding behaviour is controlled by a complex set of interconnected brain circuits that 
control different aspects of this behaviour, including hedonic or “reward” based feeding. 
Feeding evolved to initiate in response to hunger (which corresponds to the conscious 
perception of an energy deficit) and to stop once satiated, even if food remains available. 
This behaviour is commonly described as homeostatic intake and is controlled by a brain 
circuit with prominent roles of several hypothalamic subdivisions (arcuate (ARC) and 
paraventricular nucleus of the hypothalamus (PVN), dorsomedial nucleus of the 
hypothalamus (DMH)) and the nucleus of the solitary tract (NTS).  The function of these 
brain nuclei is to integrate information about the nutritional status and energy state of the 
organism to initiate or stop feeding behaviour [175]. The nuclei controlling homoeostatic 
intake relay information to the reward circuit, which is necessary for the assignment of 
incentive salience to the food and environmental cues that are present during food seeking 
and intake [176; 177].  
Feeding reward can be understood as two different processes, which have different 
neurobiological underpinnings involving several brain circuits and neurotransmitters. 
One brain circuit regulates liking (the hedonic response to food intake) and another 
regulates wanting (the motivation to seek and obtain food) [178]. In rodents, liking is 
measured through analysis of facial expressions in response to food exposure and wanting 
is operationalized as the amount of work an individual is willing to perform to obtain food 
[179]. The regulation of liking involves several brain sites located both in the midbrain 
and cortical areas, and in these circuits there is a prominent function of opioid and orexin 
peptides [180]. The neural circuit that regulates wanting is built around the mesolimbic 
dopaminergic (DA) system, in which DA neurons located in the ventral tegmental area 
(VTA) project to different forebrain regions, including the nucleus accumbens (NAcc) 
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and the prefrontal cortex (PFC) [181]. The separation between liking and wanting in the 
context of food intake is well reflected in classic experiments showing that elimination of 
VTA dopaminergic neurons does not alter facial expressions in response to intake of a 
sucrose solution [182], and that hyper-dopaminergic mice have higher motivation to 
obtain a chocolate pellet without altering facial responses to sucrose [183].  
The neurobiological regulation of liking is a distributed process over several brain regions 
[179]. Despite the definition of liking as the hedonic consequences of food intake, it is 
important to notice that liking does not describe the sensory experience associated to food 
intake and thus sensory brain regions are not considered part of the neurobiological 
substrate of liking [179].  The distributed processing of liking is reflected in evidence 
indicating the presence of brain regions called hedonic “hot-spots” or “cold-spots”, in 
which activation of opioid (mu and delta) or orexin neuropeptides receptors has a large 
positive or negative influence in liking, respectively [178]. Hedonic hot-spots have been 
identified in the NAcc, ventral pallidum (VP), medial orbitofrontal cortex (OFC) while 
cold-spots have been observed in the posterior OFC and the insula [180]. In addition to 
opioid peptides, endocannabinoids can also increase liking for sucrose by their actions in 
the NAcc [184]. Thus, neuronal regulation of liking involves endocannabinoids, opioid 
and orexin peptides acting in a distributed brain network. 
The neuronal control of “wanting” also involves different brain regions, but with a central 
role of the mesolimbic dopaminergic circuit [176]. The specific role of DA release in 
response to food intake is debated, but there is now a larger consensus that activation of 
dopaminergic VTA neurons is key for the attribution of incentive salience to food and 
environmental cues that occur during eating [181]. For example, activation of 
dopaminergic VTA neurons during intake is sufficient to change choice from a sweet 
sucralose solution to water [185]. Activation of the dopaminergic VTA neurons leads to 
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dopamine release in several brain regions, including NAcc, PFC and dorsal striatum in an 
experience and context-dependent manner [186]. Intake of palatable food increases DA 
concentration in NAcc, which is related to flavour and not caloric food content [187] but 
this effect decreases over repeated exposure [188]. In the context of operant or Pavlovian 
conditioning, the release of DA shifts from the act of intake to the act or cue that predicts 
reward, suggesting the ability of dopamine to predict reward-delivery and serve as an 
error-signal [189; 190]. This dopaminergic circuit does not operate independently and is 
regulated by input from several brain areas. For example, DA action in the NAcc is 
modulated by excitatory input from the basolateral amygdala [191] and activity of 
dopaminergic VTA neurons is regulated by excitatory and inhibitory input from the 
lateral hypothalamus (LH) [192], including orexin neurons targeting the VTA [193]. The 
mesolimbic dopaminergic circuit is also regulated by endocannabinoids, as activation of 
the CB1 receptor in the NAcc increases food intake and regulates synaptic plasticity in 
VTA, NAcc and PFC neurons with the overall effect of increasing activity in this brain 
circuit [194]. Thus, neuronal regulation of wanting is organised around the mesolimbic 
DA system, which is modulated by input from several brain regions. These pathways 
work in conjunction with homeostatic signalling pathways such as via OT, sending 
information from the periphery regarding an animal’s physiological status, and can in this 
way modify sensitivity to homeostatic and hedonic pressures for consumption. These 
networks collectively comprise the structures regulating both the homeostatic and 





Figure 1.9. Schematic representation of main brain structures implicated in hedonic and 
homeostatic food intake regulation. Main dopaminergic pathways, mesolimbic and 
mesocortical pathway, are represented with red lines, and other minor dopaminergic connections 
with broken red lines. Endogenous opioids peptides modulate the dopaminergic pathways through 
opioid receptors (µ, κ, δ). Hedonic pathways: PFC, prefrontal cortex; NAc, nucleus accumbens; 
VTA, ventral tegmentum area; LH, lateral hypothalamus; Amy, Amygdala; Hipp, Hippocampus; 
SN, substantia nigra. Homeostatic pathways: Arc, arcuate nucleus; MCH, melanin concentrating-
hormone [From Novelle et al., 2018 [195]]. 
Overall, feeding reward is regulated by distinct brain circuits that control the behaviours 
of “liking” and “wanting” food, which act together to integrate the hedonic response to 
food and the motivation to seek and obtain foods. These brain circuits operate in the 
context of a larger brain network that controls higher order contributions to food intake 
(i.e. learning, cue-induced feeding, food choice, preference) [196].  
Interestingly, a 2020 study by the Chinese Academy of Sciences proposes that they have 
been successful in preventing relapse of addiction by interrupting the brain pathways 
responsible for morphine-associated memories in mice, “erasing” the drug-associated 
memory and stopping relapse of addiction. Optogenetic stimulation of the PVT was able 
to block relapse. Keyes et al. describes how the paraventricular nucleus of the thalamus 
(PVT) orchestrates the acquisition and maintenance of opiate-associated memories via 
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projections to the central nucleus of the amygdala (CeA) and nucleus accumbens (NAc). 
PVT→CeA activity associates morphine reward to the environment, whereas using 
optogenetic transient inhibition of the PVT→NAc pathway during retrieval causes 
enduring protection against opiate-primed relapse. They revealed distributed network 
activities that are altered in non-relapsing mice, which guided them to find that activating 





1.11 Specific aims  
Feeding behaviour is therefore determined by a variety of intrinsic and extrinsic factors, 
though the ones that appear to be in the forefront of shaping the consummatory response 
involve: a feeling of hunger (which determines the motivation to seek calories and food 
choices), satiation (which underpins the process of termination of ingestive behaviour), 
and reward processing (which can to a large extent shift the hunger-satiety continuum, 
adjusting consumption to the 'pleasantness' of  food instead of to the actual energy needs 
of the organism). In our search for neuroactive agents to curb excessive food consumption, 
those that affect more than one facet of feeding control are of particular interest, as they 
target a broader range of appetite regulating processes.  
After more than a century of search for pharmacological treatments that combat obesity, 
our choice of FDA-approved pharmaceuticals is currently limited to five. Two of those 
drugs, Qsymia (phentermine + topiramate) and Contrave (bupropion + NTX), are 
combination medicines: this fact reflects the need to simultaneously target many neural 
and neuroendocrine systems in order to increase the likelihood of effectively treating this 
multifactorial condition.  
The combination medicine approach served as the basis of the recent case report in which 
hypophagic properties of OT, a molecule being subject of several clinical trials related to 
disordered appetite and obesity, were successfully augmented by co-administration of 
NTX in a patient with hypothalamic obesity caused by craniopharyngioma resection [1].  
The recent years have brought a tremendous interest in anorexigenic properties of OT. 
OT has been shown beyond reasonable doubt to promote satiation and early termination 
of food intake. Though OT also decreases feeding for palatability, its effectiveness is 
limited as it is vastly mitigated by the flavour and composition of tastants and by the 
context (e.g., social environment, novelty) in which palatable foods are offered. Thus far, 
there has been no direct evidence suggesting a link between OT and the third facet of 
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appetite control: a feeling of hunger (in other words, whether OT can delay a drive to 
search for energy). In fact, molecules that produce early satiation or affect eating for 
pleasure do not necessarily alter a self-perceived level of hunger. Though it seems 
unlikely, however, one has to consider that OT has been found to slightly increase latency 
to begin a meal, and thus a possible role of OT in hunger control certainly needs to be 
addressed.  
Therefore, in the first experimental aim of my thesis, I used a unique hunger 
discrimination paradigm, in which rats were trained to generate an operant response 
indicating a hungry versus sated state, and I studied whether OT treatment makes them 
less likely to recognize being energy-deprived. This study was accompanied by the 
assessment of neuronal activation in response to the OT treatment in hungry versus non-
deprived animals and by the analysis of OXTR gene expression. I also looked into 
whether blockade of opioid receptors with a non-selective antagonist, NTX, a compound 
known to affect predominantly eating for reward, but not through the change in the 
energy-driven consumption, has a similar effect to OT in the hunger discrimination 
operant paradigm. 
The results of the first experimental aim of my thesis showed the lack of change in 
perceived hunger levels in animals treated by OT. This strengthens the notion of OT 
acting mainly as an early satiation signal, while being ineffective in reducing a feeling of 
hunger (as per the first aim) and partially ineffective in decreasing feeding reward (as 
shown in earlier studies). Considering the recent surge in experimental and clinical 
studies exploring usability of OT in managing food intake and body weight, the question 
arises whether OT, the molecule that affects primarily only one of the three key aspects 
of feeding behaviour (early satiation), is in fact sufficient as a lone pharmacological tool 
to control food intake, or it should be used in combination with another neuroactive 
molecule which targets a different facet of feeding control that the one affected by OT.  
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Since OT's effects on feeding reward are weakened by a variety of factors, I stipulated 
that effectiveness of OT on energy balance can be potentiated by using it in a combination 
therapy with a molecule that suppresses palatability-driven consumption. Opioid receptor 
antagonists, agents that based on the first experimental aim have no effect on hunger 
discrimination (similarly to OT), powerfully diminish feeding reward. Therefore, I 
examined the effectiveness of this combination therapy in the second and third 
experimental aims: 
In the second experimental aim, I determined whether adolescent rats injected with 
subthreshold doses of OT and a non-selective opioid receptor antagonist, NTX, show a 
more robust reduction in short-term meal responsiveness. It was studied in the context of 
diets that differ in palatability/energy density. I also examined differences in brain 
activation in feeding-related sites in response to the combination treatment. 
In the third experimental aim, I evaluated long-term feeding and body weight 
consequences of combined OT-NTX daily injections in adult rats. The effects of the 





Overarching goal: Investigate the effect of combining OT and NTX at subthreshold doses, 
on food intake driven by homeostatic pressures and palatability, and the corresponding 
neuromolecular changes. 
1. Determine the effect of OT and NTX on hunger discrimination (Chapter 2 & 3). 
2. Determine the acute effects of a combination of OT and NTX at subthreshold 
doses on food intake in adolescent rats, and the corresponding changes in 
neuronal activation (Chapter 4). 
3. Determine the chronic effects of a combination of OT and NTX at subthreshold 
doses on food intake and body weight in adult rats, and the corresponding 
changes in gene expression in feeding-related brain regions (Chapter 5). 
Specific Aim 1: Determine the effect of OT and NTX on hunger discrimination. 
I used a unique hunger discrimination paradigm, in which rats were trained to generate 
an operant response indicating a hungry versus sated state, and I studied whether OT 
treatment makes them less likely to recognize being energy-deprived. This study was 
accompanied by the assessment of neuronal activation in response to the OT treatment in 
hungry versus non-deprived animals and by the analysis of OXTR gene expression. I also 
looked into whether blockade of opioid receptors with a non-selective antagonist, NTX, 
a compound known to affect predominantly eating for reward, but not through the change 





Specific Aim 2: Determine the acute effects of a combination of OT and NTX at 
subthreshold doses on food intake in adolescent rats, and the corresponding changes in 
neuronal activation. 
I determined whether adolescent rats injected with subthreshold doses of OT and a non-
selective opioid receptor antagonist, NTX, show a more robust reduction in short-term 
meal responsiveness. It was studied in the context of diets that differ in palatability/energy 
density. I then utilised immunohistochemistry to examine differences in brain activation 
in feeding-related sites in response to the combination treatment. 
Specific Aim 3: Determine the chronic effects of a combination of OT and NTX at 
subthreshold doses on food intake and body weight in adult rats, and the corresponding 
changes in gene expression. 
I evaluated long-term feeding and body weight consequences of combined OT-NTX daily 
injections in adult rats. The effects of the treatment on expression of genes relevant to 
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Effect of oxytocin on perception of hunger 
 
2.1 Abstract 
Centrally and peripherally administered OT decreases food intake and activation of the 
endogenous OT systems, which is associated with termination of feeding. Evidence 
gathered thus far points to OT as a facilitator of early satiation, a peptide that reduces the 
need for a meal that has already begun. It is not known, however, whether OT can 
diminish a feeling of hunger, thereby decreasing a perceived need to seek calories. 
Therefore, in the current project, I first confirmed that intraperitoneal (i.p.) OT at 0.3–1 
mg/kg reduces food intake in deprived and non-deprived rats. I then used those OT doses 
in a unique hunger discrimination protocol. First, rats were trained to discriminate 
between 22- and 2-h food deprivation (hungry vs. sated state) in a two-lever operant 
procedure. After rats acquired the discrimination, they were food-restricted for 22 h and 
given i.p. OT before a generalization test session. OT did not decrease 22-h deprivation-
appropriate responding to match that following 2-h food deprivation, thus, it did not 
reduce the perceived level of hunger. In order to better understand the mechanisms behind 
this ineffectiveness of OT, I used c-Fos immunohistochemistry to determine whether i.p. 
OT activates a different subset of feeding-related brain sites under 22- vs. 2-h deprivation. 
I found that in sated animals, OT induces c-Fos changes in a broader network of 
hypothalamic and brain stem sites compared to those affected in the hungry state. Finally, 
by employing qPCR analysis, I asked whether food deprivation vs. sated state have an 
impact on OT receptor expression in the brain stem, a CNS “entry” region for peripheral 
OT. Fasted animals had significantly lower OT receptor mRNA levels than their ad 
libitum-fed counterparts. I conclude that OT does not diminish a feeling of hunger before 
a start of a meal. Instead, OT's anorexigenic properties are manifested once consumption 
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has already begun which is—at least to some extent—driven by changes in brain 
responsiveness to OT treatment in the hungry vs. fed state. OT should be viewed as a 
mediator of early satiation rather than as a molecule that diminishes perceived hunger. 
2.2 Introduction 
A nine amino acid neuropeptide OT, synthesized primarily in the hypothalamic 
paraventricular (PVN) and supraoptic (SON) nuclei, released throughout the CNS and, 
via the neurohypophysis, into general circulation, has been known to regulate a number 
of functions, including parturition, lactation, and social behaviours. In 1989, Arletti et al. 
reported for the first time that intracerebral and intraperitoneal (i.p.) administration of OT 
in rats causes a marked reduction in food intake [1]. Since then, a plethora of evidence 
has emerged that supports the involvement of OT in termination of feeding. 
Injections of OT in the third and fourth cerebral ventricles as well as in numerous brain 
areas, including the hypothalamic ventromedial nucleus (VMH), dorsal vagal complex, 
central (CEA), and basolateral (BLA) amygdala, ventral tegmental area (VTA) and 
nucleus accumbens core (AcbC), and the limbic system, produce cessation of ingestive 
behaviour [2-10]. This early termination of feeding after OT treatment pertains to 
relatively bland laboratory chow, as well as those that are highly palatable [2; 3; 10; 11]. 
Despite its limited ability to cross the blood-brain barrier (BBB), peripherally 
administered OT (including via intraperitoneal (i.p.), subcutaneous, and intravenous 
routes) also potently decreases food intake, most likely by engaging the brainstem where 
the BBB protection is weak [1; 2; 9; 12-14]. 
Increased c-Fos immunoreactivity in OT neurons and elevated OT plasma levels coincide 
with meal cessation [15]. Hypothalamic OT mRNA expression is downregulated during 
fasting and restored by re-feeding [16]. Administration of molecules that support satiation, 
such as cholecystokinin (CCK), alpha-melanocyte stimulating hormone, and glucagon-
like peptide-1 (GLP-1), increases activity of the OT system [17-21]. Furthermore, OT 
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release has been associated with peripheral changes that typically occur as ingestive 
behaviour nears its end, such as elevated osmolality, an increase in select nutrient levels, 
and excessive stomach distension [9; 22-25]. 
Overall, those findings strongly point to the role of OT in promoting satiety, facilitating 
early termination of consumption, and reducing meal size. On the other hand, one aspect 
of OT's involvement in feeding control that has not been investigated in detail is whether 
OT has a capacity to reduce a feeling of hunger. That, e.g., peripherally administered OT 
increases latency to begin a meal, might suggest it to some extent, but direct evidence is 
lacking. Scarcity of data also stems from methodological difficulties in assessing hunger 
in laboratory animals. 
There is a unique protocol, however, that relies on rats reporting their hunger status using 
an operant behaviour. Animals are trained to discriminate between acute food deprivation 
lasting 22 h (hunger) or 2 h (no actual energy depletion). In one such study, Corwin et al. 
trained rats maintained at 80% of their free-feeding body weight to discriminate between 
food consumed 22 or 3 h before experimental sessions [26]. The anorexigen CCK or 
ingestion of sweetened condensed milk induced effects similar to chow consumption 
occurring 3 h before a test session, in contrast to fenfluramine which did not reliably 
produce effects similar to 3-h food ingestion. Thus, CCK produced effects that resembled 
a lack of hunger. Similar outcomes to those induced by CCK were seen in response to an 
anti-obesity drug, sibutramine [27; 28]. 
In the current project, I employed this unique hunger discrimination protocol (employing 
22-h vs. 2-h deprivation) to examine whether OT administered i.p. prior to discrimination 
testing in rats reduces a feeling of hunger. I used OT doses based on previous reports and 
on the results of two additional feeding studies in hungry and sated animals performed 
here. In order to better understand whether i.p. OT activates a different subset of feeding-
related brain sites depending on the lack of access to food for 22 or 2 h, I conducted an 
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analysis of c-Fos immunoreactivity. Finally, since i.p. OT is thought to directly act at the 
brain stem, I asked whether food deprivation vs. a sated state has an impact on OT 
receptor expression established with real-time PCR. 
2.3 Materials and Methods 
2.3.1 Animals 
Male Sprague-Dawley rats aged 12-weeks old (average b. wt. 400 g) were housed 
individually in standard plastic cages with wire tops in a temperature-controlled (22°C) 
animal facility with a 12:12 light:dark cycle (lights on at 08:30 in the discrimination 
studies and 07:00 in the remaining experiments). Water and standard laboratory chow 
(Sharpes Stock Feed, Diet 86; 3.6kcal/g) were available ad libitum unless stated otherwise. 
Animals were treated in accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals. The University of Waikato Animal Ethics 
Committee and the University of Wisconsin-Eau Claire Institutional Animal Care and 
Use Committee approved all procedures described here. 
2.3.2 Behavioural Studies 
2.3.2.1 Establishing Effective Doses of OT That Reduce Feeding in Animals 
Deprived for 22 h and 2 h 
As I sought to investigate effects of OT on consumption of the same kind of diet in both 
22-h deprived (thus, driven to eat by energy needs) and 2-h deprived (thus, not motivated 
to eat by energy needs) animals, I chose to give them episodic access to palatable high-
fat high-sugar (HFHS; Research Diets #D12451; 4.73kcal/g; 35% calories from sugar and 
45% from fat) chow. Rodents avidly consume HFHS diet even in the absence of hunger. 
This was done to test whether i.p. OT retained its anorexigenic properties in the context 
of 2 and 22 h deprivation scenarios as they were slightly different from previously 
described protocols that typically relied either on depriving animals overnight, 16 or 24 
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h (hunger) or on giving animals episodic 2–4 h access to palatable food without depriving 
them even for 2 h (relative satiety). 
2.3.2.1.1 Effect of OT on palatable food intake in rats deprived for 2 h 
In order to examine whether OT decreases the consumption of HFHS food, I adjusted our 
previously published protocol [14; 29]. Rats maintained on ad libitum food and water had 
standard chow taken away at 10:00 (water remained in the cage). Two hours later, HFHS 
chow was placed in the cages for 2 h. Fifteen minutes prior to the HFHS food presentation, 
animals received an i.p. injection of isotonic saline or 0.1, 0.3, or 1 mg/kg OT Sigma, St. 
Louis, MO, USA (n = 9/group). The animals had had previous episodic (2 h per day, 5 
and 10 days before the study) exposure to this HFHS chow to avoid neophobia. Data were 
analysed with a one-way ANOVA followed by Dunnett's post-hoc analysis, with a 
significance level set at p ≤ 0.05. 
2.3.2.1.2 Effect of OT on palatable food intake in rats deprived for 22 h 
The cohort of rats used in the previous experiment (2.2.1.1) was studied here. A 2-week 
“washout” period elapsed between the experiments. Animals that had had access to 
standard chow were food-deprived for 22 h (deprivation ending at 12:00). They were then 
given access for 4 h to the HFHS chow. Fifteen minutes prior to the HFHS food 
presentation, animals received an i.p. injection of isotonic saline or 0.1, 0.3, or 1 mg/kg 
OT. HFHS chow intake after 22 h of deprivation was measured at 1 and 4 h. Data were 
analysed with a one-way ANOVA followed by Dunnett's post-hoc analysis, with a 
significance level set at p ≤ 0.05. 
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2.3.2.2 Establishing effects of OT on discrimination between 22 and 2 h of 
food deprivation 
Experimentally naïve male Sprague Dawley rats (Harlan, Madison, WI) were ~12-weeks 
old at the beginning of the procedures. Food (Harlan Teklad chow, Madison, WI) and 
water were continuously available unless otherwise stated. 
 
2.3.2.2.1 Apparatus 
Daily discrimination sessions were conducted in standard operant chambers equipped 
with two response levers (Med-Associates, St. Albans, VT), placed in ventilated, sound-
attenuating cubicles. Forty-five mg food pellets (Bio-Serve F#0021, Frenchtown, NJ) 
reinforced lever pressing and were delivered by a pellet dispenser into a food pellet trough 
located between the two levers. A house light in the back wall of the operant chamber 
illuminated the chambers during sessions. Experimental contingencies and data recording 
were performed with Med Associates software and a computer located in an adjacent 
room. 
2.3.2.2.2 Discrimination training 
Rats were initially food deprived to ~85% of their free feeding body weight and trained 
to press a level via the method of successive approximations. First, a single lever press 
was reinforced with a 45 mg food pellet (Bio-Serv F#0021, Frenchtown NJ). Response 
requirements were increased gradually until 15 presses (fixed ratio (FR) 15) were needed 
to generate food. When reliable responding to both levers was achieved, rats were given 
free access to food for 305 days before subsequent discrimination training began. Rats 
were trained to discriminate between 22 and 2 h of acute food deprivation using multiple 
cycle training. Under 22-h conditions, food was removed 22 h before the training session. 
Rats were placed into the operant chamber 5 min before the first training cycle. When the 
first training cycle started, the house light was turned on and 15 left lever presses were 
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reinforced with 45 mg food pellet delivery (FR 15 reinforcement schedule). Incorrect 
(right) lever presses were punished with 8 s of darkness under an FR 15 schedule. 
Training continued until 5 reinforcers were earned or 5 min elapsed. At least one more 
additional training cycle, identical to the first, was conducted 30–120 min after the 
previous cycle. Under 2-h conditions, the contingencies were reversed: right lever presses 
were reinforced and left lever presses were punished under the FR 15 schedule. 
Conditions were quasi-random with the provision that the same training condition (22 or 
2 h of food deprivation) could not be given for more than two consecutive sessions. 
Discrimination training continued until the subject emitted 80% or greater condition-
appropriate responses prior to delivery of the first reinforcer and for the entire training 
session during all training cycles for 8 of 10 consecutive daily sessions. 
 
2.3.2.2.3 Generalization test: evaluation of the ability of OT to reduce the 
discriminative stimulus effects of 22-h food deprivation 
The final discrimination tests assessed the ability of OT to reduce the discriminative 
stimulus effects of 22-h food deprivation. These tests were conducted under 22-h 
deprivation conditions. During the first response period, only left lever presses were 
reinforced. Following the first response period, rats were injected i.p. with isotonic saline 
or OT (0.01–1 mg/kg range). After injections, rats were placed in stainless steel cages 
without food or water. During the next response period occurring 30 min after the 
injection, responses toward both levers were reinforced. Generalization tests lasted until 
the subject earned 5 reinforcers or until 5 min elapsed, whichever occurred first. 
Appropriate discriminative performance for at least 2 training days (one preceded by 22-
h deprivation, one preceded by 2-h deprivation) was required between generalization tests. 
Immediately after generalization tests, subjects were placed in stainless steel cages and 
had access to a pre-weighed amount of regular food (~25 g of Teklad rat chow) placed on 
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the floor of the cage, and water available in a bottle attached to the cage. Food intake was 
measured at the end of 1 h. Afterwards, rats were returned to their home cage and had 
free access to food and water until 2 h before the next training session. 
2.3.2.3 Data analysis 
One-way ANOVA was calculated (SPSS, Chicago, IL, USA) by assessing the effects of 
OT versus control conditions on the discriminative stimulus effects of 22-h food 
deprivation, lever pressing rate, and food intake. Tukey HSD post hoc tests were 
performed following significant ANOVA values to determine pairwise differences 
among conditions. Significance was set at p ≤ 0.05. 
2.3.3 Establishing OT-induced c-Fos immunoreactivity in feeding-related 
brain sites in rats deprived for 2 and 22 h 
For practical reasons, including the transfer of rats between cages and behavioural 
manipulations that could have affected baseline Fos expression, I chose a different cohort 
of animals here than those used in behavioural studies. Experimentally naive, age-
matched male Sprague Dawley rats were divided into two cohorts (n = 12 per cohort) 
which were subjected to either 2 or 22 h of food deprivation (in both cases, deprivation 
period ended at 12:00). At the end of the deprivation, half of the animals in each cohort 
received an i.p. injection of isotonic saline, and the other half, 1 mg/kg OT. An hour after 
drug administration, animals were deeply anesthetized with urethane (35% dissolved in 
0.9% saline, i.p.), and perfused through the aorta with 50 ml of saline followed by 500 ml 
of 4% paraformaldehyde in 0.1 phosphate buffer (pH 7.4). Brains were excised and post-
fixed overnight in the same fixative at 4°C. 60 μm-thick coronal sections were cut with a 
vibratome (Leica, Germany) and later processed as free-floating sections for standard 




Sections were rinsed in 50 nM TBS (pH 7.4–7.6), and then pre-treated for 10 min in 3% 
H2O2, 10% methanol (diluted in TBS). After rinsing in TBS they were incubated 
overnight at 4°C in the primary rabbit-anti-Fos antibody (diluted 1:3000; Synaptic 
Systems, Australia) washed in TBS, and subsequently incubated for 1 h at room 
temperature in the secondary goat-anti-rabbit antibody (1:400; Vector Laboratories). 
Following four washes in TBS, sections were incubated for 1 h with the avidin–biotin 
peroxidase complex (1:800; Elite Kit, Vector Laboratories). The vehicle for all 
incubations was a solution of 0.25% gelatin and 0.5% Triton X-100 in TBS. The 
peroxidase in the tissue was visualized with 0.05% diaminobenzidine (DAB), 0.01% 
H2O2 and 0.3% nickel sulfate (12-min incubation). Sections were washed four times in 
TBS to stop the reaction, mounted onto gelatin-coated slides, air-dried, dehydrated in 
ascending concentrations of ethanol, soaked in xylene (Merck KGaA, Germany) and 
embedded in Entellan (Merck KGaA, Germany). The number of Fos-positive nuclei per 
1 mm2 was counted bilaterally for each neuroanatomical region of interest using ImageJ 
Software, with boundaries defined according to the Paxinos and Watson brain atlas, on 
2–4 sections per animal. Images provided by a CCD camera attached to a Nikon Eclipse 
400 microscope were analysed using Nikon NIS Elements image software. The following 
areas were analysed (in the parentheses, anterior-posterior ranges of bregma levels of 
sections used to analyse each site are shown): AcbC—nucleus accumbens core (1.28–
0.96); AcbS—nucleus accumbens shell (1.28–0.96); AP—area postrema (−13.92 to 
−14.16); ARC—arcuate nucleus (−2.16 to −2.52); BLA—basolateral amygdala (−2.64 to 
−2.92); CEA—central nucleus of the amygdala (−2.64 to −2.92); DMH—dorsomedial 
nucleus of the hypothalamus (−3.00 to −3.24); DMV—dorsal motor nucleus of the vagus 
(−13.76 to −14.16); NTS—nucleus of the solitary tract (−13.76 to −14.16); PVN—
paraventricular nucleus of the hypothalamus (−1.56 to −1.92); SON—supraoptic nucleus 
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(−0.96 to −1.2); VMH—ventromedial nucleus (−3.00 to −3.24); VTA—ventral tegmental 
area (−6.72 to −6.84). 
2.3.3.2 Data analysis 
Densities of Fos-positive nuclear profiles (per 1 mm2) were averaged per individual, and 
then per group. Data between the two groups (saline vs. OT) in each cohort were 
compared using a t-test. Values were considered significantly different for p ≤ 0.05. 
 
2.3.4 Establishing the effect of food deprivation on brainstem expression of 
the OT receptor gene 
2.3.4.1 Deprivation and brain stem collection 
The rats were divided to two groups. One group (n = 9) had unlimited access to standard 
chow and water, whereas the other had food taken away ~24 h before the animals were 
sacrificed by decapitation (n = 13). The brain stem was dissected and put in RNAlater 
(Ambion) for 2 h at room temperature and the samples were then frozen at −80C until 
further preparation. 
2.3.4.2 rtPCR protocol and data analysis 
A standard protocol of sample preparation and rtPCR was used, as developed by our lab 
[30]. Samples were homogenized in TRIzol (Ambion); RNA was extracted with 
chloroform and precipitated in isopropanol. After centrifuging, the pellet was washed, 
air-dried, and dissolved in the DNase buffer (NEB). The samples were treated with 
RNase-free DNase I (Merck) and the absence of genomic DNA was established by PCR 
of a 5% template. 100 ng/μl genomic DNA served as a positive control, whereas MilliQ 
H2O as a negative one. The product was analysed by electrophoresis. 5 μg RNA samples 
were diluted with MilliQ H2O. RNA was reverse-transcribed in the master mix (Promega; 
20 μl). Samples were incubated for 1 h (37°C), followed by PCR to confirm cDNA 
synthesis. RtPCR reactions were performed in duplicates. Sample cDNA template (25 ng) 
 
65 
was used per primer [OT receptor primer sequences: ttcttctgctgctctgctcgt (fwd) and 
tcatgctgaagatggctgaga (rev)]. Expression of three housekeeping genes (glyceraldehyde-
3-phosphate- dehydrogenase, β-actin, and β-tubulin) was used to calculate normalization 
factors (GeNorm). Primer efficiencies were calculated with LinRegPCR (HFRC) and Ct 
values were corrected for differences in primer efficiencies. rtPCR results were analysed 
with a Student's t-test. Values are presented as means ± S.E.M and they were deemed 
significantly different when p ≤ 0.05. 
2.4 Results 
The effects of 0.1, 0.3, and 1.0 mg/kg OT i.p. on HFHS palatable chow intake were 
investigated after 2 h and after 22 h of food deprivation. Control animals that had standard 
food taken away for 2 h and subsequently gained short-term access to the HFHS chow 
(thus, these rats were in effect sated) ate approximately 6 grams of the HFHS diet. OT at 
0.3 mg/kg and 1 mg/kg decreased HFHS food consumption [F(3, 32) = 6.44; 0.3 mg, p = 
0.042; 1 mg, p = 0.016] during the 2-h access period by approximately 33% (Figure 2.1A). 
In animals subjected to 22-h food deprivation (which is a much more challenging energy 
deprivation scenario and it promotes search of and intake of caloric tastants) after which 
they gained access to the HFHS chow, 1 mg/kg OT decreased consumption by 
approximately 25% at 2 h [F(3, 32) = 3.38; p = 0.015] and 4 h [F(3, 32) = 5.12; p = 0.004) 
of re-feeding (Figure 2.1B). There was a trend toward a decrease for 0.3 mg/kg OT at 4 






Figure 2.1: Effect of i.p. OT injection (0–1.0 mg/kg) on HFHS chow intake after a period of 
having no access to food for 2 h (A) or 22 h (B). Saline was the vehicle. HFHS availability 
period was 2 h in the sated (2-h deprived) rats and 4 h in the 22-h deprived animals. Water was 
available ad libitum. OT at 0.3 mg and 1 mg/kg decreased HFHS food consumption [F(3, 32) = 
6.44; 0.3 mg, p = 0.042; 1 mg, p = 0.016] during the 2-h access period (A). In animals subjected 
to 22-h food deprivation after which they gained access to the HFHS chow, 1 mg/kg OT decreased 
consumption at 2 h [F(3, 32) = 3.38; p = 0.015] and 4 h [F(3, 32) = 5.12; p = 0.004] of re-feeding 
(B). There was a trend toward a decrease for 0.3 mg/kg OT at 4 h (p = 0.073). *p < 0.05; **p < 
0.01. Saline was the vehicle. HFHS availability period was 2 h in the sated (2-h deprived) rats 
and 4 h in the 22-h deprived animals. Water was available ad libitum. OT at 0.3 mg and 1 mg/kg 
decreased HFHS food consumption [F(3, 32) = 6.44; 0.3 mg, p = 0.042; 1 mg, p = 0.016] during the 
2-h access period (A). In animals subjected to 22-h food deprivation after which they gained 
access to the HFHS chow, 1 mg/kg OT decreased consumption at 2 h [F(3, 32) = 3.38; p = 0.015] 
and 4 h [F(3, 32) = 5.12; p = 0.004] of re-feeding (B). There was a trend toward a decrease for 0.3 
mg/kg OT at 4 h (p = 0.073). *p < 0.05; **p < 0.01. 
 
 
Rats learned to discriminate between 22- and 2-h food deprivation in a mean of 90 
sessions. Operant studies revealed that OT even at doses that reduced HFHS diet intake 
in the experiments described above, did not alter the discriminative stimulus effects of 
22-h food deprivation [F(4, 16) = 1.00, p = 0.436, Figure 2.2A]. OT did significantly alter 
response rates in rats [F(4, 31) = 8.08, p = 0.0001, Figure 2.2B]. OT significantly reduced 
rates of lever pressing following 0.1 mg/kg OT (p = 0.044), 0.32 (p = 0.001) and 1 mg/kg 
OT i.p. (p < 0.001) (Figure 2.2B). As shown in Figure 2C, OT-treated animals deprived 
for 22 h and subjected to the hunger discrimination paradigm, did not show significantly 
reduced consumption of regular chow when they were transferred to a transition cage for 






Figure 2.2: Effect of i.p. OT on the stimulus effects of 22-h food deprivation (A), lever 
pressing response rates (B), and regular laboratory chow intake in 1 h immediately 
following the completion of the discrimination test (C). Animals had access to regular chow 
ad lib, before chow was withheld for 22 h and animals were injected. Saline was the vehicle. 
Operant studies revealed that OT did not alter the discriminative stimulus effects of 22-h food 
deprivation [F(4, 16) = 1.00, p = 0.436 (A)]. OT did significantly alter response rates in rats [F(4, 
31) = 8.08, p = 0.0001 (B)]. OT significantly reduced rates of lever pressing following 0.1 (p = 
0.044), 0.32 (p = 0.001), and 1 mg/kg OT i.p.(p < 0.0001) (B). (C) Shows that animals deprived 
for 22 h and treated with OT, did not show significantly reduced consumption of regular chow in 
1hr after the completion of the operant test. *p < 0.05. 
 
In a separate set of studies, I sought to investigate the effects of i.p. OT on neuronal 
activation in animals that are hungry and in animals that are sated. Intraperitoneal 
injection of OT at 1 mg/kg in rats deprived for 2 h affected c-Fos immunoreactivity in 
eight of the 13 feeding-related brain sites studied here (Figure 2.3). The number of c-Fos 
positive nuclei per mm2 in response to OT was elevated in the PVN (p = 0.011), SON 
(***p < 0.001), NTS (p = 0.003), DMV (***p < 0.001), and CEA (***p < 0.001). A 
decrease was noted in the ARC (p = 0.019), VMH (***p < 0.001), and DMH (***p < 
0.001). On the other hand, in animals deprived for 22 h (Figure 2.4), six areas showed 
differences in c-Fos levels: an increase was noted in the PVN (p = 0.042), SON (***p < 
0.001), VMH (p = 0.013), CEA (***p < 0.001), and BLA (p = 0.012), whereas a decrease, 






Figure 2.3: c-Fos immunoreactivity in feeding-related brain sites following i.p. 
administration of saline or OT (1 mg/kg) in animals that had no access to food for 2 h (A). 
Panel (B) presents photomicrographs depicting sites that showed a significant difference in 
c-Fos levels (saline-treated rats—left side; OT-treated rats—right side). Densities of Fos-
positive nuclear profiles (per 1 mm2 of a site) were averaged per individual, and then per group. 
AcbC, nucleus accumbens core; AcbS, nucleus accumbens shell; AP, area postrema; ARC, 
arcuate nucleus; BLA, basolateral amygdala; CEA, central nucleus of the amygdala; DMH, 
dorsomedial nucleus of the hypothalamus; DMV, dorsal motor nucleus of the vagus; NTS, 
nucleus of the solitary tract; PVN, paraventricular nucleus of the hypothalamus; SON, supraoptic 








Figure 2.4: c-Fos immunoreactivity in feeding-related brain sites following i.p. 
administration of saline or OT (1 mg/kg) in animals that had no access to food for 22 h (A). 
Panel (B) presents photomicrographs depicting sites that showed a significant difference in 
c-Fos levels (saline-treated rats—left side; OT-treated rats—right side). Densities of Fos-
positive nuclear profiles (per 1 mm2 of a site) were averaged per individual, and then per group. 
AcbC, nucleus accumbens core; AcbS, nucleus accumbens shell; AP, area postrema; ARC, 
arcuate nucleus; BLA, basolateral amygdala; CEA, central nucleus of the amygdala; DMH, 
dorsomedial nucleus of the hypothalamus; DMV, dorsal motor nucleus of the vagus; NTS, 
nucleus of the solitary tract; PVN, paraventricular nucleus of the hypothalamus; SON, supraoptic 
nucleus; VMH, ventromedial nucleus; VTA, ventral tegmental area. *p < 0.05; ***p < 0.001. 
 
Finally, by applying rtPCR analysis, I showed a downregulation of the OT receptor gene 
in the brain stem of rats that underwent deprivation compared to their sated counterparts 
(p = 0.0024; Figure 2.5). 
 
 
Figure 2.5: Effect of 24-h food deprivation on expression of the OT receptor gene established 






The fundamental drive that initiates food intake is a feeling of hunger. Hunger increases 
our motivation to seek high-energy foods and generates an avid feeding behavior upon 
encountering such ingestants. There are evolutionarily conserved neural and endocrine 
processes, such as those involving ghrelin or neuropeptide Y (NPY) [31-33], that promote 
eating for hunger, thereby ensuring that enough energy is obtained in order for the 
organism to maintain its functioning. However, in the obesogenic environment, where 
highly palatable and energy-rich diets are readily available, those mechanisms coupled 
with reward processes appear to be active even in the absence of actual energy needs, 
producing a feeling of hunger that leads to excessive food intake. Therefore, an important 
question that arises in the context of peptides that reduce consumption that can be 
potentially used clinically is whether they are capable of diminishing hunger 
responsiveness. Several decades of research on anorexigenic properties of OT have 
indicated that administration of OT supports early cessation of ingestive behavior [for 
review, see [34]]. Evidence gathered thus far has strongly linked OT with termination of 
feeding due to enhanced satiation or in response to adverse physiological changes (such 
as plasma osmolality or stomach distension) that endanger homeostasis. The current set 
of data shows for the first time that anorexigenic effects of OT do not stem from 
promoting a reduced feeling of hunger. 
 
Previous experiments have shown beyond reasonable doubt that peripherally injected OT 
decreases consumption. It seems that OT is particularly effective in reducing intake of 
energy-dense solid foods regardless of their composition and/or palatability [2; 8; 13; 14]. 
On the other hand, unlike central OT (particularly, targeting the VTA, AcbC or amygdala) 
or OT receptor ligands that cross the BBB, peripheral OT is not effective in modifying 
consumption of calorie-dilute sweet solutions that are ingested primarily for pleasure [3; 
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5; 10; 35]. Our feeding experiments indicate that i.p. OT decreases calorie-dense palatable 
food consumption regardless of whether intake is stimulated predominantly by hunger (as 
in animals deprived for 22 h) or by palatability (as in animals that had the standard chow 
removed only 2 h prior to episodic access to the HFHS diet). Hence, the relative calorie 
needs do not impact the ability of OT to produce hypophagia. The effective dose range 
(0.3–1 mg/kg) is also similar regardless of a feeding paradigm used here and by others. 
 
It should be noted that craving and motivation are not factors that are directly measurable 
in either our discrimination or consumption procedures. As we and others have reported, 
simple measures of food consumption do not necessarily relate to motivation to work to 
obtain food [e.g., [36; 37]]. Assuming there are only two motivating factors driving 
consumption (reward/pleasure or “free or hedonic” drives) and energy, the “free” or 
“hedonic” drives would be the key influence mediating consumption under the 2 h 
deprivation. In our experiments, OT was somewhat more potent in reducing HFHS 
consumption in subjects that were 2 h-deprived compared to subjects that were 22 h-
deprived. OT (0.3 and 1.0 mg) reduced HFHS consumption by approximately 33% in the 
former group. OT (0.3 mg) did not reduce consumption of the HFHS diet in the subjects 
food-restricted for 22 h. The reduction in intake under 22-h deprivation was about 25% 
suggesting that the contribution of the “free or hedonic” food intake may be at least to 
some extent reduced following the 22-h deprivation. We and others have shown that 
opioid antagonists are more potent in reducing consumption of sweet food compared to 
regular chow [for review, see e.g., [38; 39]]. These findings would also support the 
statement above. Craving is often associated with dependence-like behaviors during times 
of restriction or deprivation of the item inducing the “cravings.” I noted no dependence-




The hunger discrimination protocol that relies on the animals' ability to discriminate 
between short- (2–3 h) and long-term (e.g., 22 h) food deprivation and “report” it through 
operant behavior, has defined anorexigenic and orexigenic characteristics of several 
molecules. As food preloads appropriately change animals' perception of the length of 
deprivation, the parallel effect of anorexigens given instead of a food preload, indicates 
that they reduce a feeling of hunger. This approach allowed to implicate CCK and 
sibutramine as agents that can aid in controlling hunger (and deemed rimonabant 
ineffective in this process) [27; 40]. Of note is the fact that, in contrast to anorexigens, 
some orexigens (NPY or ghrelin) make animals perceive the short 2-h deprivation as the 
state of hunger [28; 41]. The fact that i.p. OT did not reduce operant responding to 22 h 
of deprivation strongly suggests that OT does not interfere with mechanisms that promote 
a feeling of hunger. It did not have an effect on hunger discrimination even though it was 
used at doses that are anorexigenic, and despite the fact that it did decrease bar pressing 
rate in general. It also produced a trend toward a reduction in chow intake in the 1 h after 
the completion of the operant test when animals were placed in a transition cage with 
chow present on the floor. Consequently, it can be inferred that OT induces hypophagia 
by being part of neuroendocrine processes that facilitate satiation and early cessation of 
feeding. This is in line with experiments showing a functional relationship between OT 
and numerous other mediators of satiety [for example, see [42; 43]], including 
melanocortins, which appear to form a common circuit with OT to support satiation. On 
the other hand, to our knowledge, there is no evidence that OT might be able to silence 
activation of, e.g., the NPY system, which could potentially suggest a link with hunger 
processing. 
 
That i.p. OT differently affects neural processing under deprivation than in satiety is 
further substantiated by the outcomes of the c-Fos mapping study that revealed distinct 
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patterns of c-Fos immunoreactivity in response to the OT treatment in hungry vs. sated 
animals. In individuals subjected to 2 h of deprivation, OT affected c-Fos 
immunoreactivity in a number of hypothalamic and brain stem sites: an increase in c-Fos 
staining occurred in the PVN, SON, NTS, and DMV, whereas a decrease was noted in 
the DMH, ARC, and VMH. The broad change in c-Fos levels in this network of sites that 
regulate energy intake is consistent with the role of OT as an anorexigen. Outside the 
hypothalamic-brainstem circuit, elevated c-Fos levels were in the CEA, which might 
potentially be related to emotional processing related to feeding [44-46] and it aligns well 
with the ability of OT itself to decrease consumption by acting at this site [5]. Overall, 
the subset of sites activated by OT is quite similar to what had been reported before in 
various paradigms unrelated to food intake. For example, Carson et al. found an increase 
in the PVN, SON and CEA after 2 mg/kg OT in rats subjected to 80-min locomotor testing 
[47], and Hicks et al. found elevated activation in the PVN, SON, CEA and NTS after 1 
mg/kg OT and a brief locomotor test [48]. In another study, Hicks and colleagues reported 
an increase in the PVN, CEA, and NTS in adolescent animals [49]. 
 
In hungry (thus, 22-h deprived) rats, systemic OT induced c-Fos in a smaller subset of 
areas. In the hypothalamus and brain stem, the PVN, SON, VMH, and—unlike under 2-
h deprivation—the AP showed a significant change (it should be noted though that the 
AP c-Fos levels in hungry animals treated with OT were higher too, though only a trend 
was observed). No difference was noted in the DMH, ARC, NTS, and DMV. It appears 
therefore that in the hungry state, OT loses the capacity to engage as broad a network of 
sites that regulate energy balance as that activated during satiety. rtPCR data showing a 
decreased expression of the OT receptor gene in the brain stem, a region thought to 
mediate anorexigenic properties of systemic OT, provide an additional insight into a 
mechanistic change that might be a key contributor to the changed, hunger/satiety-
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dependent receptivity of the CNS to OT. Of note is the fact that the rtPCR analysis 
revealed global brain stem expression changes and did not include individual areas. 
Considering that specific brain stem sites (and within these sites, specific neuronal 
populations) play distinct roles in appetite regulation, future studies will have to refine 
our understanding of a relationship between energy state, OT receptor, and these 
particular circuits within the brain stem. Finally, it should be noted that in both 22-h and 
2-h deprived rats the amygdala was affected by OT, however in hungry animals, not only 
the CEA, but also the BLA expressed higher c-Fos immunoreactivity. It allows us to 
speculate that—considering the role of the amygdala in emotional processing [44-46]—
OT affects emotional aspects of feeding regardless of the deprivation level. 
 
We conclude that systemic OT does not diminish a feeling of hunger before the start of a 
meal. Instead, OT's anorexigenic properties can be manifested once consumption has 
already begun and this, at least to some extent, is driven by changes in brain 
responsiveness to OT treatment in the hungry vs. fed state. Therefore, OT's role in feeding 
control should be viewed as a mediator of early satiation rather than as a molecule that 
diminishes a perceived need to seek calories. 
As I aim to develop a drug combination that targets multiple aspects of feeding behavior, 
and find that OT predominantly acts on satiety alone, I propose next, to explore the effects 
of opioid receptor antagonists. While these molecules are known to target another aspect 
of consumption, in palatability and pleasure, I aim to understand if they might act on the 
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In the previous chapter, I found that while OT inhibits food intake by mediating 
homeostatic signals of satiety, it does not influence the perception of hunger. In the search 
for neuropeptides that target different facets of consummatory behaviour, of particular 
interest are opioid receptor antagonists, known to influence palatability and reward 
signals, acting to inhibit palatable food intake. What is not known, however, is whether 
opioid receptor antagonists such as NTX might also influence the third aspect that drives 
consumption, which is hunger. Some studies suggest a potential involvement in hunger-
driven intake, but they suffer from the scarcity of methodologies differentiating between 
factors that intersect eating for pleasure versus energy. Here, I used a unique hunger 
discrimination paradigm to test a hypothesis that, since opioids appear to control feeding 
reward, injection of opioid agonists would not produce effects akin to 22 h of food 
deprivation. I trained rats to discriminate between 22 h and 2 h food deprivation in a two-
lever, operant discrimination procedure. I tested whether opioid agonists at orexigenic 
doses produce discriminative stimulus effects similar to 22 h deprivation. I injected 
DAMGO, DSLET, or orphanin FQ in the paraventricular hypothalamic nucleus (PVN), 
a site regulating hunger/satiety, and butorphanol subcutaneously (to produce maximum 
consumption). I assessed the ability of the opioid antagonist, NTX, to reduce the 
discriminative stimulus effects of 22 h deprivation and of the 22 h deprivation-like 
discriminative stimulus effects of PVN-injected hunger mediator, neuropeptide Y (NPY). 
In contrast to PVN NPY, centrally or peripherally injected opioid agonists failed to induce 
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discriminative stimuli similar to those of 22 h deprivation. In line with that, NTX did not 
reduce the hunger discriminative stimuli induced by either 22 h deprivation or NPY 
administration in 2 h food-restricted subjects, even though doses used therein were 
sufficient to decrease deprivation-induced feeding in a non-operant setting in animals 
familiar with consequences of 2 h and 22 h deprivation. I conclude that opioids do not 




Among a host of neuropeptides that affect food intake, some appear to alter consumption 
associated with energy needs, while others, eating associated with taste and reward [1]. 
In the previous chapter, I investigated the effects of one such neuropeptide in particular, 
OT, on whether it induces its anorexigenic effects by altering a feeling of hunger. While 
OT seems to be associated with modulating aspects of feeding related to energy needs by 
signaling satiation, I found that it did not reduce a feeling of hunger when examined using 
an operant procedure, even though it did act to significantly reduce food intake in 
deprived and non-deprived rats.  I therefore aim to investigate here if neuropeptides that 
modulate feeding associated with palatability and reward might exert their effects by 
modulating a feeling of hunger, in a similar operant paradigm. 
Opioids seem to be involved in the rewarding aspects of eating behavior, particularly 
related to intake of sugar and fat [2]. In contrast, neuropeptide Y (NPY) primarily 
modifies feeding driven by energy needs [3]. Food deprivation or restriction increases 
gene expression of NPY, but decreases gene expression of opioid peptides [4; 5]. As both 
opioids and NPY are orexigens, one would expect an increase in gene expression of an 
orexigenic peptide following food restriction if that peptide was indeed involved in 
energy-related feeding. What adds to the confusion is the fact that opioid receptor ligands, 
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though particularly effective at modifying intake of palatable diets, at higher doses also 
affect intake of bland foods in animals motivated to eat by hunger [2; 6]. Interestingly, 
these effects occur with generalized peripheral or central injections, as well as even when 
injections are done directly in brain sites typically associated with mediating eating for 
energy, such as hypothalamic areas [2; 7]. 
 
To distinguish whether peptides are involved in eating due to reward or energy needs, 
most investigators conduct studies with specific macronutrient diets or with diets that are 
more or less preferred by rats [8; 9]. Such methods do not directly differentiate reward- 
from energy-induced eating. Rats often prefer a high-fat diet compared to a high-starch 
(carbohydrate) diet. However, one cannot determine whether preference for fat is due to 
reward or energy needs since - while fat is preferred and presumably tastes good to a rat 
- fat is also the most energy-dense macronutrient. 
In order to address the issue of feeding for energy versus feeding for pleasure, a 
discrimination paradigm has been developed in which rats are trained to recognize the 
difference between discriminative stimuli produced by acute food deprivation (22 h 
deprivation) compared to discriminative stimuli produced by 2 h food deprivation. 
Corwin et al. trained rats to discriminate between recent (3 h) and more distant (22 h) 
food consumption and reported that the satiety peptide cholecystokinin (CCK), or 
ingestion of sweetened condensed milk, induced effects similar to 3 h food ingestion in 
chronically deprived rats [10]. This suggests that CCK administration resulted in a state 
that resembled a satiation (recent food ingestion) rather than deprivation. Using a similar 
methodology in non-deprived animals, I found that when rats were food-restricted for 
only 2 h and centrally-injected with NPY or ghrelin, rats responded on the lever associated 
with a 22 h deprivation [11]. This suggests that internal stimuli associated with NPY or 
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ghrelin resembled stimuli produced by 22 h of food deprivation. Thus, one might 
conclude that central injections of NPY or ghrelin result in hunger. 
 
In the current study, I hypothesized that since opioids appear to be involved in the 
rewarding aspects of eating, injection of opioid agonists would not produce internal 
stimuli associated with 22 h of food deprivation. To test this hypothesis, I studied the 
ability of select opioid agonists known to increase food intake to produce discriminative 
stimulus effects similar to those of 22 h food deprivation. I injected the opioid agonists 
(DAMGO, DSLET, nociceptin/orphanin FQ) in the paraventricular hypothalamic nucleus 
(PVN), a brain site that integrates mostly signaling related to energy needs [12]. We also 
administered butorphanol tartrate, which when injected peripherally, produces the most 
avid consumption of standard chow [13] Furthermore, I assessed the ability of the opioid 
antagonist, NTX, at peripheral doses sufficient to decrease deprivation-induced feeding 
in animals familiar with consequences of 2 and 22 h of food deprivation, to reduce the 
discriminative stimulus effects of 22 h food deprivation and of the 22 h deprivation-like 




3.2 Materials and methods 
3.2.1 Animals 
In all our studies, I used male adult Sprague-Dawley rats, individually housed in standard 
polycarbonate cages, under a 12:12 light:dark cycle (lights on at 8:30 AM in all 
discrimination studies and at 7:00 AM in the remaining experiments) in a temperature-
controlled (22 °C) animal facility. Standard laboratory chow (Sharpes Stock Feed, Diet 
86; 3.6kcal/g) and water were available ad libitum unless noted otherwise. Animals were 
maintained in accordance with the National Institute of Health Guide for the Care and 
Use of Laboratory Animals [14]. The University of Waikato Animal Ethics Committee 
and the University of Wisconsin-Eau Claire Institutional Animal Care and Use 
Committee approved all experimental procedures described in this project. 
3.2.2 Drugs 
Sodium pentobarbital (Sigma Chemical Co., St. Louis, MO) was dissolved in 30 % 
propylene glycol. Nociceptin/orphanin FQ (Phoenix Pharmaceuticals Inc., Burlingame, 
CA), NPY, DSLET and DAMGO (all three obtained from Sigma Chemical Co., St. Louis, 
MO) were dissolved in 0.9 % saline and stored in sealed plastic containers at -20 degrees 
C. NTX and butorphanol tartrate (Sigma Chemical Co., St. Louis, MO) was dissolved in 
0.9 % saline and refrigerated at 4 degrees C. All chemicals were slowly warmed to room 
temperature 20 min prior to administration. In experiments involving central injections, 
compounds were slowly (60 s) administered via an indwelling cannula directed toward 
the periventricular nucleus of the hypothalamus (PVN). Injection volumes were 0.5 μl, 
similar to previously published PVN studies [15; 16]. In peripheral (subcutaneous (s.c.)) 
injection experiments, butorphanol and NTX were dissolved in 0.9 % saline and 
administered at a volume of 1 ml/kg. 
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3.2.3 Operant studies: establishing the effects of drugs on discrimination 
between 22h and 2h of food deprivation 
3.2.3.1 Animals 
Experimentally naïve male Sprague Dawley rats (Harlan, Madison, WI) were 
approximately 12-weeks old at the beginning of the procedures. Food (Harlan Teklad 
chow, Madison, WI) and tap water were continuously available unless otherwise stated. 
3.2.3.2 Operant chambers, reinforcement stimuli and data acquisition 
Daily discrimination sessions were conducted in eight standard operant chambers (Med-
Associates, St. Albans, VT). Operant chambers were located in ventilated, sound-
attenuating cubicles equipped with fans. The chambers were equipped with two response 
levers. Forty-five mg food pellets (Bio-Serve F#0021, Frenchtown, NJ) reinforced lever 
pressing and were delivered by a pellet dispenser into a food pellet trough located between 
the two response levers. A house light located in the back panel of the operant chamber 
illuminated the operant chambers during experimental sessions. Experimental 
contingencies and data recording were executed via Med Associates software and a 
personal computer located in an adjacent room. 
3.2.3.3 Training procedure to discriminate between 22 and 2 h of food deprivation 
Twenty-four rats were initially food deprived to ∼85 % of their free feeding body weight 
and they were first trained to lever press via the method of successive approximations. 
Initially, a single lever press was reinforced with a 45 mg food pellet, and response 
requirements were gradually increased until 15 lever presses (fixed ratio 15; FR 15) were 
required to produce food. When responding occurred reliably to both levers, rats were 
given free access to food for 305 days before discrimination training began. 
 
In the discrimination phase of training, rats (having free access to chow except during the 
deprivation periods) were trained to discriminate between 22 and 2 h acute food 
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deprivation using multiple cycle training. Under 22 h conditions, food was removed 22 h 
before the training session. Rats were placed into the operant chamber 5 min before the 
first training cycle. When the first training cycle began, the house light was illuminated 
and 15 left lever presses were reinforced with the 45 mg pellet delivery under an FR 15 
reinforcement schedule. Incorrect (i.e., right) lever presses were punished with 8 s of 
darkness under a FR 15 schedule. Training continued until 5 reinforcers were earned or 5 
min elapsed. One or more additional training cycles, identical to the first, commenced 
30−120 min after the previous training cycle. 
 
Under 2 h conditions, the contingencies were reversed. Right lever presses were 
reinforced and left lever presses were punished under the FR 15 schedule. Conditions 
were quasi-randomly assigned with the provision that the same training condition (22 or 
2 h of food deprivation) could not be given for more than two consecutive sessions. 
 
Discrimination training continued until the subject emitted 80 % or greater condition-
appropriate responses prior to delivery of the first reinforcer and for the entire training 
session during all training cycles for 8 of 10 consecutive daily sessions. 
3.2.3.4 Surgeries 
Following acquisition of the deprivation discrimination, animals designated for 
experiments involving site-specific brain injections, were implanted with a cannula 
directed toward the PVN. Rats were anesthetized with sodium pentobarbital (60 mg/kg, 
i.p.) and mounted into a stereotaxic instrument (David Kopf Instruments, Tujunga, CA). 
A 26-gauge stainless steel guide PVN cannula was positioned according to the 
coordinates from the Paxinos and Watson rat brain atlas [17]: -1.9 mm anteroposterior, -
0.5 mm lateral, and -7.3 mm dorsoventral to bregma. After surgery, rats were maintained 
on chow and water ad libitum for at least 1 week before discrimination training resumed. 
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Prior to and after generalization tests, animals were injected in the PVN with NPY (0.5 
μg) to ensure that the cannula was functioning properly throughout the experiment: only 
those animals in whom NPY reliably produced increases in food intake greater than 5 g 
within 30 min post-injection were retained in the study. 
3.2.3.5 Generalization tests I: Effects of opioid agonists in rats deprived for 2h 
Following recovery from the surgical procedure and re-establishment of discriminative 
control, generalization testing began. Initial generalization tests assessed the ability of 
opioid agonists to induce discriminative stimulus effects similar to those of 22 h food 
deprivation. 
During these tests the rats were food-deprived for 2 h, and during the first response period 
only right lever presses were reinforced with the 45-mg pellet. If condition-appropriate 
behavior occurred, rats were slowly injected with saline (0.5 μl, PVN) DAMGO (0.1–3.2 
nmol, PVN), DSLET (0.1–3.2 nmol, PVN), orphanin FQ (0.1–3.2 nmol, PVN), or 
butorphanol (1.0–5.6 mg/kg, s.c.). The small injectant volumes for PVN injections have 
not been shown to diffuse to other brain areas [16; 18]. After drug administration, rats 
were placed in stainless steel cages without food or water. During the second response 
period occurring 1 h after the PVN injections and 2 h after butorphanol injection, 
responses made on either lever were reinforced under the FR 15 reinforcement schedule. 
 
Generalization tests lasted until the subject earned 5 reinforcers or until 5 min elapsed, 
whichever occurred first. Appropriate discriminative performance for at least 2 training 
days (one preceded by 22 h deprivation, one preceded by 2 h deprivation) was required 
between generalization tests. 
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3.2.3.6 Generalization tests II: Effects of daily s.c. butorphanol in rats deprived for 
2h 
Since acute pre-treatment with butorphanol produced significant reductions in lever 
pressing rates, but did not produce discriminative stimulus effects similar to 22 h food 
deprivation, I examined the effects of daily butorphanol (3.2 mg/kg, s.c.) administered 2 
h before the operant test session. These tests followed the same protocol as described 
above in section 3.2.3.5. 
3.2.3.7 Generalization tests III: Examining the ability of NTX to reduce the 
discriminative stimulus effects of 22h deprivation and the 22h deprivation-
like discriminative stimulus effects of PVN NPY 
Additional discrimination tests were designed to assess the potential ability of NTX 
(injected to either intra-PVN or s.c.) to reduce the discriminative stimulus effects of 22 h 
food deprivation and the 22 h deprivation-like stimulus effects of PVN NPY. To assess 
NTX’s effects on the discriminative stimulus effects of 22 h deprivation, 22 h deprived 
rats were given saline (0.5 μl, PVN or 1 ml/kg, s.c.) or NTX (10−100 nmol, PVN or 
0.32−10 mg/kg, s.c.) and generalization tests were conducted 30 min after the injection. 
To assess the effects of NTX on the 22 h deprivation-like discriminative stimulus effects 
of NPY, 2 h deprived rats were injected with NPY (1.0 μg/0.5 μl). Thirty minutes later, 
rats were injected with (0.5 μl, PVN or 1 ml/kg, s.c.) or NTX (10−100 nmol, PVN or 
0.32−10 mg/kg, s.c.). Generalization tests were conducted 30 min after the second 
injection. As before, responses toward both levers were reinforced and rats could earn 5 
reinforcers during the 5-minute generalization test session. 
 
3.2.4 Home cage feeding studies: Effect of NTX on deprivation-induced 
chow intake in rats subjected to 2 or 22h of recurrent deprivation 
Somewhat surprisingly, even at large doses that typically reduce deprivation-induced 
food intake [19; 20], NTX failed to affect the discriminative stimulus effects of either 22 
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h food deprivation or NPY-induced, deprivation-like discriminative stimuli in the 
aforementioned operant studies. This raised a question of whether NTX retains its ability 
to reduce consumption in animals subjected to the recurrent 2 h and 22 h deprivation 
schedule even outside the operant setting, i.e., in their home cage. 
Therefore, 12 rats (16 weeks old; b. wt. ∼450 g) were given access to food according to 
a 19-day long familiarization schedule with access to standard chow (Sharpes Stock Feed, 
Diet 86) after either 2 h or 22 h of recurrent deprivation (see Fig. 3.1 for a flow-chart of 
study design). Rats were divided into two cohorts (n = 12 per cohort) which received 
injections prior to re-feeding after 2 or 22 h of food deprivation. NTX (0.1, 0.3, 1.0, and 
3.2 mg/kg) or saline (vehicle) were administered s.c. just prior to returning the chow to 
the hoppers. Food intake measurements were taken 1, 2 and 24 h post injection and 
corrected for spillage. Each animal received each dose of the drug in a counterbalanced 
fashion. 
 
Figure 3.1: Flow-chart delineating drug treatment in rats acquainted with a random, 
recurrent energy deprivation schedule. In order to assess whether NTX reduces chow 
consumption in animals subjected to the recurrent 2 h and 22 h deprivation schedule outside the 
operant setting, i.e., in their home cage, single-housed rats underwent first the feeding schedule 
familiarization phase followed by the drug treatment phase in which NTX or vehicle (saline) were 
administered. Familiarization phase (days 1–19): Rats were acquainted with the random chow 
deprivation schedule (either 22 h or 2 h of food access or food deprivation as indicated by green 
boxes (access) and red boxes (deprivation)). Three-to-four days of no deprivation were allowed 
before the beginning of the drug treatment phase (saline, 0.1, 0.3, 1.0, or 3.2 mg/kg NTX were 





3.2.5 Data analysis 
All descriptive data are presented as means ± the standard error of the mean (SEM). One-
way analysis of variance (ANOVA) was used to assess the ability of each opioid-agonist 
to induce the discriminative stimulus effects similar to those of 22 hr food deprivation. 
One-way, ANOVA was also used to assess NTX’s ability to decrease the discriminative 
stimulus effects of 22 h food deprivation and the 22 h deprivation-like discriminative 
stimulus effects of neuropeptide Y. Lever pressing rates in all generalization tests were 
examined using a one-way ANOVA, except for the five day, daily butorphanol tests in 
which a repeated measures ANOVA was used to analyse response rates. Significant 
effects were noted if p < 0.05. If the results of the ANOVA were statistically significant, 
Dunnett post-hoc tests were performed to determine conditions that were significantly 
different than control. 
3.3 Results 
Rats acquired the 22 h deprivation versus 2 h deprivation discrimination in an average of 
77 trials (SEM 12 trials). Generalization tests were conducted under 2 h deprivation and 
rats were injected with various opioid agonists at doses that have previously been shown 
to increase food intake in non-deprived rats. Results revealed that opioid agonists failed 
to induce discriminative stimulus effects similar to 22 h deprivation. PVN-administration 
of the mu-opioid agonist DAMGO (F(4,15) = 0.70. p = 0.60, Fig. 3.2a, top panel), the 
delta-opioid agonist DSLET (F(4,19) = 0.70, p = 0.55, Fig. 3.2b, top panel), and the NOP 
receptor agonist orphanin FQ (F(4,27) = 0.98, p = 0.44, Fig. 3.2c, top panel), did not 
produce significant increases in 22 h deprivation responding. Response rates were also 
unaffected by DAMGO (F(4,21) = 0.22, p = 0.92, Fig. 3.2a, bottom panel), DSLET 
(F(4,21) = 0.87, p = 0.50, Fig. 3.2b, bottom panel), and orphanin FQ (F(4,36) = 0.41, p = 





Figure 3.2: Effect of PVN (a) DAMGO, (b) DSLET, and (c) orphanin FQ on hunger 
discrimination responses and rates of lever pressing. In order to assess whether PVN-
administered opioid agonists induce 22 hr deprivation-like discriminative stimuli, rats (n = 16, 3–
7 per condition) under 2 h deprivation conditions were injected with saline (open symbols), 
DAMGO, DSLET, or Orphanin (filled symbols represent data from drug tests) and generalization 
tests began 60 min later. Generalization test performance is expressed as the average percentage 
of 22 hr deprivation responses (± SEM, top panel) and response rates (lever pressing expressed 
as average responses per minute ± SEM, bottom panel). No significant changes in either 
discriminative performance or response rate were observed following administration of either 
opioid agonist. 
Peripheral administration of butorphanol (1.0–5.6 mg/kg, s.c.) also did not induce 
increases in 22 h deprivation-appropriate responding, (F(4,17) = 0.63, p = 0.65, Fig. 3.3, 
top panel), however lever pressing rates were significantly decreased by butorphanol 
(F(4,26) = 6.92, p < 0.001, Fig. 3.3, bottom panel). All doses of butorphanol tested (1.0–
5.6 mg/kg, s.c.,) significantly reduced response rates (Dunnett post-hoc test, p < 0.05). It 
is possible that the rate decreasing effects of butorphanol were preventing deprivation-
induced discriminative stimuli from being expressed. To test this possibility, six rats 
trained to discriminate between 22 and 2 h food deprivation were given daily 
administration of 3.2 mg/kg butorphanol (s.c) for five days. There was an overall effect 
of butorphanol on response rates, but the rate-decreasing effects of butorphanol were 
significantly different than response rates following saline administration only following 
the first day of 3.2 mg/kg butorphanol administration (Dunnett post-hoc test, p < 0.05, 
Fig. 3.4, bottom panel). Although response rates were not significantly different from 
 
95 
saline on days 2–5 of butorphanol administration, daily butorphanol administration did 
not significantly increase 22 h deprivation-appropriate responses (F(5,18) = 1.67, p = 0.19, 
Fig. 3.4, top panel). 
 
 
Figure 3.3: Effect of s.c. butorphanol on hunger discrimination responses and rates of lever 
pressing. In order to assess whether peripherally-administered doses of the opioid orexigenic 
butorphanol, induced 22 hr deprivation-like discriminative effects, eight rats (4–8 per condition) 
under 2 h deprivation conditions were injected s.c. with saline (open symbol) or butorphanol 
(filled symbols). Generalization tests began 120 min after the injection. Generalization test 
performance is expressed as the average percentage of 22 hr deprivation responses (± SEM, top 
panel) and response rates (lever pressing expressed as average responses per minute ± SEM, 
bottom panel). Butorphanol did not produce increases in 22 hr deprivation responding (F(4,17) = 
0.63, p = 0.65) but did significantly reduce response rates (F(4,26) = 6.92, p = 0.0006). Response 
rates following 1.0–5.6 mg/kg butorphanol were significantly reduced compared to response rates 





Figure 3.4: Effect of daily s.c. butorphanol administration on discrimination responses. In 
order to assess whether daily administration of butorphanol induced 22 hr deprivation-like 
discriminative effects or affected response rates, six rats under 2 h deprivation conditions were 
injected s.c. with saline (open symbol) or butorphanol (filled symbols). Daily generalization tests 
began 120 min after the injection. Generalization test performance is expressed as the average 
percentage of 22 hr deprivation responses (± SEM, top panel) and response rates (lever pressing 
expressed as average responses per minute ± SEM, bottom panel).When 3.2 mg/kg butorphanol 
was given to six rats daily for five days, butorphanol did not significantly increase 22 hr 
deprivation-appropriate responding. (F(5,18) = 1.67, p = 0.65). Butorphanol did significantly alter 
response rates (F(5,25) = 5.91, p = 0.03). Responses rates following butorphanol administration 
on day 1 were significantly reduced compared to response rates following saline (Dunnett post 
hoc test, p < 0.05). Response rates on days 2 through 5 were not significantly different than control 





The effects of the opioid antagonist NTX were assessed both in rats under 22 h 
deprivation conditions and in rats under 2 h deprivation conditions that received NPY 
(1.0 μg, PVN). NTX administered subcutaneously (0.32–10.0 mg/kg) failed to alter the 
discriminative stimulus effects of 22 h food deprivation (F(4,25) = 1.36, p = 0.28, Fig. 
3.5) and rates of lever pressing (F(4,25) = 0.15, p = 0.96, Fig. 3.5). PVN administered 
NTX also failed to alter either the discriminative stimulus effects of 22 h food deprivation 
(F(3,11) = 0.49, p = 0.69, Fig. 3.6) or response rates (F(3,11) = 0.15, p = 0.96, Fig. 3.6). 
NPY (1.0 μg) administered into the PVN produced complete generalization to the 22 h 
discriminative stimulus (Fig. 3.5, Fig. 3.6). The 22 h deprivation-like discriminative-
stimulus effects of NPY were not altered by NTX administered subcutaneously (F(4,19) 
= 0.52, p = 0.72, Fig. 3.5) or when administered directly into the PVN (F(3,10) = 0.88, p 
= 0.48, Fig. 3.6). Response rates following PVN administration of NPY were not altered 
by NTX administered s.c. (F(4,19) = 0.29, p = 0.82, Fig. 3.5) or directly into the PVN 





Figure 3.5: Effect of PVN naltrexone on discrimination responses. To examine the possible 
effects of PVN NTX on the discriminative stimulus effects of 22 h deprivation, four rats were 
food deprived for 22 h and injected PVN with saline (open squares) or NTX (10−100 nmol, filled 
squares). During other tests, eight rats (3-6 per condition) were food deprived for 2 h and injected 
with NPY (1.0 μg, PVN) and injected PVN. with saline (open circles) or NTX (10−100 nmol, 
filled circles). Generalization tests were conducted 30 min later and the discriminative stimulus 
effects and rates of lever pressing were assessed. Both 22 h deprivation and NPY administration 
engendered 22 h-appropriate deprivation responses. NTX did not alter the discriminative stimulus 






Figure 3.6: Effect of s.c. NTX on PVN NPY and 22 h deprivation discrimination responses. 
To examine the possible effects of NTX on the discriminative stimulus effects of 22 h deprivation, 
six rats were food deprived for 22 h and injected s.c. with saline (open squares) or NTX (1.0–10.0 
mg/kg, filled squares). During other generalization six rats (3–6 per condition) were food deprived 
for 2 h and injected with NPY (1.0 μg, PVN) and 15 min later injected s.c. with saline (open 
circles) or NTX (1.0–10.0 mg/kg, filled circles). Generalization tests were conducted 30 min after 
the second injection and the discriminative stimulus effects and rates of lever pressing were 
assessed. Both 22 h deprivation and NPY administration engendered 22 h-appropriate deprivation 
responses. NTX did not alter the discriminative stimulus effects of either 22 h food deprivation 
or NPY administration and NTX did not alter the rates of lever pressing. 
 
Administration of NTX at 0.32, 1 and 3.2 mg/kg s.c. prior to re-feeding caused a decrease 
in chow intake 2 h post-injection (p < 0.001) in animals deprived for 22 h (Fig. 3.7). The 
largest dose of the opioid antagonist (3.2 mg/kg) decreased chow intake already 1 h post-
injection (p < 0.01). The same doses of NTX failed to affect chow intake in animals 
deprived for only 2 h, though baseline consumption levels were very low in controls (Fig. 






Figure 3.7: Effect of s.c. NTX on chow intake after 2 (top) or 22 h (bottom) of food 
deprivation. To examine the possible effects of NTX on food intake induced by 2 or 22 h food 
deprivation, 12 rats were food restricted according to the descriptions in the methods and Fig. 3.1. 
Following deprivation, animals were injected with either saline or NTX 0.032 mg/kg, 0.1 mg/kg, 








In 1990, Corwin et al. described a new method to compare the interoceptive stimuli of 
anorexogenic drugs and satiation in rats [10]. In their experiments, these investigators 
trained rats to distinguish between 3 h and 22 h food deprivation and press levers in an 
operant chamber according to recent (3 h) or past (22 h) food access. They found that not 
only can rats learn to reliably discriminate between 3 h and 22 h food deprivation, but 
their perception of the length (or severity) of food deprivation can also be influenced by 
preloads of sweetened condensed milk or administration of CCK. The findings were in 
line with the hypothesis that satiety factors, including CCK, can produce effects similar 
to those of a food load or recent food ingestion [10]. The hunger discrimination method 
has been used in subsequent studies to demonstrate that, for example, sibutramine aids in 
weight loss by reducing hunger sensations in animals and that intra-PVN administration 
of NPY and ghrelin increase feeding by simulating hunger [11; 21]. 
 
In the present studies, I asked whether opioids are able to regulate hunger-induced 
feeding. I employed a similar method to train rats to discriminate between stimuli 
associated with 22 h food deprivation (“hunger”) and 2 h food deprivation (“satiation”). 
After 2 h of food deprivation, opioid receptor agonists DAMGO, DSLET, orphanin FQ 
(site-specifically) and butorphanol (systemically) all failed to induce discriminative 
stimuli associated with deprivation. This is in contrast to NPY, which induced 22 h 
deprivation-like discriminative stimulus effects in animals deprived for 2 h. It should be 
emphasized that the effect of NPY shown here parallels the effects of another orexigen, 
ghrelin, in a similar operant experimental scenario [11; 22]. It should be noted that, while 
it cannot be completely excluded that by using even higher (thus, above 3.2 nmol) doses 
of intra-PVN opioid receptor ligands, one might be able to affect hunger discrimination, 
the doses selected for the current set of experiments likely represent a range relevant for 
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feeding stimulation. For example, 2 nmol PVN DAMGO has been reported to increase 
chow intake, as little as 3 nmol ICV N/OFQ stimulated chow consumption, and in the 
case of DSLET, its generalized ICV administration at 10 nmol -- what would be just one 
½ log increment higher dose compared to the one used by us site-specifically -- produced 
hyperphagia (and as little as 100 pmol intra-PVN N/OFQ has been shown to affect water-
electrolyte balance) [18; 23-25]. 
 
One of the key functional characteristics distinguishing NPY and ghrelin from opioids 
that may help conceptualize the differential response to opioid receptor ligands in the 
discrimination context, is the role in eating for hunger versus for palatability. In the vast 
majority of studies published to date, NPY and ghrelin have produced feeding in response 
to energy deficit; their release has also been associated with the states of hunger. For 
example, acute brain injections of NPY increase food intake and repeated administration 
of NPY into the hypothalamus lead to obesity [26]. PVN perfusions with NPY result in 
dramatic increases in food intake [27], and PVN NPY-treated rats (unlike DAMGO-
injected animals) given a choice between calorie-dense and bland chow versus calorie-
dilute and palatable sucrose solution, shift their preference towards chow [28]. Similarly 
to NPY, central ghrelin increases consumption of “bland” diets, such as a cornstarch mix 
[1; 29-32]. Plasma ghrelin levels are elevated after a fast and decrease upon glucose 
stomach infusions [33]. In humans, ghrelin levels mirror a curve of perceived hunger 
scores between a scheduled lunch and a freely requested dinner [34]. As replenishing 
lacking calories after a period of deprivation has a component of pleasure regardless of 
actual palatability of food, NPY and ghrelin have also been shown to affect feeding for 
reward [35-38], however, that aspect of their function in the central regulation of food 




Unlike NPY, opioid agonists increase feeding for pleasure and promote maintenance of 
food intake. This characteristic – to a lesser or greater degree - pertains to virtually all 
opioid receptor subtypes and, thus, to all of the ligands used here. For example, intra-Acb 
administration of a mu agonist DAMGO increases the intake of palatable high-fat and 
high-carbohydrate diets, yet neither nucleus accumbens shell (AcbSh) nor core (AcbC) 
DAMGO infusions motivate animals to acquire lever pressing for food in an operant 
chamber; in contrast, food-deprived animals learn this task rapidly [39]. A delta opioid 
ligand, DSLET, is particularly effective at increasing the intake of a cafeteria diet and 
enhancing dopaminergic tone in the striatum [40]. Butorphanol tartrate, which acts at both 
the mu and kappa receptors, promotes particularly vigorous food intake [41]. Finally, 
orphanin FQ, which acts via kappa-resembling opioid-like receptor 1, is involved in 
stress-induced binge-like palatable food consumption [42]. 
 
That opioid receptor agonists employed in our experiments did not produce 22 h 
deprivation-like discriminative stimulus effects, further substantiates the notion that 
peptides belonging to the opioid family do not produce a feeling of hunger. It is more 
likely that opioid-derived hyperphagia stems from the pleasure-derived component of 
eating behavior and/or meal prolongation. It should be mentioned that even in the case of 
opioid-induced consumption observed in the absence of palatable food, orexigenic effects 
may be related to the fact that calories (and, thus, high-calorie foods regardless of their 
attractiveness) have a capacity to engage the activity of the reward system [43]. 
 
In line with opioid receptor agonists’ inability to affect operant responses after 2 h of 
deprivation, an antagonist of opioid receptors, NTX, failed to diminish 22 h deprivation 
discriminative stimulus effects. Importantly, NTX also failed to modify NPY-induced 
responses of animals subjected to 2 h deprivation. The finding of relative insensitivity of 
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the NPY-elicited operant response to NTX is particularly crucial taking into account the 
fact that opioid antagonists have been shown to diminish animals’ ability to discriminate 
NPY from vehicle injections [44], as well as affect other NPY-driven parameters, 
including its anxiolytic effects [45]. It indicates that NPY serves as a stimulus molecule 
that facilitates hunger-driven eating behavior, whereas opioids may – at best – serve as 
modifying factors in shaping the magnitude and length of a consummatory response in 
animals that have already commenced a meal. This hypothesis is supported by earlier 
reports showing that brainstem-acting NTX weakens but does not completely abolish 
hyperphagia elicited by PVN NPY injections [46]. Furthermore, that opioid receptor 
activity is not critical for hunger responses is also reflected by the results of our current 
experiment in which – in the random schedule of 2 h:22 h food deprivation – lower 
effective doses of NTX (0.3 and 1 mg/kg) did not change food intake during the first hour 
post re-feeding, and their effect was visible only during the more advanced portion of a 
meal, i.e., after 2 h. Only a large 3.2 mg dose of NTX affected food intake during the first 
hour. Moreover, food intake after 2 h of deprivation, albeit minimal, was unaffected by 
the opioid receptor antagonist. Thus, for NTX to be effective, a vigorous consummatory 
activity should already be under way, whereas the feeling of hunger per se is not affected 
by opioid antagonists. 
 
Our findings are particularly important from the standpoint of addressing a long-standing 
debate as to why opioid receptor ligands modify intake of foods that are not palatable. It 
has been shown beyond reasonable doubt that opioid agonists, including DAMGO, 
DSLET, orphanin FQ and butorphanol also increase consumption of bland diets, whereas 
antagonists, such as NTX and naloxone, reduce intake of standard laboratory chow [28; 
47-54]. It has also been suggested that subpopulations of opioid expressing neurons 
located throughout a dispersed neuronal network of sites classically viewed as 
 
105 
‘homeostatic’ (e.g., hypothalamic PVN, arcuate, dorsomedial and ventromedial nuclei) 
and reward-related (e.g., the nucleus accumbens, ventral tegmental area and amygdala 
complex) mediate feeding effects of opioids (for review, see [55]). The current set of data 
strongly suggests that the orexigenic effects of opioids observed in the context of bland 
foods should not be attributed to a change in hunger levels, but rather be associated with 
energy balance-unrelated aspects of ingestive behavior, such as consummatory activity-
derived reward, which modifies the magnitude of a feeding response. This stipulation is 
further strengthened by the fact that not only did PVN-injected delta-, mu- and NOP-
specific receptor ligands -- thus molecules acting through a small, anatomically isolated 
population of the opioid receptor expressing neurons -- fail to affect the hunger 
discrimination (though in the future, it might be potentially useful to test intra-PVN kappa 
ligands as well), but so did the intra-PVN and systemically administered non-selective, 
opioid antagonist (NTX) and mixed agonist (butorphanol) of the opioid receptors. 
Systemic NTX antagonizes effects of mu-, kappa-, and delta-opioid agonists [56-59]. 
These data serve as yet another example of the complexity of the functional cross-link 
between intake for calories and intake for pleasure and the dynamic responsiveness of 
neural networks (sometimes, even seemingly conflicting effects within the same circuit) 
to energy- and palatability-driven challenges. In this context, in a recent paper, Wei and 
colleagues found that selective activation of hypothalamic POMC neurons inhibits energy 
intake in hungry animals, whereas activation of hypothalamic neurons that arise from 
POMC-expressing progenitors promotes hyperphagia [60]. 
In sum, I conclude that opioid receptor antagonism using NTX inhibits intake of palatable 
foods by regulating signals of pleasure and reward, and not by influencing the perception 
of hunger. Similarly, I found in the previous chapter that OT, while it targets the satiety 
aspect of feeding behaviour, does not produce its anorexigenic effects by influencing the 
perception of hunger. While these two peptides do not appear to influence the perception 
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of hunger, they indeed target distinct facets that drive consummatory behaviour and in 
doing so, may be able to be combined to address both satiety and reward-processing, and 
due to the interlinked nature of these two systems, may indeed produce a synergistic effect 
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Combined oxytocin and naltrexone at 
subthreshold doses acutely reduces food intake 
and induces a unique pattern of neuronal 




In our search for neuroactive agents to curb excessive food consumption, those that affect 
more than one facet of feeding control are of particular interest, as they target a broader 
range of appetite regulating processes. In the previous chapters, I have investigated two 
such peptides and characterised which aspects of feeding control they target.  
Interestingly, I found that while both OT and NTX have proven effective at inhibiting 
food intake in certain situations, they appear to target differing aspects of the motivation 
to consume, without influencing the feeling of hunger. These disparate systems are indeed 
intrinsically linked, as the opioidergic reward system can act to modulate the magnitude 
of a homeostatic feeding response by altering the neuronal sensitivity to satiety signals. I 
therefore hypothesized that by combining peptides that target these different aspects of 
feeding behavior, such a treatment might produce potentiating effects that can translate 
to robust therapeutic effects on curbing excessive consumption and seeking of palatable 
foods. I indeed found that while OT reduces deprivation-induced chow intake, and NTX 
reduces palatable food intake, that I could combine these drugs at subthreshold doses that 
have no effect alone, to produce a synergistic hypophagic effect on acute food intake. 
Furthermore, using c-Fos immunochemistry, I found robust changes in feeding-related 
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brain regions within the brain stem-hypothalamic network, as a result of this drug 
combination. I conclude that combining OT and NTX targets multiple facets of feeding 
behavior that are intrinsically linked, and so produces a synergistic effect on reducing 








Within the last two chapters, I have investigated the effects of various neuropeptides that 
are effective at modulating different aspects of feeding behavior. In the first chapter, I 
found that OT, while proven to be effective at reducing food intake in deprived and non-
deprived rats, produces its anorexigenic effect without altering a feeling of hunger, as 
explored by an operant testing paradigm. I show that this peptide influences feeding for 
energy, and acts as a homeostatic mediator of early satiation. However, feeding behaviour 
can be influenced by multiple factors, and the drive for caloric intake is only one aspect 
of this. Pleasure and palatability also act to modify the magnitude of a feeding response, 
and can alter the sensitivity of an organism to the signals that drive the motivation to 
consume. The opioidergic neuronal systems are commonly attributed to playing a 
significant role in altering perception of pleasure and reward, and so, can powerfully 
influence consummatory behavior. In chapter two, I therefore examined whether opioid 
ligands perhaps also modulate the intake of palatable foods by altering the animal’s 
perception of hunger, as tested with a similar operant paradigm. While some orexigenic 
peptides such as neuropeptide Y (NPY) indeed proved to be effective at altering a 
perception of hunger within this paradigm, opioid receptor ligands failed to modify 
hunger-associated responses, even at doses sufficient to alter deprivation-induced feeding. 
Non-selective opioid receptor antagonists, such as NTX, indeed significantly reduce 
consumption of palatable foods, but did not reduce behavioural responses associated with 
hunger, and so, I conclude, inhibit feeding for reward rather than in order to replenish 
lacking energy.  
While both OT and NTX have proven effective at inhibiting food intake in certain 
situations, they appear to target differing aspects of the motivation to consume, without 
influencing the feeling of hunger. These disparate systems are indeed intrinsically linked, 
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as the opioidergic reward system can act to modulate the magnitude of a homeostatic 
feeding response by altering the neuronal sensitivity to satiety signals [32].  
We therefore hypothesize that by combining peptides that target these different aspects 
of feeding behavior, such a treatment might produce potentiating effects that can translate 
to robust therapeutic effects on curbing excessive consumption and seeking of palatable 
foods. 
 
The past years have brought a surge in interest in exploring anorexigenic properties of the 
nonapeptide OT. As shown in a wealth of laboratory animal experiments and supported 
by human trials, OT administration promotes early cessation of ingestive behavior, a 
reduction of meal size and, under some circumstances, a decrease in consumption of 
palatable tastants. 
In rodent experiments, hypophagia has been observed after peripheral (intravenous, 
intraperitoneal (IP), subcutaneous, intranasal (IN)) and central (intracerebroventricular 
and site-specific) administration of the peptide. While IP OT does not diminish an 
animal’s ability to perceive hunger, OT has been consistently shown to decrease meal 
duration and lower consumption of standard chow. These outcomes are consistent with 
the fact that increased activation of hypothalamic OT neurons and neurohypophyseal 
release of the hormone coincide with satiation and stomach distension. Data on OT and 
feeding for palatability are promising albeit somewhat less conclusive and they indicate 
that, even though OT tends to decrease consumption of rewarding tastants, the route and 
chronicity of OT administration, the macronutrient composition, flavor and energy 
density of a diet, and even social vs non-social setting of a meal, collectively influence 
the effectiveness of OT treatment. It should be noted that OT administration evokes 
changes in activity (assessed through c-Fos analysis) of broad brain circuits, from the 
hypothalamus to the brain stem to the limbic system, involved in various facets of feeding, 
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including eating induced by energy needs, homeostasis, reward and emotionality. In line 
with that, energy deprivation and palatable tastant exposure scenarios affect mRNA levels 
of OT and its receptor in the CNS. 
Translational studies in humans have largely confirmed the basic research findings. A 
single supraphysiological dose of IN OT in obese and normal-weight subjects decreased 
energy consumption [1-5]. The link between OT and eating for pleasure has also been 
suggested, though specific aspects of hedonic eating affected by OT remain unclear with 
some studies reporting preferential effects in reducing consumption of sweet [3, 4, 6], 
fatty [1] or salty [4] foods. Functional magnetic resonance analyses (fMRI) have found 
that OT modifies responsiveness of hypothalamic [7, 8] and limbic [5, 7] sites in response 
to food images, suggesting that not only homeostatic, but also some reward circuits might 
indeed be modulated by OT. 
In a recent human case study, Hsu and colleagues administered OT peripherally to reduce 
energy intake and body weight in an adolescent male with hypothalamic obesity and 
uncontrollable hedonic food-seeking caused by craniopharyngioma resection [2]. 
Considering a potentially suboptimal effectiveness of OT on eating for reward, the 
authors co-administered OT with NTX, a non-selective opioid receptor antagonist, 
thereby capitalizing on the primary effect of opioid receptor blockade on diminishing 
reward-driven consumption. They found that while OT alone reduced body weight and 
hyperphagia during the first 10 weeks, subsequent co-administration with NTX was a 
successful adjunctive therapy leading to further improvements in body weight and satiety 
parameters. 
Taking into account the exciting findings of that case report and the lack of any basic 
research studies pertaining to effects of OT-NTX combination treatment on food intake, 
in the current set of experiments, I tested the effectiveness of co-administration of 
subthreshold doses of IP OT and NTX in adolescent male rats given a meal of (i) energy-
 
117 
dense, palatable high-fat high-sugar (HFHS) chow, (ii) energy-dense, “bland” chow, or 
(iii) energy-dilute, palatable sucrose solution. By testing for a conditioned taste aversion 
(CTA), I assessed whether the anorexigenic effect of the combined drugs is independent 
from gastrointestinal sickness/malaise. I also employed c-Fos immunohistochemistry to 
determine whether an effective IP OT-NTX combination produces a unique neuronal 
activation response in select brain areas associated with feeding. 
4.3 Materials and methods 
4.3.1 Animals and injectants 
Experimentally naïve adolescent male Sprague-Dawley rats (postnatal day 28) (average 
b. wt. 190 g) were housed individually in standard plastic cages with wire tops in a 
temperature-controlled (22◦C) animal facility with a 12:12 light:dark cycle (lights on at 
07:00). Water and standard laboratory chow (Sharpes Stock Feed, Diet 86; 3.6kcal/g) 
were available ad libitum unless stated otherwise. Animals were treated in accordance 
with the National Institute of Health Guide for the Care and Use of Laboratory Animals. 
The University of Waikato Animal Ethics Committee approved all procedures described 
herein. 
Animals were accustomed to receiving IP injections. NTX (Abcam, Cambridge, UK) and 
OT (Sigma, St. Louis, MO, USA) were dissolved in isotonic saline just prior to use. 
4.3.2 Effect of OT and NTX on consumption 
4.3.2.1 Effect of IP NTX and OT on palatable HFHS chow intake 
Animals (n = 8–9/group) were injected IP with saline or NTX (1, 3 or 10 mg/kg) prior to 
presenting with 2h access to palatable high-fat high-sugar (HFHS; Research Diets 
#D12451; 4.73kcal/g; 35% calories from sugar and 45% from fat) chow. Rodents avidly 
consume HFHS diet even in the absence of hunger. Food intake was measured 2h post-
injection. Water was available at all times. I aimed to find the highest dose of NTX that 
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did not produce a significant effect alone on consumption, in order to combine with OT 
for a synergistic effect. 
The above procedure was then repeated with OT. Animals (n = 8–9/group) were injected 
IP with saline or OT (0.1, 0.3 or 1mg/kg) prior to presenting with 2h access to palatable 
high-fat high-sugar chow. Food intake was measured 2h post-injection. Water was 
available at all times. I aimed to find the highest dose of OT that did not produce a 
significant effect alone on consumption, in order to combine with NTX for a potentiating 
effect. 
Since 0.1mg/kg OT was found to be the optimal dose of OT that did not produce an effect 
on consumption alone, animals (n = 8–9/group) were injected IP with either saline, OT 
(0.1mg/kg), or OT (0.1mg/kg) combined with NTX (1, 3 or 10mg/kg). Injection was 
immediately followed by 2h access to palatable high-fat high-sugar chow. Food intake 
was measured 2h post-injection. Water was available at all times. I aimed to find the 
lowest effective combined dosage of NTX with OT, for significant, synergistic effect on 
reducing consumption. 
4.3.2.2 Effect of IP NTX and OT on deprivation-induced regular chow intake 
Animals (n = 6/group) were food-deprived overnight and injected IP with saline or NTX 
(0.3, 1 or 3mg/kg) prior to refeeding (food returned to cages at 10:00). Food intake was 
measured 2h post-injection. Water was available at all times. I aimed to find the highest 
dose of NTX that does not produce a significant effect alone on consumption, in order to 
combine with OT for a potentiating effect. 
Since 0.1mg/kg OT was found to be the optimal dose of OT that did not produce an effect 
on consumption alone, animals (n = 6/group) were food-deprived overnight and injected 
IP with either saline, OT (0.1mg/kg), or OT (0.1mg/kg) combined with NTX (0.3, 1 or 
3mg/kg) prior to refeeding (food returned to cages at 10:00). Food intake was measured 
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2 h post-injection. Water was available at all times. I aimed to find the lowest effective 
combined dosage of NTX with OT, for a significant, synergistic effect on consumption. 
4.3.2.3 Effect of IP NTX and OT on sucrose intake 
Animals (n = 6/group) were injected IP with saline or NTX (0.1, 0.3 & 1mg/kg) prior to 
presenting with 2h access to 10% sucrose solution. Sucrose solution intake was measured 
2h post-injection. I aimed to find the highest dose of NTX that does not produce a 
significant effect alone on palatable-solution intake, in order to combine with OT for a 
synergistic effect. 
Since 0.1mg/kg OT was found to be the optimal dose of OT that did not produce an effect 
on food intake alone, animals (n = 9/group) were injected IP with either saline, OT 
(0.1mg/kg), or OT (0.1mg/kg) combined with NTX (0.1, 0.3 or 1 mg/kg) prior to 
presenting with 2h access to 10% sucrose solution. Sucrose solution intake was measured 
2h post-injection. I aimed to find the lowest effective combined dose of NTX with OT, 
for a significant, synergistic effect on palatable-solution intake. 
4.3.2.4 Conditioned taste aversion test 
To investigate whether the reduced consumption effect was due to an aversive effect of 
the drugs, animals (n=6/group) were initially deprived of water overnight before being 
given access to a novel 0.1% saccharin solution for 1hr, during which time, regular chow 
was removed. Immediately following this, animals were injected IP with either lithium 
chloride (LiCl) as a positive control for CTA (Sigma; 0.56 mEq/kg body weight or 
23.9mg/kg; isotonic solution), saline, OT (0.1mg/kg), NTX (3mg/kg), or OT/NTX 
combined. After 2 days without deprivation, animals were then deprived of water 
overnight, and on the following day, regular chow was removed and animals were 
presented with a two-bottle choice test, with 2h access to both water and 0.1% saccharin 
solution. Bottles of saccharin and water were weighed before and after the two-bottle 
choice test to determine the amount of liquids consumed, and the percentage of saccharin 
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intake in the cumulative (saccharin and water) consumption was established. Results were 
compared to LiCl group for evidence of CTA. 
All descriptive data are presented as means ± the standard error of the mean (SEM). One-
way analysis of variance (ANOVA) (GraphPad Prism) was used to assess the effects of 
OT and NTX in reducing food intake and compared against control group. Tukey HSD 
post hoc tests were performed following significant ANOVA values to determine 
differences among conditions. Significance was set at p ≤ 0.05. 
4.3.3 Establishing OT-NTX-induced c-Fos immunoreactivity (IR) in 
feeding-related brain sites in adolescent rats 
Age-matched male Sprague Dawley rats were divided into four groups (n = 9 per group) 
and each received an IP injection of either isotonic saline, 0.1 mg/kg OT, 3mg/kg NTX 
or 0.1mg/kg OT/ 3mg/kg NTX. An hour after drug administration, animals were deeply 
anesthetized with urethane (35% dissolved in 0.9% saline, IP), and perfused through the 
aorta with 50ml of saline followed by 500ml of 4% paraformaldehyde in 0.1 phosphate 
buffer (pH 7.4). Brains were excised and post-fixed overnight in the same fixative at 4◦C. 
60 μm-thick coronal sections were cut with a vibratome (Leica, Germany) and later 
processed as free-floating sections for standard single antigen immunostaining of c-Fos. 
Sections were rinsed in 50 nM TBS (pH 7.4–7.6), and then pretreated for 10min in 3% 
H2O2, 10% methanol (diluted in TBS). After rinsing in TBS they were incubated 
overnight at 4◦C in the primary rabbit-anti-Fos antibody (diluted 1:3000; Synaptic 
Systems, Australia) washed in TBS, and subsequently incubated for 1 h at room 
temperature in the secondary goat-anti-rabbit antibody (1:400; Vector Laboratories). 
Following four washes in TBS, sections were incubated for 1 h with the avidin–biotin 
peroxidase complex (1:800; Elite Kit, Vector Laboratories). The vehicle for all 
incubations was a solution of 0.25% gelatin and 0.5% Triton X-100 in TBS. The 
peroxidase in the tissue was visualized with 0.05% diaminobenzidine (DAB), 0.01% 
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H2O2 and 0.3% nickel sulfate (12-min incubation). Sections were washed four times in 
TBS to stop the reaction, mounted onto gelatin-coated slides, air-dried, dehydrated in 
ascending concentrations of ethanol, soaked in xylene (Merck KGaA, Germany) and 
embedded in Entellan (Merck KGaA, Germany). The number of Fos-positive nuclei per 
1 mm2 was counted bilaterally for each neuroanatomical region of interest using ImageJ 
Software, with boundaries defined according to the Paxinos and Watson brain atlas, on 
2–4 sections per animal. Images provided by a CCD camera attached to a Nikon Eclipse 
400 microscope were analyzed using Nikon NIS Elements image software. The following 
areas were analysed (in the parentheses, anterior-posterior ranges of bregma levels of 
sections used to analyze each site are shown): AcbC—nucleus accumbens core (1.28–
0.96); AcbS—nucleus accumbens shell (1.28–0.96); AP—area postrema (−13.92 to 
−14.16); ARC—arcuate nucleus (−2.16 to −2.52); BLA—basolateral amygdala (−2.64 to 
−2.92); CEA—central nucleus of the amygdala (−2.64 to −2.92); DMH—dorsomedial 
nucleus of the hypothalamus (−3.00 to −3.24); DMNV—dorsal motor nucleus of the 
vagus (−13.76 to −14.16); NTS—nucleus of the solitary tract (−13.76 to −14.16); PVN—
paraventricular nucleus of the hypothalamus (−1.56 to−1.92); SON—supraoptic nucleus 
(−0.96 to −1.2); VMH—ventromedial nucleus (−3.00 to −3.24); LH-lateral hypothalamic 
nucleus (-1.20 to -1.44); BNST-bed nucleus of the stria terminalis (-0.24 to -0.48). 
Densities of Fos-positive nuclear profiles (per 1 mm2) were averaged per individual, and 
then per group. Group means were compared using a one-way ANOVA (GraphPad Prism) 
with Tukey’s post-hoc test. Values were considered significantly different for p ≤ 0.05. 
 
4.4 Results 
IP NTX at 10 mg/kg was effective at decreasing episodic HFHS chow intake in non-
deprived rats, whereas 3 and 1 mg/kg doses did not produce any change (Fig. 4.1 A). Only 
the highest, 1mg/kg, dose of IP OT reduced the amount of HFHS diet consumed during 
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the 2-h meal (Fig. 4.1B). When animals were injected with the subthreshold 0.1 mg/kg 
OT in combination with NTX, both 3 and 10 mg/kg NTX combined with OT generated 
hypophagia in the HFHS diet meal (Fig. 4.1C).  
 
Figure 4.1: Effect of IP NTX (A), OT (B), and OT–NTX combination (C) on 2-h HFHS chow 
intake in non-deprived rats. Doses are shown in mg/kg body weight. In (C) 0.1mg/kg OT and 





The CTA test revealed that, unlike IP LiCl, the anorexigenic 0.1 mg/kg OT – 3 mg/kg 
NTX drug combination did not produce an aversion to the 0.1% saccharin solution (Fig. 
4.2). 
 
Figure 4.2. Conditioned taste aversion test. Effect of OT (0.1mg/kg), NTX (0.1mg/kg), 
OT/NTX combination and LiCl (23.9mg/kg) on preference for 0.1% saccharin solution. LiCl 
following ingestion of 0.1% saccharin solution by rats significantly affected their later preference 
for the saccharin solution compared with controls. *p < 0.05. Administration of OT, NTX or 
OT/NTX combined did not alter saccharin consumption compared with controls. 
 
 
IP NTX alone was ineffective at decreasing episodic deprivation-induced intake of 
standard chow at all doses, up to 3mg/kg (Fig. 4.3A). Similarly, 0.1mg/kg OT did not 
produce any change in consumption. However, when this subthreshold dose of 0.1mg/kg 
OT was administered in combination with NTX, 3mg/kg NTX combined with OT 
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generated hypophagia (Fig. 4.3B). Notably, a trend toward a hypophagic response was 
observed at lower doses of NTX (0.3 and 1mg/kg) when combined with OT, however did 
not reach significance (P=0.0681 and P=0.0678 respectively).   
 
Figure 4.3. Effect of IP NTX (A) and OT/saline and OT-NTX combination (B) on 2-h 
deprivation-induced chow intake in rats. Doses are shown in mg/kg body weight. In (B) 
0.1mg/kg OT, and 0.3,1 and 3 mg/kg NTX were administered. Isotonic saline served as the 




NTX at 0.3 and 1mg/kg was effective at decreasing episodic sucrose solution intake in 
non-deprived rats, whereas 0.1mg/kg did not produce any change (Fig. 4.4A). While 
0.1mg/kg OT did not produce any change in sucrose intake, when this subthreshold dose 
of OT was administered in combination with NTX, doses as low as 0.1mg/kg NTX 




Figure 4.4. Effect of IP NTX (A) and OT/saline and OT-NTX combination (B) on 2-h sucrose 
solution intake in non-deprived rats. Doses are shown in mg/kg body weight. In (B) 0.1mg/kg 





IP combination of OT and NTX at doses found to induce acute hypophagia in all episodic 
meal scenarios (OT 0.1mg/kg and NTX 3mg/kg) produced robust changes in neuronal 
activation as measured by cFos IR, particularly in regions associated with satiation. 
Notably, activation of DMH and CeA was significantly increased by the drug 
combination, when compared to vehicle and OT or NTX alone (Fig. 4.5). Inversely, 
activation of ARC was significantly reduced by the drug combination (Fig. 4.5), when 
compared to vehicle and OT or NTX alone. 
 
Figure 4.5: Effect of IP OT-NTX combination on cFos IR activation in adolescent rats (A). 
Doses of 0.1mg/kg OT and 3mg/kg NTX were administered. Isotonic saline served as the 
vehicle. Panel (B) presents photomicrographs depicting sites that showed a significant 
difference in c-Fos levels. Densities of Fos-positive nuclear profiles (per 1 mm2 of a site) were 
averaged per individual, and then per group. AcbC, nucleus accumbens core; AcbS, nucleus 
accumbens shell; AP, area postrema; ARC, arcuate nucleus; BLA, basolateral amygdala; CEA, 
central nucleus of the amygdala; DMH, dorsomedial nucleus of the hypothalamus; DMNV, dorsal 
motor nucleus of the vagus; NTS, nucleus of the solitary tract; PVN, paraventricular nucleus of 
the hypothalamus; SON, supraoptic nucleus; VMH, ventromedial nucleus; LH, lateral 








A case-study of an adolescent male suffering from craniopharyngioma described how this 
condition led to uncontrollable overeating of palatable foods and excessive increases in 
body-weight [2]. Treatment by co-administration of OT and NTX was trialed, and the 
authors reported a significant decrease in the seeking and intake of palatable foods, and 
in turn, in the subject’s body weight. That study may outline a synergistic effect of OT 
and NTX when combined. Therefore, in the current study, I utilized adolescent male rats 
to investigate the effects of OT and NTX directly administered intraperitoneally, and 
observed changes in food intake and neuronal activation. 
Initial studies showed that the anorexigenic peptide OT regulates gastric motility, 
responds to stomach distention and to elevated osmolality, and blocks consumption of 
toxic foods. Most recently, OT has been proposed to act as a mediator of general and 
carbohydrate-specific satiety and regulator of body weight. It is now understood that OT 
plays a role as a homeostatic inhibitor of consumption, capable of mitigating multiple 
aspects of ingestive behavior and energy metabolism [9]. 
We have showed in a previous chapter that OT does not diminish a feeling of hunger 
before a start of a meal. Instead, OT's anorexigenic properties are manifested once 
consumption has already begun, which is—at least to some extent—driven by changes in 
brain responsiveness to OT treatment in the hungry vs. fed state. OT should therefore be 
viewed as a mediator of early satiation rather than as a molecule that diminishes perceived 
hunger [10]. 
In the present set of experiments, I first investigated the effect of IP NTX administration 
on acute intake of HFHS palatable chow. The data showed that only the highest of the 
three doses of NTX (10mg/kg) was effective in reducing HFHS intake 2h after injection. 
NTX alone has been previously reported to produce only a relatively limited effect on 
consumption. NTX has been found not to reduce feeding for energy, but only to reduce 
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consumption of palatable diets, in line with opioid involvement in reward [11]. NTX 
reduces consumption of novel HFHS diets and sucrose solutions, and inhibits 
development of preference for high-sucrose diets, yet is ineffective in altering 
consumption of standard chow when animals are not deprived [12]. This is consistent 
with the finding shown in the previous chapter that opioid-receptor antagonists were 
effective at reducing deprivation-induced consumption, while not reducing perceived 
hunger.  
This study was then repeated with the IP administration of OT, which only produced a 
reduction in HFHS chow intake by the highest dose of OT (1mg/kg). This dose of OT has 
consistently been reported to produce hypophagia in adult rodent models [10]. 
Interestingly, when subthreshold doses of OT and NTX were combined, i.e. doses that 
did not produce an effect alone, this resulted in a significant reduction in HFHS intake. 
This experiment showed that a dose of 0.1mg/kg OT alone, while insufficient to reduce 
HFHS intake, when combined with 3mg/kg NTX, also found to be ineffective at reducing 
HFHS intake alone, produced significant reductions in palatable HFHS intake. This 
finding is remarkable as neither of these doses were effective at reducing food intake 
alone, yet when combined produce a synergistic hypophagic effect. 
This phenomenon of synergy between OT and NTX was then replicated in other episodic 
feeding scenarios, firstly with deprivation-induced standard laboratory chow intake. 
Again, NTX was ineffective at inducing acute decrease in deprivation-induced chow 
intake at all doses tested. Similarly, OT (0.1mg/kg) alone was ineffective at reducing food 
intake, however, when combined with a subthreshold dose of NTX (3mg/kg), induced 
significant acute hypophagia 2h after injection. Notably, in this deprivation-induced 
standard chow intake paradigm, combinations of OT (0.1mg/kg) with NTX at 0.3 and 
1mg/kg also generated a trend toward reduced consumption. 
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By establishing that these hypophagic doses of OT-NTX did not produce a conditioned 
taste aversion, we were able to confirm that the hypophagic effect of this drug 
combination was not the result of malaise or an aversive association. This is important 
considering that previous reports have shown that opioid receptor blockade with naloxone 
can potentiate the aversive effects of LiCl treatment, though one should note that in order 
for this to occur, the doses of naloxone need to high [14]. Similarly, opioid receptor 
agonism has been found to completely block the acquisition of conditioned taste aversions 
in some paradigms [15]. Therefore, as the aversive properties of LiCl and other malaise-
inducing agents, are mediated by both the opioid system, and OT and vasopressin cells in 
the PVN and SON [15], the finding that the hypophagic dose of this drug combination 
did not produce an aversion similar to that of LiCl is encouraging. 
Furthermore, using a non-caloric palatable tastant feeding paradigm, such as episodic 
intake of sucrose solution, similar findings were observed. Both NTX 0.1mg/kg and OT 
0.1mg/kg alone were insufficient to induce acute hypophagia, yet when these 
subthreshold doses were combined, they produced a significant reduction in sucrose 
intake. Of interest is the observation that in the sucrose solution paradigm, doses of 0.3 
and 1mg/kg of NTX alone, were indeed sufficient to significantly reduce sucrose intake. 
In contrast, these same doses of 0.3 and 1mg/kg NTX did not produce this hypophagic 
effect toward more calorie-dense tastants, such as HFHS chow in sated animals and 
standard chow in deprived animals. This outcome is in concert with the notion that NTX, 
being a non-selective opioid receptor antagonist, specifically influences the reward aspect 
of feeding, or eating for pleasure, rather than energy. It therefore explains how a lower 
dose of the opioid receptor antagonist was necessary to influence feeding for reward in 
the palatable sucrose solution experiment, than was required to induce hypophagia in 
paradigms involving caloric consumption.  
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Following the completion of food intake studies, the subsequent experiment focused on 
identifying neuronal activation patterns induced by (OT 0.1mg/kg and NTX 3mg/kg) 
treatment. This aimed to elucidate cFos changes in neuronal circuitry relevant to the 
observed alterations in feeding behavior. I analyzed expression in feeding and reward-
related brain regions for significant changes in neuronal activation, when compared to 
saline vehicle, and each drug alone. The combination of OT and NTX was found to induce 
some robust changes in neuronal activity, particularly in regions associated with satiety. 
Of particular interest was a significant increase in cFos IR in the dorsomedial 
hypothalamic (DMH) nucleus. Activity in this region has previously been associated with 
satiation, or the lack of hunger. Renner et al. reported that satiation, by refeeding fasted 
rats, evoked a significant increase in cFos expression in the DMH, and that this activation 
was elicited by satiation, rather than craving for food; in fact food presentation without 
consumption did not induce increased Fos activation in the DMH [16]. 
One of the commonly accepted theories of appetite control involves gut-derived 
hormones that signal hunger and satiety to brain circuitries regulating homeostatic and 
hedonic aspects of feeding [17, 18]. These hormones and signals act via anorexigenic and 
orexigenic pathways originating in the hypothalamic arcuate nucleus (ARC) that hosts 
the proopiomelanocortin (POMC) and neuropeptide Y (NPY)/agouti-related protein 
(AgRP) neurons, which in turn relay signaling to the hypothalamic paraventricular 
nucleus (PVN) [19-21]. The ARC and PVN pathways also converge in the lateral 
parabrachial nucleus, which sends anorexigenic calcitonin gene-related peptide (CGRP) 
projections to the central nucleus of the amygdala (CeA) [22]. The CeA, among other 
forebrain areas, has been shown to integrate homeostatic and motivational aspects of 
feeding, and to receive sensory input from the brainstem [23-26]. 
In line with this, after treatment with OT and NTX combined, I observed a significant 
decrease in cFos activation in the ARC. Interestingly, ARC neurons have been shown to 
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be activated during fasting, via the inputs stimulated through ghrelin input derived from 
the empty stomach [27]. Inversely, PYY is released when the stomach is full, and in turn, 
it inhibits ARC activation. This corresponds with the finding of this study that 
combination of OT and NTX significantly reduced both consumption and activity of the 
ARC, previously associated with positive energy-balance states. 
Similarly, increases in cFos activation in the CeA have previously been associated with 
satiety, and shown to correlate with reduced food intake [26]. This parallels the finding 
from this study that the combination of OT and NTX significantly increases cFos 
activation of the CeA, and effectively reduces consumption. The presence of both OT and 
opioid receptors in the DMH and the CeA may contribute to the effect of this drug 
combination on food intake [28-30]. 
Taken together, these results imply that OT and NTX combination reduces food intake 
synergistically, possibly by combining the properties of each drug component to reduce 
both homeostatic and hedonic pressures for consumption. OT may have promoted satiety 
through activating the DMH, and reducing of activity of the ARC, whereas NTX affected 
the reward circuitry component i.e. the CeA, acting to reduce hedonic pressures for 
consumption. Moreover, since these systems are intrinsically linked, the drug 
combination not only produced additive effects, but also appear to have acted 
synergistically to produce a combined effect greater than that of its components, and 
therefore is effective in reducing consumption and food-seeking by targeting multiple 
aspects of the motivation to eat. 
It should be noted, adolescents may be more responsive to anorexigenic signals than 
adults. Rigamonti et al. found that obese adolescents produced an increase in endogenous 
anorexigenic peptides GLP1 and PYY in response to slow-rate feeding, while obese adult 
subjects did not. However, postprandial responses of insulin and triglycerides were higher 
in obese adults than in obese adolescents [31]. This suggests that adolescents may be 
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more responsive to satiety cues than adults, and therefore anorexigenic treatments may 
be more effective in adolescents.  
In conclusion, I find that the combination of OT and NTX administered I.P. in adolescent 
rats at subthreshold doses produces significant reduction in acute intake of a range of 
tastants. Changes in neuronal activation found in brain regions associated with satiety and 
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Determining the chronic effects of a combination 
of oxytocin and naltrexone at subthreshold doses 
on food intake and body weight in adult rats, and 
the corresponding changes in gene expression in 
feeding-related brain regions 
5.1 Abstract 
As I have shown in previous chapters, OT and NTX indeed target different facets of 
feeding control. For this reason, combining these anorexigens holds promise as an 
effective treatment in reducing excessive consumption by influencing a broad range of 
appetite regulating processes. While OT influences satiety, and NTX modulates aspects 
of consumption related to palatability and pleasure, their combination at subthreshold 
doses has proven to synergistically induce acute reductions of food intake in adolescent 
animals. In the present study, I therefore aimed to investigate if the OTNTX combination 
might produce beneficial reductions in total caloric intake and body weight when 
administered chronically over 24 days. I found here that in adult animals, OTNTX did 
not appear to produce a significant acute effect on standard chow intake as in adolescents, 
while I still observed the acute hypophagic effect in palatable feeding scenarios. 
Futhermore, while the combination indeed had a cumulative effect on reducing palatable 
food intake with chronic administration, the beneficial effects on caloric intake and body 
weight were offset by compensatory feeding of non-palatable standard chow in the 
remainder of the day. The results of the PCR gene expression analysis across multiple 
brain regions showed that the drug combination produced robust changes in brain stem-
hypothalamic networks relating to reward and pleasure, as well as homeostatic signals for 
feeding. This change in neuromolecular activation aligns well with the behavioural results, 
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showing decreased cumulative consumption of HFHS palatable food intake presented 
immediately after OTNTX drug administration. However, this did not result in a 
significant, beneficial reduction of total caloric intake or body weight over the 24-day 
period, as acute effects of the drug combination appear to be offset by a compensatory 
increase in standard chow intake later in the day. 
5.2 Introduction 
In the previous chapter, I investigated the effect of the OT and NTX drug combination 
on meal size in adolescent rats, which found robust effects on acute food intake, and 
associated changes in neuronal activation of homeostatic- and reward-related brain 
regions. These results align well with the results of the adolescent human case-study, 
which showed significant reduction in food intake after the drug combination [15]. 
Translational studies in humans have largely confirmed the basic research findings. A 
single supraphysiological dose of IN OT in obese and normal-weight subjects decreased 
energy consumption [15-19]. The link between OT and eating for pleasure has also been 
suggested, though specific aspects of hedonic eating affected by OT remain unclear with 
some studies reporting preferential effects in reducing consumption of sweet [17, 18, 20], 
fatty [16] or salty [18] foods. Functional magnetic resonance analyses (fMRI) have found 
that OT modifies responsiveness of hypothalamic [21, 8] and limbic [19, 21] sites in 
response to food images, suggesting that not only homeostatic, but also some reward 
circuits might indeed be modulated by OT. 
After more than a century of search for pharmacological treatments that combat obesity, 
our choice of FDA-approved pharmaceuticals is currently limited to five. Two of those 
drugs, Qsymia (phentermine + topiramate) and Contrave (bupropion + NTX), are 
combination medicines: this fact reflects the need to simultaneously target many neural 
and neuroendocrine systems in order to increase the likelihood of effectively treating this 
multifactorial condition.  
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The combination medicine approach served as the basis of the recent case report in which 
hypophagic properties of OT, a molecule being subject of several clinical trials related to 
disordered appetite and obesity, were successfully augmented by co-administration of 
NTX in a patient with hypothalamic obesity caused by craniopharyngioma resection [15].  
In the recent human case study, Hsu and colleagues administered OT peripherally to 
reduce energy intake and body weight in an adolescent male with hypothalamic obesity 
and uncontrollable hedonic food-seeking caused by craniopharyngioma resection [15]. 
Considering a potentially suboptimal effectiveness of OT on eating for reward, the 
authors co-administered OT with NTX, a non-selective opioid receptor antagonist, 
thereby capitalizing on the primary effect of opioid receptor blockade on diminishing 
reward-driven consumption. They found that while OT alone reduced body weight and 
hyperphagia during the first 10 weeks, subsequent co-administration with NTX was a 
successful adjunctive therapy leading to further improvements in body weight and satiety 
parameters. 
While the results of the previous chapter are promising, an important drawback of the 
study was that the adolescent period in rodents is very short (ca. 2 weeks), which did 
not allow us to examine the longer-term effects of these drugs on food intake and body 
weight. I therefore sought to evaluate the validity of this therapeutic combination over 
an extended period. A recent meta-analysis shows that OT alone does not significantly 
reduce food intake over long-term use, and therefore utilizing a drug combination that 
aims to target multiple aspects of feeding may alleviate this issue [1].  
For this purpose, adult rodents were studied over a 24-day period here, and body weight 
was monitored. The current study utilized a feeding paradigm in which animals 
maintained on standard laboratory chow were given a daily meal of high-fat high-sugar 
(HFHS) palatable chow for 2 hours. During this time, standard chow was removed from 
the cages. Animals were given daily intravenous (I.V.) injections immediately before 
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HFHS presentation, and the intake of the HFHS chow, and total calorie consumption 
over the 24hr period was measured. I used subthreshold doses of both OT and NTX 
alone, in order to investigate if their combination might produce a significant, 
potentiating effect on food intake and body weight. 
Similarly, while our adolescent study investigated effects in cFos expression, showing 
the immediate neuronal activation in response to the treatment, in a longer-term project, 
I wanted to see if this had any effect on expression of genes related to food intake, and 
if the effect of the drug combination can be associated with changes in related transcript 
profiles. 
 
5.3 Materials and methods 
5.3.1 Animals and injectants 
Adult male Sprague-Dawley rats (average b. wt. 555 g) were housed individually in 
standard plastic cages with wire tops in a temperature-controlled (22°C) animal facility 
with a 12:12 light:dark cycle (lights on at 07:00). Water and standard laboratory chow 
(Sharpes Stock Feed, Diet 86; 3.6kcal/g) were available ad libitum unless stated otherwise. 
Animals were treated in accordance with the National Institute of Health Guide for the 
Care and Use of Laboratory Animals. The University of Waikato Animal Ethics 
Committee approved all procedures described here. Animals were accustomed to 
receiving intravenous (I.V.) injections in the tail vein. NTX (Abcam, Cambridge, UK) 
and OT (Sigma, St. Louis, MO, USA) were dissolved in isotonic saline just prior to use. 
Drugs were injected as combination. 
5.3.2 Feeding studies 
First, by using acute feeding paradigms, we confirmed that the doses of individually 
administered OT and NTX were too low to reduce consumption for energy (intake of 
energy-dense standard chow in food-deprived animals) and for palatability (intake of 
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energy-dilute 10% sucrose solution in sated animals). The effect of the combined OT and 
NTX was established in these conditions. 
5.3.2.1 Acute effect of low doses of IV OT, NTX and OT+NTX on 
deprivation-induced intake of energy-dense standard chow 
Low doses of peripheral NTX and OT were chosen based on previously published studies: 
in the case of both ligands, we selected doses that were previously reported as ineffective 
in reducing deprivation-induced intake of standard chow [2]. Standard chow was removed 
at 16:00 on the day preceding administration (water was available at all times). At 10:00 
on the experimental day, animals were injected IV with either isotonic saline (control), 
OT (0.3µg/kg), NTX (0.1mg/kg) or OT (0.3ug/kg) + NTX (0.1mg/kg) (n=10/group). 
Immediately after the injection, standard chow was returned, and consumption was 
measured 2 hours later. Data from drug-injected groups were compared to saline controls 
with ANOVA followed by Dunnett’s post-hoc test. Values are presented as means ± 
S.E.M and they were deemed significantly different when p ≤ 0.05. 
5.3.2.2 Acute effect of low doses of IV OT, NTX and OT+NTX on calorie-
dilute, palatable 10% sucrose solution intake in non-deprived rats 
Low doses of peripheral NTX and OT were chosen based on previously published studies: 
in the case of both ligands, we selected doses that were previously reported as ineffective 
in reducing intake of sucrose solutions in non-deprived rodents [2]. Rats maintained on 
ad libitum standard chow and water were pre-exposed to 10% sugar water to avoid 
neophobia 5 and 10 days prior to the experiment (for 2 h on each occasion). On the 
experimental day, standard chow and water were removed from cages at 10:00, and the 
animals were given an IV injection of either isotonic saline (control), OT (0.3µg/kg), 
NTX (0.1mg/kg) or OT (0.3ug/kg) + NTX (0.1mg/kg) (n=10/group). Immediately after 
the injection, the animals were presented with a 10% sucrose solution and the amount of 
ingested solution was measured by weighing bottles (in grams) 2 hours later. Data from 
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drug-injected groups were compared to saline controls with ANOVA followed by 
Dunnett’s post-hoc test. Values are presented as means ± S.E.M and they were deemed 
significantly different when p ≤ 0.05. 
5.3.2.3 Effect of 24-day daily single injections of low doses of IV OT, NTX, 
and OT+NTX on HFHS palatable chow consumption, standard chow 
intake and body weight in non-deprived rats 
Low doses of peripheral NTX and OT were chosen based on the outcome of the studies 
described above as well as on the previously published experiments [2]. Rats were pre-
exposed to the calorie-dense, palatable HFHS chow (Research Diets chow #D12451; 
4.73kcal/g; 35% calories from sugar and 45% from fat) on two occasions prior to the 
study to avoid neophobia. From experimental day 1 until day 24, the rats were given a 
daily meal of HFHS chow between 10:00 and 12:00. At the onset of the 2-h HFHS meal, 
standard chow was removed from the cages and returned immediately afterward the meal 
(water was present at all times).  Just before the HFHS chow presentation, animals 
(n=9/group) were injected IV with either isotonic saline (control), OT (0.3µg/kg), NTX 
(0.1mg/kg) or OT (0.3ug/kg) + NTX (0.1mg/kg). HFHS food intake was measured 2h 
post-injection. Intake of standard chow was also measured daily at the time of removing 
the standard pellets from the cages at 10:00. Body weight was assessed daily between 
08:00 and 09:00. Data from cumulative intake were analysed and shown for 3-day 
cumulative intervals. Data from drug-injected groups were compared to saline controls 
with ANOVA followed by Dunnett’s post-hoc test. A significance level was set at p ≤ 
0.05. 
5.3.3 Effect of 7-day IV OT and NTX on gene expression in the 
hypothalamus, brain stem and nucleus accumbens 
Considering that the 24-day exposure period resulted in overall changes in food intake, 
and these changes became more apparent in the second week of treatment, in order to 
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understand the effect of the drugs alone when administered longer term, we used a 
different cohort of rats and subjected them to the same injection regimen, understanding 
that the food intake changes will not yet be a confound of the PCR study. It will therefore 
reflect mainly the effect and the ongoing changes in the CNS that later result in 
cumulative changes in food intake.  
Animals (n=8/group) were injected IV with either isotonic saline (control), OT (0.3ug/kg), 
NTX (0.1mg/kg) or OT (0.3ug/kg) + NTX (0.1mg/kg) at 10:00 daily for 7 days, 
immediately prior to being presented with palatable HFHS chow for 2 h (as described 
above). HFHS food intake was measured 2 h post-injection. Animals then received 22h 
daily access to standard chow. Water was available at all times.  
On the final day, animals received their injection 120 minutes before being sacrificed by 
decapitation. The brain stem, nucleus accumbens and hypothalamus were dissected and 
placed in RNAlater (Ambion, Stockholm, Sweden) for 2 h at room temperature and the 
samples were then frozen at −80˚C until further preparation. 
5.3.3.1 RNA isolation and cDNA synthesis  
A standard protocol of sample preparation and rtPCR was used, as established by our lab 
previously [3]. Samples were homogenized in TRIzol (Ambion); RNA was extracted with 
chloroform, centrifuged at 10,000 × g at 4 ˚C for 15 min, and RNA precipitated in 
isopropanol. After centrifuging, the pellet was washed with 75% ethanol, air-dried, and 
dissolved in the DNase buffer (NEB). The samples were treated with RNase-free DNase 
I (Merck, Germany) and the absence of genomic DNA was established by PCR of a 5% 
template. 100 ng/μl genomic DNA served as a positive control, whereas MilliQ H2O as 
a negative one. RNA concentration was determined using a Nanodrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, DE). 5 μg RNA samples were 
diluted with MilliQ H2O. RNA was reverse-transcribed to cDNA in the master mix 
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(Promega; 20 μl). Samples were incubated for 1 h (37°C), followed by PCR to confirm 
cDNA synthesis.  
The cDNA for the tissue panels was analysed in quantitative real-time PCR with a CFX96 
thermal cycler (Bio-Rad Laboratories, Stockholm, Sweden). Each real-time PCR with a 
total volume of 20 μl contained cDNA synthesized from 25 ng total RNA, 0.25 M each 
primer, 20 mM Tris/HCl (pH 8.4), 50 mM KCl, 4 mM MgCl2, 0.2 mM dNTP, SYBR 
Green (1:50,000). Real-time PCR was performed with 0.02 U/liter Taq DNA polymerase 
(Invitrogen) under the following conditions: initial denaturation for 3 min at 95 ˚C, 
followed by 50 cycles of 15 sec at 95 ˚C, 15 sec at 54–61 ˚C (optimal annealing 
temperature), and 30 sec at 72 ˚C. This was followed by 84 cycles of 10 sec at 55 ˚C 
(increased by 0.5 ˚C per cycle). All real-time PCR experiments were performed in 
duplicates, and the measurements where the threshold cycle (Ct) values between the 
duplicates had a difference of over 0.9 were repeated. A negative control for each primer 
pair was included on each plate. Sample cDNA template (25 ng) was used per primer, 
and listed below in Figure 5.1. Expression of three housekeeping genes (TBP, H3B and 
β-tubulin) was used to calculate normalization factors (GeNorm). Melting point curves 
were included after the thermocycling to confirm that only one product with the expected 
melting point was formed.  
The CFX Maestro software (Bio-Rad) was used to analyse real-time PCR data and derive 
Ct values, and used delta-Ct to produce relative expression levels with SD. Melting curves 
were analysed manually for each individual sample to confirm that only one product was 
amplified and that it was significantly shifted compared with the melting curve for the 
negative control. Differences in gene expression between groups were analysed using 
ANOVA followed by Dunnett’s post-hoc test on genes significantly up- or down-
regulated in the ANOVA. p < 0.05 was used as the criterion of statistical significance for 
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the ANOVA. Statistics were performed using Prism (GraphPad). Values are presented as 
means ± S.E.M. 
 
 
Housekeeping genes forward primer reverse primer  
BTUB CGGAAGGAGGCGGAGAGC AGGGTGCCCATGCCAGAGC 
H3B CCTTGTGGGTCTGTTTGA CAGTTGGATGTCCTTGGG 
TBP AGAACAATCCAGACTAGCAGCA GGGAACTTCACATCACAGCTC 
Functional genes   
AGRP AGAGTTCCCAGGTCTAAGTCTG GCGGTTCTGTGGATCTAGCA 
DOR GCTCGTCATGTTTGGCATC AAGTACTTGGCGCTCTGGAA 
DYN TACCAGCGTCCCAGAGGAAAA GGCTTCATCATTCATCCGGTC 
GHSR TGGAGATCGCGCAGATCAG CCGGGAACTCTCATCCTTCAG 
KOR AGACCGCAACCAACATCTACAT GCACAGAACATCTCCAAAAGG 
MC3R TCCGATGCTGCCTAACCTCT GGATGTTTTCCATCAGACTGACG 
MC4R CTTATGATGATCCCAACCCG GTAGCTCCTTGCTTGCATCC 
MOR CGGACTCGGTAGGCTGTAAC CCTTGCGCTCTTCTCTGG 
NOFQ CAGACAGGGAGGACATGGAT GGACTGCAAAGTGCAGACCA 
NOP CAGCCAAGGCTACACAGACA AGACGTGAGGCTCCAACACT 
NPY ATGCTAGGTAACAAGCGAATGG TGTCGCAGAGCGGAGTAGTAT 
OPRL1 GTTCAAGGACTGGGTGTTCAG CGTGGTACTGTCTCAGAGGTC 
ORX1R CCCTCAACTCCAGTCCTAGC CAGGGAGGGCCTATAATTGA 
ORX2R CAATGTTGTTGGGGTGCTTA TCCCCCTCTCATAAACTTGG 
OXT GACGGTGGATCTCGGACTGAA CGCCCCTAAAGGTATCATCACAAA 
OXTR GATCACGCTCGCCGTCTA CCGTCTTGAGTCGCAGATTC 
PENK GAGAGCACCAACAATGACGAA TCTTCTGGTAGTCCATCCACC 
POMC TGGGCGAGCTGATGACCT GCCGACTGTGAAATCTGAAAGG 
 
Figure 5.1: Primer sequences used for PCR analysis Primer base sequences: A, 
adenine; C, cytosine; G, guanine; T, thymine. Housekeeping genes: BTUB, beta tubulin; 
H3B, histocompatibility 3b; TBP, TATA-box binding protein. Functional genes: AGRP, 
agouti-related protein; DOR, delta-opioid receptor; DYN, dynorphin; GHSR, growth 
hormone secretagogue receptor; KOR, kappa-opioid receptor; MC3R, melanocortin 3 
receptor; MC4R, melanocortin 4 receptor; MOR, mu-opioid receptor; NOFQ, 
nociception/orphanin FQ; NOP, nociception opioid receptor; NPY, neuropeptide Y; 
OPRL1, opioid receptor-like; ORX1R, orexin 1 receptor; ORX2R, orexin 2 receptor; 





5.4.1 Feeding Studies 
Acutely administered OT (0.3µg/kg), NTX (1mg/kg), or OT (0.3µg/kg)+NTX (1mg/kg) 
did not decrease deprivation-induced intake of energy-dense and ‘bland’ standard chow 
during a 2-hour meal (Fig 5.2). On the other hand, while the doses of OT or NTX alone 
were not sufficiently high to decrease intake of the palatable yet calorie-dilute sugar 
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solution, the combination of OT+NTX significantly decreased consumption in non-
deprived animals  (p=0.0073, Fig 5.3).  
Daily co-administration of OT (0.3µg/kg) + NTX (0.1mg/kg) significantly reduced the 
cumulative intake of HFHS palatable chow over the 24-day period (p=0.0359; Fig 5.4). 
 
 
Figure 5.2 Effect of saline (control), OT (0.3µg/kg), NTX (0.1mg/kg) or OT (0.3ug/kg)+NTX 
(0.1mg/kg) on deprivation-induced intake of standard chow during a 2-hour meal. I.V. 
administration of either OT (0.3µg/kg), NTX (1mg/kg), or a combination of OT 
(0.3µg/kg) and NTX (1mg/kg) was ineffective at significantly altering deprivation-






Figure 5.3 Effect of I.V. OT and NTX on sucrose solution intake after 2 hours. I.V. 
administration of a combination of OT (0.3µg/kg) and NTX (0.1mg/kg) significantly 
reduced intake of palatable sucrose solution 2 hours post-injection (p=0.0073). I.V. 
administration of OT (0.3µg/kg) or NTX (1mg/kg) alone did not significantly reduce 





Figure 5.4: Cumulative HFHS intake over 24 days. 2-way ANOVA results show that only the 
OTNTX-treated group show significantly reduced cumulative consumption of HFHS diet over 






Animals treated with OT (0.3µg/kg) + NTX (0.1mg/kg) consumed more standard chow 
as established through cumulative intake analysis from day 15 onwards (day 15: 
p=0.0183, day 18: p=0.002, day 21: p=0.0004, and day 24: p<0.001, Fig 5.5). 
Administration of OT (0.3µg/kg) or NTX (1mg/kg) alone also produced an increase in 
cumulative standard chow intake (day 18: OT - p=0.0328 and NTX - p=0.0262; day 21: 
OT - p=0.0127 and NTX - p=0.0086; day 24: OT - p=0.0037 and NTX - p=0.0028; Fig 
5.5). Daily administration of OT (0.3µg/kg), NTX (0.1mg/kg) or OT (0.3µg/kg) + NTX 
(0.1mg/kg) all significantly increased total calorie intake over the 24-day period 
(p=0.0107, p=0.0456 and p=0.0412, respectively, Fig. 5.6). Neither of the treatments 
















Figure 5.5: Cumulative standard chow intake over 24 days. 2-way ANOVA results show that 
daily I.V. administration of a combination of OT (0.3µg/kg) and NTX (0.1mg/kg) produced a 
significant increase in cumulative standard chow intake from day 15 onwards. Similarly, daily 
I.V. administration of OT (0.3µg/kg) or NTX (1mg/kg) alone, also produced a significant increase 




Figure 5.6: Total caloric intake over 24 days. ANOVA results show that daily I.V. 
administration of OT (0.3µg/kg), NTX (0.1mg/kg) or a combination of OT (0.3µg/kg) and NTX 
(0.1mg/kg) all significantly increased total caloric intake over the 24-day period, when compared 
to saline-treated control group (Dunnett’s post hoc test, *p<0.05). 
  




Figure 5.7: Body weight over the 24-day period. 2-way ANOVA with Dunnett’s post hoc test 





5.4.2 Gene expression 
5.4.2.1 Hypothalamus 
7-days of daily I.V. drug administration resulted in some significant changes in 
hypothalamus gene expression of homeostatic- and reward-related genes. OT-treated 
animals (0.3µg/kg) showed a significant increase in expression of KOR (p=0.0129, Fig 
5.8). NTX-treated animals (0.1mg/kg) showed a significant increase in expression of 
KOR (p<0.001, Fig. 5.8) and POMC (p<0.001, Fig. 5.8). Animals treated with a 
combination of OT (0.3µg/kg) and NTX (0.1mg/kg) showed a significant increase in 
expression of KOR (p<0.001, Fig. 5.8) and POMC (p<0.001, Fig. 5.8). 
 
Figure 5.8: Effect of treatment on expression of feeding-related genes established with real-
time PCR in the hypothalamus. Hypothalamus gene expression after 7-days I.V. administration 
of either OT (0.3µg/kg), NTX (1mg/kg), or a combination of OT (0.3µg/kg) and NTX (1mg/kg). 
AGRP, Agouti-related protein; DOR, delta-opioid receptor; DYN, dynorphin; GHSR, growth 
hormone secretagogue receptor; KOR, kappa-opioid receptor; MC3R, melanocortin 3 receptor; 
MC4R, melanocortin 4 receptor; MOR, mu-opioid receptor; NOFQ, nociception/orphanin FQ; 
NOP, nociception opioid receptor; NPY, neuropeptide Y; OPRL1, opioid receptor-like 1; 
ORX1R, orexin 1 receptor; ORX2R, orexin 2 receptor; OXT, oxytocin; OXTR, oxytocin receptor; 










7-days of daily I.V. drug administration resulted in some significant changes in brainstem 
gene expression of homeostatic- and reward-related genes. NTX-treated animals showed 
a significant increase in MOR expression (p=0.0052, Fig. 5.9). Animals treated with a 
combination of OT (0.3µg/kg) and NTX (0.1mg/kg) showed a significant increase in 
expression of MOR (p=0.003, Fig. 5.9), ORX2R (p=0.0194, Fig. 5.9) and POMC 
(p=0.192, Fig 5.9).  
 
Figure 5.9: Effect of treatment on expression of feeding-related genes established with real-
time PCR in the brain stem. Brainstem gene expression after 7-days I.V. administration of either 
isotonic saline, OT (0.3µg/kg), NTX (1mg/kg), or a combination of OT (0.3µg/kg) and NTX 
(1mg/kg). DOR, delta-opioid receptor; DYN, dynorphin; GHSR, growth hormone secretagogue 
receptor; KOR, kappa-opioid receptor; MC3R, melanocortin 3 receptor; MC4R, melanocortin 4 
receptor; MOR, mu-opioid receptor; NOFQ, nociception/orphanin FQ; NOP, nociception opioid 
receptor; NPY, neuropeptide Y; OPRL, opioid receptor-like; ORX1R, orexin 1 receptor; ORX2R, 
orexin 2 receptor; OXT, oxytocin; OXTR, oxytocin receptor; PENK, proenkephalin; POMC, 









5.4.2.3 Nucleus Accumbens 
7-days of daily I.V. drug administration resulted in some significant changes in nucleus 
accumbens gene expression of homeostatic- and reward-related genes. OT-treated 
animals (0.3µg/kg) showed a significant increase in expression of PENK (p<0.001, Fig. 
5.10). Animals treated with a combination of OT (0.3µg/kg) and NTX (0.1mg/kg) also 
showed a strong trend of increased expression of PENK (p=0.0508, Fig. 5.10), although 
this did not reach criteria for statistical significance. 
 
Figure 5.10: Effect of treatment on expression of feeding-related genes established with real-
time PCR in the nucleus accumbens. Nucleus accumbens gene expression after 7-days I.V. 
administration of either isotonic saline, OT (0.3µg/kg), NTX (1mg/kg), or a combination of OT 
(0.3µg/kg) and NTX (1mg/kg). DOR, delta-opioid receptor; DYN, dynorphin; GHSR, growth 
hormone secretagogue receptor; KOR, kappa-opioid receptor; MOR, mu-opioid receptor; NOFQ, 
nociception/orphanin FQ; NOP, nociception opioid receptor; OPRL1, opioid receptor-like 1; 
ORX1R, orexin 1 receptor; ORX2R, orexin 2 receptor; OXTR, oxytocin receptor; PENK, 







As shown in the previous chapter in adolescent animals, administration of OTNTX-
combination has a beneficial effect on reducing acute feeding. Here, the data show that 
in adult animals, the combination does not appear to have this significant acute effect on 
standard chow intake, as in adolescents. However, in adult animals, I still observe the 
acute effect on certain palatable feeding scenarios, and the combination has a cumulative 
effect on reducing palatable food intake with chronic administration, yet the beneficial 
effects on caloric intake and body weight are offset by compensatory feeding of non-
palatable standard chow in the remainder of the day.  
A dose of 0.1mg/kg of NTX was selected to be combined with OT, as this was the highest 
dose that did not produce significantly reduced palatable food intake when administered 
alone. I then established that I.V. administration of 0.3µg/kg OT alone was insufficient 
to reduce food intake, and therefore was the optimal subthreshold dose to combine with 
the 0.1mg/kg subthreshold dose of NTX. Interestingly, while NTX selectively inhibits 
intake of palatable sucrose, and does not have an effect on deprivation-induced chow 
intake, I.V. OT administration selectively inhibits deprivation-induced chow intake, but 
fails to effect consumption of palatable sucrose solutions [2], and so target different 
aspects of feeding behaviour. Therefore, by combining subthreshold doses of OT and 
NTX, I aimed to investigate if these drugs would work synergistically to inhibit both the 
homeostatic- and reward-based drives to consume, and thus produce a significant 
reduction in food intake, and body weight. 
We then verified that this combination of OT (0.3µg/kg) and NTX (0.1mg/kg) indeed 
acutely produced a significant reduction in intake of palatable sucrose solution 2 hours 
post-injection, while the individual drugs alone did not produce a significant effect.  
After 24-days of chronic I.V. drug administration, I found that cumulative HFHS food 
intake was significantly reduced by the combination of OT (0.3µg/kg) and NTX 
 
156 
(0.1mg/kg). HFHS food was presented for 2 hours daily, immediately after drug 
administration, and represents the acute effect of the drug combination on palatable food 
consumption. Interestingly, this same group that received the combination of OT 
(0.3µg/kg) and NTX (0.1mg/kg), and which showed reduced HFHS intake, conversely 
showed a significant increase in standard chow intake over the 24-day period. Animals 
treated with OT (0.3µg/kg) or NTX (0.1mg/kg) alone, also showed increased 
consumption of standard chow, although did not show the same significant reduction in 
palatable HFHS intake. Standard chow was presented for 22-hours daily following the 2-
hour HFHS period. This appears to show that while OTNTX combination indeed induced 
a reduction in palatable chow intake immediately after injection, that animals showed a 
compensatory increase in regular chow intake. This conclusion is further reinforced by 
the result of the total caloric intake of the animals, which shows that all three drug-treated 
groups consumed a significantly greater amount of total calories over the 24-day period, 
when compared to the control group. Furthermore, the effect of the chronic drug 
administration on animal body weights shows no significant decrease or change in body 
weights over the 24-day treatment period. This again shows that while OTNTX treatment 
indeed produced a significant acute reduction in palatable HFHS food intake, any 
reduction in HFHS caloric intake was offset by a compensatory increase in consequent 
standard chow intake, and therefore produced no significant change in body weight over 
the treatment period.  
We had hoped that by blocking the opioid receptors with NTX, acting as a non-selective 
opioid receptor antagonist to diminish reward-based drives to consume, and with OT 
stimulating the homeostatic response for early cessation of meal termination, that I 
might regulate both aspects of feeding motivation, to reduce caloric intake and body 
weight. This combination treatment has proven to be effective at reducing palatable 
food intake of the immediate meal, utilizing a dose of NTX that produces no significant 
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effect on HFHS intake when administered alone, and therefore implying that the 
combination with OT produced a synergistic, potentiating effect. However, while OT is 
effective at reducing acute consumption of standard chow [4], OT’s anorexigenic effects 
may have worn off after the 2hr daily HFHS period, and therefore did not combat 
against a compensatory increase in regular chow intake in the following 22 hours of the 
day. OT has been shown to be an important signal for early meal termination, however, 
is primarily effective after the beginning of a meal [4]. For this reason, what might be 
beneficial is to administer OT directly before each meal. Studies have shown that while 
OT is effective at reducing food intake acutely, it fails to maintain efficacy with chronic 
administration, as it is rapidly metabolized within 20 minutes in the CNS [5; 6]. This 
therefore accounts for the observed effects of the OTNTX drug combination that 
significantly reduced intake of the immediate meal, but fails to influence a 24-hour 
feeding period. Indeed, a systematic review and quantitative meta-analysis on the 
effects of OT on food intake was recently published, which examined over 2000 studies 
in animals and humans. This review showed that while a single dose of OT was 
effective at reducing food intake, whether administered centrally or peripherally, 
chronic administration did not produce a significant anorexigenic effect [1]. It is 
interesting to note that the drug administration produced a very slight increase in 
compensatory caloric intake, albeit not enough to significantly increase body weight 
over the 24-day period. 
 
Furthermore, by utilizing PCR gene expression analysis, we were able to investigate the 
neuromolecular changes in gene expression that underlie these observed behavioural 
effects. Within the hypothalamus, a brain region associated with regulating the 
homeostatic drives for consumption, I observed a significant increase in expression of 
KOR and POMC mRNA after OTNTX combination treatment. Increases in hypothalamic 
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proopiomelanocortin (POMC) mRNA have been previously associated with the 
homeostatic signalling of satiety, and the lack of hunger. POMC mRNA is decreased by 
food-deprivation and fasting [7]. The POMC gene encodes the alpha-melanocyte-
stimulating hormone (α-MSH), which has been shown to stimulate satiety, while 
inversely, its reduction is associated with obesity [7], and therefore this result implies that 
the OTNTX treatment significantly increased neuromolecular signals of satiety that act 
to reduce homeostatic drives for consumption.  
Similarly, the observed upregulation of KOR mRNA within the hypothalamus has 
previously been associated with modulating the orexigenic effect of ghrelin. Ghrelin 
produces potent orexigenic effects, but recent studies show that the hypothalamic opioid 
system can modulate these effects, and that hypothalamic KOR blockade can reduce food 
intake by blocking ghrelin signalling [8]. Our observation here that hypothalamic KOR 
mRNA has been upregulated by OTNTX treatment may imply that these opioid receptors 
are being blocked by the drug combination, inhibiting the orexigenic effect of ghrelin 
release, and thus reducing food intake in this way.  
 
Within the brainstem, administration of the combination of OT (0.3µg/kg) and NTX 
(0.1mg/kg) produced a significant increase in expression of MOR mRNA, the mu-opioid 
receptor. NTX is a non-selective opioid receptor antagonist, and it therefore follows that 
expression of this opioid receptor might be up-regulated as a result of the opioid receptors 
being blocked, which act to reduce sensitivity to rewarding stimuli, and the drive to 
consume palatable foods. Glass et al. similarly found that MOR gene expression was 
significantly increased within the brainstem of rats treated with NTX, and resulted in 
reduction of food intake [9]. They presented evidence of a distributed functional network 
of opioid receptor pathways that were responsible for regulating consumption for both 
reward- and energy-related feeding. They conclude that based on the wide distribution of 
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CNS opioid receptors, and the presence of other neuropeptides in the vicinity of 
opioidergic pathways, it seems likely that opioids can indeed affect multiple aspects of 
feeding [9]. This effect may have been further modulated by the addition of OT, being a 
prominent neuropeptide in the vicinity of this receptor network, and which also acts on 
homeostatic aspects of feeding.  
We also observed a significant increase in ORX2R mRNA within the brainstem after the 
OTNTX combination treatment. ORX2R is a G protein-coupled receptor for orexin, a 
neuropeptide implicated in feeding and circadian sleep/wake cycles. An increase in 
ORX2R expression has been previously correlated with an inhibition of food intake, as 
increased orexin peptide levels are shown to increase consumption, and the increased 
expression of the receptor ORX2R, could imply an upregulation of the receptor due to a 
decrease in the orexin peptide levels that stimulate feeding and arousal. A study by Sunter 
et al. found that ORX2R mRNA was expressed in the nucleus of the solitary tract (NTS) 
of the rat brainstem [10], and showed that this region received orexin immunoreactive 
fibres originating in the lateral hypothalamus (LH), an area implicated in feeding and 
circadian control [11]. They proposed that the presence of ORX2R mRNA in the NTS of 
the brainstem can result in hypophagia, and also influences activity levels [10]. 
Interestingly, I also observed a significant increase in POMC mRNA expression within 
the brainstem, which has similarly been implicated with NTS activation. Activation of 
POMC neurons in the NTS of the brainstem has been shown to immediately produce an 
inhibition of food intake, while activation of POMC neurons within the hypothalamus, 
for which I also observed a significant increase in POMC expression, has been implicated 
with only inhibiting food intake with chronic stimulation [12]. This shows that the 
administration of OTNTX was capable of increasing POMC mRNA expression that has 
been demonstrated to reduce food intake acutely, by modulating satiety signals within the 
brainstem-hypothalamus network.  
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Within the nucleus accumbens (NAcc), a brain region associated with regulating the 
reward-based drives for consumption, I found that OT (0.3µg.kg) significantly increased 
PENK mRNA expression. Increases in NAcc PENK mRNA expression has previously 
been associated with reducing food intake in rats, specifically the intake of fats and chow 
[13]. PENK, or proenkephalin has been characterised as an opioid agonist, and may be 
upregulated due to the blocking of the opioid receptors within the NAcc [14]. This 
signifies the reduced sensitivity of the animals to reward-related signalling after the drug 
administration that acts to reduce the consumption of palatable foods. Similarly, I also 
observed a strong trend of the combination of OT and NTX in increasing the expression 
of PENK within the NAcc (P=0.0508, Fig. 5.10). While this did not reach statistical 
significance due to variability in samples, we can see a trend of an increase in this opioid-
receptor agonist that may reflect the blocking of the opioid receptors, acting to reduce 
sensitivity to reward-related signals for consumption, and this reduce palatable food 
intake.  
Taken together, the results of the PCR gene expression analysis across multiple brain 
regions shows that each of the drugs influences aspects of feeding relating to reward and 
pleasure of consumption, as well as homeostatic signals for feeding. The OTNTX 
combination produced the most pronounced change in expression of POMC transcripts 
relating to satiety. This change in neuromolecular activation is then shown to result in 
decreased cumulative consumption of HFHS palatable food intake immediately after 
chronic OTNTX drug administration. However, this did not result in a significant, 
beneficial reduction of total caloric intake or body weight, as any acute effects of the drug 
combination appear to be offset by a compensatory increase in standard chow intake later 
in the day. This may be because OT has shown to be rapidly metabolized in the CNS [1], 
and therefore OT effects the immediate meal, but does not serve as a long-term tool to 
curb 24-hour appetite. 
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While in the human case-study of craniopharyngioma, this single administration schedule 
produced successful outcomes on body weight, one can imagine that multiple acute drug 
administrations before each meal, or sustained release of the drug combination may 
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FTO, is of ancient origin, up-regulated during food deprivation and expressed in 
neurons of feeding-related nuclei of the brain. Endocrinology, 149(5), 2062-2071. 
[4]  Head, M. A., Jewett, D. C., Gartner, S. N., Klockars, A., Levine, A. S., & Olszewski, P. K. 
(2019). Effect of oxytocin on hunger discrimination. Frontiers in Endocrinology, 10, 
297. 
[5]  Striepens, N., Kendrick, K. M., Hanking, V., Landgraf, R., Wüllner, U., Maier, W., & 
Hurlemann, R. (2013). Elevated cerebrospinal fluid and blood concentrations of 
oxytocin following its intranasal administration in humans. Scientific reports, 3, 3440. 
[6]  Mens, W. B., Witter, A., & Greidanus, T. B. V. W. (1983). Penetration of neurohypophyseal 
hormones from plasma into cerebrospinal fluid (CSF): half-times of disappearance of 
these neuropeptides from CSF. Brain research, 262(1), 143-149. 
[7]  Mizuno, T. M., Kleopoulos, S. P., Bergen, H. T., Roberts, J. L., Priest, C. A., & Mobbs, C. V. 
(1998). Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting in ob/ob and 
db/db mice, but is stimulated by leptin. Diabetes, 47(2), 294-297. 
[8]  Romero-Pico, A., Vázquez, M. J., González-Touceda, D., Folgueira, C., Skibicka, K. P., 
Alvarez-Crespo, M., Van Gestel, M. A., Velásquez, D. A., Schwarzer, C., & Herzog, H. 
(2013). Hypothalamic κ-opioid receptor modulates the orexigenic effect of ghrelin. 
Neuropsychopharmacology, 38(7), 1296-1307. 
[9]  Covey, L. S., Glassman, A. H., & Stetner, F. (1999). Naltrexone effects on short-term and 
long-term smoking cessation. Journal of Addictive Diseases, 18(1), 31-40. 
[10]  Sunter, D., Morgan, I., Edwards, C. M. B., Dakin, C. L., Murphy, K. G., Gardiner, J., Taheri, 
S., Rayes, E., & Bloom, S. R. (2001). Orexins: effects on behavior and localisation of 
orexin receptor 2 messenger ribonucleic acid in the rat brainstem. Brain research, 
907(1-2), 27-34. 
[11]  Nambu, T., Sakurai, T., Mizukami, K., Hosoya, Y., Yanagisawa, M., & Goto, K. (1999). 
Distribution of orexin neurons in the adult rat brain. Brain research, 827(1-2), 243-260. 
[12]  Zhan, C., Zhou, J., Feng, Q., Zhang, J.-e., Lin, S., Bao, J., Wu, P., & Luo, M. (2013). Acute 
and long-term suppression of feeding behavior by POMC neurons in the brainstem and 
hypothalamus, respectively. Journal of Neuroscience, 33(8), 3624-3632. 
[13]  van den Heuvel, J. K., Furman, K., Gumbs, M. C., Eggels, L., Opland, D. M., Land, B. B., Kolk, 
S. M., Narayanan, N. S., Fliers, E., & Kalsbeek, A. (2015). Neuropeptide Y activity in the 
nucleus accumbens modulates feeding behavior and neuronal activity. Biological 
psychiatry, 77(7), 633-641. 
 
163 
[14]  Vucetic, Z., Kimmel, J., & Reyes, T. M. (2011). Chronic high-fat diet drives postnatal 
epigenetic regulation of μ-opioid receptor in the brain. Neuropsychopharmacology, 
36(6), 1199-1206. 
[15]  Hsu, E.A., et al., Oxytocin and naltrexone successfully treat hypothalamic obesity in a boy 
post-craniopharyngioma resection. The Journal of Clinical Endocrinology & 
Metabolism, 2018. 103(2): p. 370-375. 
[16] Lawson, E.A., et al., Oxytocin reduces caloric intake in men. Obesity, 2015. 23(5): p. 950-
956. 
[17] Thienel, M., et al., Oxytocin’s inhibitory effect on food intake is stronger in obese than 
normal-weight men. International journal of obesity, 2016. 40(11): p. 1707-1714. 
[18] Burmester, V., S. Higgs, and P. Terry, Rapid-onset anorectic effects of intranasal oxytocin 
in young men. Appetite, 2018. 130: p. 104-109. 
[19] Spetter, M.S., et al., Oxytocin curbs calorie intake via food-specific increases in the activity 
of brain areas that process reward and establish cognitive control. Scientific reports, 
2018. 8(1): p. 1-11. 
[20] Ott, V., et al., Oxytocin reduces reward-driven food intake in humans. Diabetes, 2013. 
62(10): p. 3418-3425. 
[21] Plessow, F., et al., Effects of intranasal oxytocin on the blood oxygenation level-dependent 
signal in food motivation and cognitive control pathways in overweight and obese men. 







5.7 Supplementary Material 
5.7.1.1 Establishing effect of different doses of I.V. NTX on deprivation-
induced chow intake 
We sought to investigate the effect of different doses of I.V. NTX on reducing 
deprivation-induced chow intake in adult rats. Regular chow was removed at 16:00 on 
the day preceding administration. At 10:00 on the experimental day animals were injected 
intravenously with either isotonic saline or 0.1, 0.3, 1 or 3mg/kg NTX (n=7/group) before 
regular chow was returned, and consumption was measured 2 hours after administration. 
Water was available at all times. Data were analysed with a Student's t-test. Values are 
presented as means ± S.E.M and they were deemed significantly different when p ≤ 
0.05. 
5.7.1.2 Establishing effect of different doses of I.V. NTX on sucrose solution 
intake 
We sought to investigate the effect of different doses of I.V. NTX on reducing palatable 
sucrose solution intake in adult rats. Rats maintained on ad libitum food and water had 
standard chow and water removed, before receiving an intravenous injection of either 
isotonic saline (n=15/group) or 0.003, 0.1, 0.3 or 1mg/kg NTX (n=7/group). Animals 
were then presented with 10% sucrose solution and consumption was measured 2 hours 
post-injection. The animals had received previous episodic (2 h per day, 5 and 10 days 
before the study) exposure to this sucrose solution to avoid neophobia. Data were 
analysed with a Student's t-test. Values are presented as means ± S.E.M and they were 




5.7.2 Establishing effect of different doses of I.V. NTX on deprivation-
induced standard chow intake 
I.V. administration of NTX was ineffective at significantly reducing deprivation-induced 
standard chow intake after 2 hours post-injection (Fig 4.2). 
 
 
Figure 5.11 Effect of I.V. NTX on deprivation-induced standard chow intake after 2 hours. 
No significant difference in deprivation-induced standard chow intake 2 hours after I.V. 





5.7.3 Establishing effect of different doses of I.V. NTX on sucrose solution 
intake 
I.V. administration of NTX at 0.3 and 1mg/kg significantly reduced palatable sucrose 
intake at 2 hours (P=0.0045 and P=0.0016, respectively; Fig 4.5) post-injection. 0.1mg/kg 
NTX was the highest dose that did not produce a significant effect on sucrose intake 
alone. 
 










































Discussion and Perspectives 
 
Overeating, and addiction in general, can develop from a dysregulation of one or more aspects 
of the complex feedback loops that maintain homeostasis. As repeated stimulation of any one 
system occurs, biology consistently responds by altering the sensitivity of these systems, until 
eventually requiring the maintenance of a much higher level of stimulation to reach equilibrium. 
Over time, this can allow saturated receptor systems to shift the threshold for homeostasis 
outside regular boundaries, and begin driving behaviour beyond what is healthy, and into 
dangerous levels. 
These factors that drive consumption involve: a feeling of hunger (which determines the 
motivation to seek calories and food choices), satiation (which underpins the process of 
termination of ingestive behaviour), and reward processing (which can to a large extent shift 
the hunger-satiety continuum, adjusting consumption to the 'pleasantness' of  food instead of 
to the actual energy needs of the organism). In our search for neuroactive agents to curb 
excessive food consumption, those that affect more than one facet of feeding control are of 
particular interest, as they target a broader range of appetite regulating processes. 
One system responsible for regulating these factors is that of OT. While OT has been reliably 
shown to reduce food intake in deprived and non-deprived rats [1-5], it appears to 
predominantly act on one of these factors in particular, as a mediator of early satiation, 
regulating homeostatic drives for consumption.  While satiation initiates the early termination 
of consumption, hunger and reward processing can be powerful in their ability to shift the 
threshold for satiation signals to occur, and so should also be regulated for any robust treatment 
aiming to reduce unhealthy consumption. Reward processing is a key factor in this goal, as in 
this evolutionarily unique time of living in an ‘environment of plenty’, humans in particular 
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are bombarded with rewarding stimuli, and our physiology responds by constantly shifting the 
sensitivity of this system to deal with the ‘new normal’ level of arousal. Aiming to reduce 
activation of the reward system is one strategy to bring it back into a more balanced state, and 
so blocking these reward signals would act to allow the system to bring its threshold for 
equilibrium back to a healthy level. This reward processing system is relatively well understood, 
and opioid neurotransmitter signals have been consistently implicated as integral in its function 
[6-8]. Utilizing opioid receptor antagonists has proven effective at reducing the rewarding 
signals derived from addictive behaviour, ranging from tobacco smoking cessation, 
consumption of drugs of abuse, overeating palatable foods, and even running in models of 
anorexia [8-12]. While OT has been shown to communicate homeostatic signals of satiety, 
opioid antagonists can similarly regulate reward-related aspects of consumption, and so may 
present a robust therapeutic combination to target multiple facets of the drive to consume.  
After more than a century of search for pharmacological treatments that combat obesity, our 
choice of FDA-approved pharmaceuticals is currently limited to five. Two of those drugs, 
Qsymia (phentermine + topiramate) and Contrave (bupropion + NTX), are combination 
medicines: this fact reflects the need to simultaneously target many neural and neuroendocrine 
systems in order to increase the likelihood of effectively treating this multifactorial condition.  
The combination medicine approach served as the basis of the recent case report in which 
hypophagic properties of OT, a molecule being subject of several clinical trials related to 
disordered appetite and obesity, were successfully augmented by co-administration of NTX in 
a patient with hypothalamic obesity caused by craniopharyngioma resection [13]. Indeed, the 
recent case-study describing the therapeutic combination of OT and NTX in treating 
hypothalamic obesity of an adolescent boy post-craniopharyngioma has shown promise for this 
strategy [13]. The current set of studies, using a systematic analysis of food intake, body weight 
and gene expression in laboratory animals, shows for the first time that some beneficial effects 
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of the OT+NTX combination extend beyond the etiologically unique case described by Hsu et 
al. I aimed here, to investigate this drug combination and elucidate underlying neuromolecular 
mechanisms of its action.  
To begin with, I note that while this combination seeks to target aspects of feeding related to 
both satiety, and reward-processing, this strategy has not addressed the important facet that is 
hunger. This visceral signal alters motivation to seek calories and shapes food choices, while 
being subtly distinct from satiation, which underlies the termination of ingestive behaviour. 
Satiation can occur as a response to physiological signals of distress, and is evoked by physical 
and chemical qualities of ingested food, triggering hormonal responses from the 
gastrointestinal tract and neural activation within the brain [14]. Signals of stomach distension, 
where the stomach is becoming full and may burst if feeding continues, or signals of gastric 
motility, where something toxic has been ingested and its consumption should be terminated, 
are communicated via OT release [15-17]. One might imagine that drinking a lot of water will 
eventually fill the stomach, and result in feeling “full” or sated, even though there may remain 
an energy deficit, and still feel hungry. OT will, in such a case, signal the inhibition of food 
intake, acting to regulate homeostatic signals for consumption [18]. In this way, satiation is 
distinct from hunger, or the perception of energy deficit, and so when developing a strategy to 
target multiple aspects of food intake, I first aimed to investigate if OT or NTX might also 
influence this third factor driving ingestive behaviour, as they do with satiation and reward-
processing respectively.  
In the first chapter, I aimed to ask this question of OT, by investigating if, while significantly 
reducing food intake, OT can alter a feeling of hunger. I utilized a unique hunger discrimination 
paradigm using operant techniques to allow rats to respond with a lever-press associated with 
a feeling of hunger. After successful training, rats were able to reliably report on their 
subjective feeling of hunger, and so we were able to investigate the effects of certain peptides 
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on this important facet of ingestive behaviour. Importantly, this behavioural paradigm has 
shown efficacy in parsing satiation from hunger, as I show that neuropeptide Y (NPY) 
administration indeed produces behavioural responses associated with hunger [19].  
We first show that I.P. OT decreases calorie-dense palatable food consumption in both 2h- and 
22h-deprived animals, however is more potent in its anorexigenic effect in the 2h-deprived 
group. Consumption of sweet food after 2h-deprivation would be predominantly stimulated by 
palatability, whereas after 22h-deprivation, more so by hunger or energy deficit. This begins 
to suggest that OT’s hypophagic effect can influence “free” or “hedonic” intake, but may be 
less related to hunger, which is then reinforced by the operant behavioural studies. The fact 
that i.p. OT did not reduce operant responding to 22 h of deprivation strongly suggests that OT 
does not interfere with mechanisms that promote a feeling of hunger. OT did not have an effect 
on hunger discrimination even though it was used at doses that are anorexigenic, and despite 
the fact that it did decrease bar pressing rate in general. It also produced a trend toward a 
reduction in chow intake in the 1 h after the completion of the operant test when animals were 
placed in a transition cage with chow present on the floor. Consequently, it can be inferred that 
OT induces hypophagia by being part of neuroendocrine processes that facilitate satiation and 
early cessation of feeding, rather than affecting hunger. 
Furthermore, that i.p. OT differently affects neural processing under deprivation than in satiety 
is further substantiated by the outcomes of the c-Fos mapping study that revealed distinct 
patterns of c-Fos immunoreactivity in response to the OT treatment in hungry vs. sated animals. 
In animals deprived for only 2h, and thus relatively sated, OT affected c-Fos immunoreactivity 
in a broad range of hypothalamic and brain stem sites related to energy balance, including the 
DMH, ARC, NTS and DMV, while this network was unaffected by OT in 22h-deprived, 
hungry animals. Similarly, our PCR data show a decreased expression of the OT receptor gene 
in the brain stem of deprived or hungry animals, a region thought to mediate anorexigenic 
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properties of systemic OT, providing an additional insight into a mechanistic change that might 
be a key contributor to the changed hunger/satiety-dependent receptivity of the CNS to OT. 
We therefore conclude that systemic OT does not diminish a feeling of hunger before the start 
of a meal. Instead, OT's anorexigenic properties can be manifested once consumption has 
already begun and this, at least to some extent, is driven by changes in brain responsiveness to 
OT treatment in the hungry vs. fed state. Therefore, OT's role in feeding control should be 
viewed as a mediator of early satiation rather than as a molecule that diminishes a perceived 
need to seek calories. 
We find that OT indeed influences one aspect that drives consumption, and that is 
predominantly satiety alone.  In our goal to target multiple facets of food intake, I then hope to 
explore the effects of NTX, a non-selective opioid receptor antagonist acting primarily on 
reward-related drivers of consumption, but again must ask if targeting the opioid system 
perhaps might also influence the third factor, that is hunger. I subsequently utilized our same 
hunger discrimination paradigm to measure behavioural responses associated with hunger to 
explore if modulating the opioid receptor network will alter the perception of energy deficit, or 
hunger. Our behavioural data show that opioid receptor agonists fail to induce operant 
responses associated with hunger or 22h deprivation, while neuropeptide Y (NPY) 
administration does significantly induce such hunger-associated responses in sated animals 
deprived for only 2h. Most importantly, NTX, our candidate molecule to diminish reward-
related consumption, correspondingly did not reduce the hunger discriminative stimuli induced 
by either 22 h deprivation, or NPY administration in 2 h food-restricted subjects. This is 
interesting given that the doses of NTX used therein were indeed sufficient to decrease 
deprivation-induced feeding in a non-operant setting in animals familiar with consequences of 
2 h and 22 h deprivation. I therefore conclude that the opioid system indeed promotes feeding 
for reward rather than in order to replenish lacking energy, or the perception of hunger, and 
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that blocking opioid receptors with NTX, while effective at reducing palatable food intake, 
does not do so by influencing the perception of hunger. 
I find that while both OT and NTX have proven effective at inhibiting food intake in certain 
situations, they appear to target differing aspects of the motivation to consume, without 
influencing the feeling of hunger. These disparate systems are indeed intrinsically linked, as 
the opioidergic reward system can act to modulate the magnitude of a homeostatic feeding 
response by altering the neuronal sensitivity to satiety signals [29].  
I therefore hypothesized that by combining treatments that target these two different aspects of 
feeding behavior, such a treatment might produce potentiating effects that can translate to 
robust therapeutic benefits on curbing excessive consumption and seeking of palatable foods. 
To investigate this, I first aimed to find the subthreshold I.P. doses of both OT and NTX when 
administered alone, on reducing food intake. Then, using a range of feeding scenarios and 
different tastants, I found that when subthreshold doses of OT and NTX were combined, i.e. 
doses that did not produce an effect alone, this resulted in a significant reduction in food intake, 
including reducing deprivation-induced standard chow intake. This experiment showed that a 
dose of 0.1mg/kg OT, while insufficient to reduce high-fat high-sugar (HFHS) chow intake 
alone, when combined with 3mg/kg NTX, also found to be ineffective at reducing HFHS intake 
alone, produced significant reductions in palatable HFHS intake. This finding is remarkable as 
neither of these doses were effective at reducing food intake alone, yet when combined, seem 
to produce a potentiating hypophagic effect. 
By subsequently testing these hypophagic doses of OT-NTX in a CTA test, we were able to 
confirm that the hypophagic effect of this drug combination was not the result of malaise or an 
aversive association. This is important considering that previous reports have shown that opioid 
receptor blockade with naloxone can potentiate the aversive effects of LiCl treatment [20]. 
Similarly, opioid receptor agonism has been found to completely block the acquisition of 
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conditioned taste aversions in some paradigms [21]. Therefore, as the aversive properties of 
LiCl and other malaise-inducing agents, are mediated by both the opioid system, and OT and 
vasopressin cells in the PVN and SON [21], the finding that the hypophagic dose of this drug 
combination did not produce an aversion similar to that of LiCl is encouraging. 
Furthermore, using the combination of OT and NTX at the doses found to induce acute 
hypophagia in all episodic meal scenarios (OT 0.1mg/kg and NTX 3mg/kg), neuronal 
activation was investigated with c-Fos immunohistochemistry. This aimed to elucidate changes 
in neuronal circuitry that underlie the observed alterations in feeding behavior. The findings of 
this study showed that the OTNTX drug combination resulted in robust changes in brainstem-
hypothalamic networks related to satiety and energy, as well as reward-processing regions, thus 
targeting multiple aspects of feeding behavior.  
While this is indeed promising, investigating longer-term effects of the drug combination on 
total caloric intake and bodyweight is necessary. While here I used adolescent animals to match 
the human case study, observing chronic effects was not feasible due to the relatively short 
adolescent period in rats of around 2 weeks [22]. For this reason, further studying the effect of 
this therapeutic combination on chronic food intake and body weight in adult rats would be 
advantageous. To do this, I again aimed to find subthreshold doses of the drugs alone on 
reducing food intake, and combined these for a potentiating effect, before investigating the 
chronic effect of the drug combination on caloric intake, body weight and gene expression. 
Interestingly, in adult rats, the OTNTX drug combination, while effective at reducing palatable 
food intake, did not produce a significant decrease in deprivation-induced chow intake, as it 
did in adolescent rats. We indeed find that adolescents may be more responsive to anorexigenic 
signals than adults. Rigamonti et al. found that obese adolescents produced an increase in 
endogenous anorexigenic peptides GLP1 and PYY in response to slow-rate feeding, while 
obese adult subjects did not. However, postprandial responses of insulin and triglycerides were 
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higher in obese adults than in obese adolescents [23]. This outlines that adolescents may be 
more responsive to satiety cues than their adult counterparts, and therefore anorexigenic 
treatments may be more effective for adolescents than in adults. 
However, in adult animals, I still observed the acute effect on certain palatable feeding 
scenarios, and found that the combination had a cumulative effect on reducing palatable food 
intake with chronic administration, yet the beneficial effects on caloric intake and body weight 
were offset by compensatory feeding of non-palatable standard chow in the remainder of the 
day. While palatable HFHS chow intake, available for 2h daily after drug administration, 
showed a significant reduction, total caloric intake over the entire study was not reduced, as 
animals showed a compensatory increase in standard chow intake in the remaining 22hrs of the 
day, resulting in no significant decrease in bodyweight over the study period.  
We had hypothesised that by blocking the opioid receptors with NTX, acting as a non-selective 
opioid receptor antagonist to diminish reward-based drives to consume, and with OT 
stimulating the homeostatic response for early cessation of meal termination, that I might 
regulate both aspects of feeding motivation, to reduce caloric intake and body weight. This 
combination treatment has proven to be effective at reducing palatable food intake of the 
immediate meal, utilizing a dose of NTX that produces no significant effect on HFHS intake 
when administered alone, and therefore implying that the combination with OT produced a 
synergistic, potentiating effect. However, while OT is effective at reducing acute consumption 
of standard chow [1], OT’s anorexigenic effects may have worn off after the 2hr daily HFHS 
period, and therefore did not protect against a compensatory increase in standard chow intake 
in the following 22 hours of the day. OT has been shown to be an important signal for early 
meal termination, however, is primarily effective after the beginning of a meal [1]. For this 
reason, what might be beneficial is to administer OT directly before each meal. Studies have 
shown that while OT is effective at reducing food intake acutely, it fails to maintain efficacy 
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with chronic administration, as it is rapidly metabolized within 20 minutes in the CNS [24; 25]. 
This therefore accounts for the observed effects of the OTNTX drug combination that 
significantly reduced intake of the immediate meal, but fails to influence a 24-hour feeding 
period. Indeed, a systematic review and quantitative meta-analysis on the effects of OT on food 
intake was recently published, which examined over 2000 studies in animals and humans. This 
review showed that while a single dose of OT was effective at reducing food intake, whether 
administered centrally or peripherally, chronic administration did not produce a significant 
anorexigenic effect [26]. 
By then investigating changes in gene expression, I found robust neuromolecular changes 
within brain regions associated with energy-intake and reward-processing. I found changes in 
hypothalamic and brain stem POMC mRNA expression as the most significant changes after 
anorexigenic drug administration, and evidence supporting POMC activity within the NTS of 
the brain stem being previously associated with inhibition of food intake [20]. This is 
interesting as our adolescent study using immunohistochemistry also found changes in brain 
activation of DMH, ARC and NTS networks associated with POMC neurons that inhibit food 
intake.  
We therefore find that OTNTX combination indeed reduces acute food intake, but did not result 
in long-term beneficial reductions in body weight, as animals showed a compensatory increase 
in standard chow consumption that offset the acute reductions in HFHS intake.  
In sum, I aimed to target multiple aspects of feeding and found that, while OT predominantly 
targets satiation, and opioid receptor antagonism by NTX targets eating for palatability, neither 
of these drugs influence the third aspect driving consumption, which is perception of hunger. 
Nonetheless, I found by combining these two peptides targeting satiation and reward, that they 
produce a synergistic effect on reducing acute food intake, as subthreshold doses of these drugs 
were able to be combined to produce a significant reduction in consumption. This effect was 
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most pronounced in adolescent animals, which showed acute hypophagia in all feeding 
scenarios, and may be more responsive to satiety cues than their adult counterparts [23].  
We have found that while these peptides target satiety and reward-related drives for 
consumption, that they do not influence the perception of hunger, and so in future studies, 
investigation of a third peptide that might also target the final aspect of feeding behaviour, 
could improve efficacy. I found in the hunger discrimination studies that NPY was indeed 
capable of inducing hunger-associated behavioural responses, and therefore one might propose 
that an NPY antagonist or similar may be a candidate for this combination. Cholecystokinin 
(CCK) is another molecule that has shown merit in influencing hunger in such hunger 
discrimination paradigms [27], and may be a promising candidate for combination with OT 
and NTX to further target all aspects driving consummatory behaviour.  
In general, I have shown that the strategy of targeting multiple aspects of feeding in order to 
reduce consumption is a promising approach in developing more advanced treatments for this 
purpose. This method has proven to produce synergistic hypophagic effects, as the systems of 
satiety, reward and hunger are indeed intrinsically linked [29]. Therefore, in the long term it 
might be beneficial to explore further methods of targeting these distinct facets of feeding, 
especially to further incorporate the elusive role of hunger. This may involve the combination 
with a hunger-mediating peptide such as CCK, or perhaps stimulation of the vagus nerve, 









The overarching aim of this doctoral thesis was to investigate the effect of combining OT and 
NTX at subthreshold doses, on food intake and the corresponding neuromolecular changes. 
The findings of the study are: 
- OT inhibits food intake of the immediate meal by regulating homeostatic signals of satiety, and 
not by influencing the perception of hunger. 
- Opioid receptor antagonism inhibits intake of palatable foods by regulating signals of pleasure 
and reward, and not by influencing the perception of hunger. 
- OT and NTX combination significantly reduces acute food intake by acting synergistically to 
target both homeostatic- and reward-related brain networks. 
- OT and NTX combination reduce acute food intake by targeting multiple aspects of feeding, 
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